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Abstract 
 
Breast cancer is the most common cancer in women worldwide, with an estimated 1.7 
million newly diagnosed cases in 2012. Despite the many clinical manifestations, 
metastatic disease is the main cause of death, and is responsible for 90% of all breast 
cancer-related deaths. Aggressive carcinomas of the breast preferentially spread via the 
lymphogenous route, and often co-opt and actively remodel the lymphatic vasculature in 
order to invade and metastasize to their draining lymph nodes (LNs) and, ultimately, to 
distant organs. Indeed, expression of vascular endothelial growth factor (VEGF)-C, the 
principal lymphangiogenic growth factor, by the tumor or recruited ancillary cells has 
been shown to correlate both with LN and distant metastasis, and shorter overall 
survival (OS), and LN status represents an important prognostic factor for patients 
diagnosed with breast cancer. Although traditionally considered as passive conduits that 
solely mediate tumor cell escape, more recent research aimed at discerning the 
interactions between the developing tumor and its associated lymphatic vessels has 
revealed that the lymphatic vasculature actively promotes lymphogenous metastasis of 
invasive tumor cells. Likewise, collaborative interactions between tumor cells and a 
multitude of other tissue-resident and recruited ancillary cells, which together constitute 
the tumor microenvironment, not only coercively contribute to tumor growth, 
progression and metastasis, but also suggest that interactions among primed stromal cells 
themselves may be important in the process of metastatic dissemination as well. Notably, 
expansion of tumor-associated lymphatic vessels in the tumor periphery leads to 
increased lymphatic drainage from the tumor to the tumor-draining LN, and interstitial 
flow-induced mechanical changes may alter tensional homeostasis within the tumor 
through stimulation of local fibroblasts that remodel and stiffen the extracellular matrix 
(ECM). Furthermore, VEGF-C-induced remodeling of the tumor-associated lymphatic 
vasculature has been shown to directly suppress the anti-tumor immune response, 
thereby promoting tolerance to the nascent tumor. Thus, to explore whether tumor-
associated lymphatic vessels promote tumor metastasis not only via interactions with the 
incipient tumor, but also through cross-talk with the surrounding stromal cells, the 
different components of the tumor microenvironment, specifically tensional 
homeostasis and anti-tumor immunity, were evaluated upon modulation of lymphatic 
vessel growth in various experimental models of breast cancer. Accordingly, inhibition 
of VEGFR-3-mediated signaling upon administration of an antagonistic antibody in a 
genetically engineered preclinical mouse model specifically reduced the number of 
lymphatic endothelial cells (LECs) in the tumor, whereas conversely, orthotopic 
inoculation of a stable murine breast cancer cell line with enhanced expression of 
VEGF-C induced an expansion of the lymphatic endothelium. Although either 
experimental approach affected either regional or distant metastatic dissemination of the 
primary tumor to LN or the lungs, respectively, these effects did not seem to be 
mediated by interactions of the tumor-associated lymphatic vasculature with the tumor 
microenvironment in these particular experimental models.  
 
Key words: breast cancer, metastasis, tumor microenvironment, lymphatic vessels, 
VEGF-C, VEGFR-3 
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Zusammenfassung 
 
Brustkrebs ist weltweit die am häufigsten auftretende Krebsart bei Frauen mit 
geschätzten 1,7 Millionen neu diagnostizierte Fälle im Jahr 2012. Obwohl es sehr viele 
klinische Erscheinungsformen dieser Erkrankung gibt, sind Metastasen als 
Haupttodesursache für 90% aller von Brustkrebs verursachten Todesfälle 
verantwortlich. Aggressive Karzinome der Brust verbreiten sich bevorzugt über die 
lymphogene Route, wobei die invasiven Tumorzellen die Gefäße oft kooptieren und das 
lymphatische Gefäßsystem umgestalten um so in den Lymphknoten (LN) einzudringen 
und dort zu metastasieren, sowie letztlich auch entfernte Organe anzugreifen. 
Tatsächlich korreliert die Expression des vaskulären endothelialen Wachstumsfaktors 
(VEGF)-C, des primären lymphangiogenetischen Wachstumsfaktors, im Tumor oder 
durch rekrutierte Zusatzzellen mit der Präsenz von LN und weiter entfernten 
Metastasen, sowie einer generell kürzeren Überlebenszeit (OS), und der LN-Status ist 
daher ein wichtiger prognostischer Faktor für Patienten bei denen Brustkrebs 
diagnostiziert wurde. Obwohl die Lymphgefäße traditionell nur als passive Kanäle, die 
invasiven Tumorzellen bei ihrer Ausbreitung einen Ausweg vom primären Tumor 
bieten, betrachtet wurden, ist es durch rezente Forschung, welche darauf zielte die 
Interaktionen zwischen dem Tumor und ihrer assoziierten Gefäße besser zu verstehen 
klar geworden, dass das lymphatische Gefäßsystem eine aktivere Rolle bei der Förderung 
des Tumorwachstums und der Metastasierung spielt als bisher angenommen. Allerdings 
führt ein Zusammenspiel zwischen Tumorzellen und einer Vielzahl an sowohl residente 
als auch rekrutierte Hilfszellen, welche zusammen das Tumor Mikroumfeld bilden, nicht 
nur zu einem beträchtlichen Beitrag zum progressiven Wachstums und der Ausbreitung 
des Tumors, sondern deutet auch darauf hin, dass Interaktionen zwischen den 
aktivierten Zellen des Stromas auch Bedeutung im Prozess der Metastase haben. So 
führt eine Erweiterung der Lymphgefäße in der Peripherie des Tumors zu einer 
erhöhten Lymphdrainage zu den ableitenden LNs, und die daraus folgenden 
mechanischen Änderungen könnten durch die Stimulation von lokalen Fibroblasten, 
welche die extrazelluläre Matrix formen und erneuern, einen Einfluss auf das 
Kraftgleichgewicht im Tumor nehmen. Des Weiteren kann eine VEGF-C-induzierte 
Umgestaltung des Tumor-assoziierten lymphatischen Gefäßsystems außerdem die Anti-
Tumor-Immunantwort direkt unterdrücken, wodurch das Wachstum des sich 
ausbreitenden Tumors erleichtert wird. Um deshalb herauszufinden, ob die mit dem 
Tumor assoziierten Lymphgefäße die Metastase des primären Tumors nicht nur durch 
Interaktionen mit den heranreifenden Tumorzellen, sondern auch durch eine Synergie 
mit den umliegenden Zellen des Stromas begünstigen, wurden die verschiedenen 
Komponenten des Tumor Mikroumfelds, insbesondere das Kraftgleichgewicht und die 
Anti-Tumor Immunantwort, nach Modulation der Lymphgefäße in experimentellen 
Modellen von Brustkrebs evaluiert. Dementsprechend führte eine Inhibierung des 
VEGFR-3-induzierten Signalweges durch die Verabreichung eines antagonistischen 
Antikörpers in einem genetischen präklinischen Brustkrebs-Modell zu einer Reduktion 
in der Anzahl lymphatischer Endothelzellen (LECs) im Tumor, sowie umgekehrt auch 
die orthotope Inokulation einer stabilen Brustkrebszelllinie, die eine erhöhte Expression 
von VEGF-C aufwies, zu einer Expansion des lymphatischen vaskulären Endotheliums. 
 ? ??
Obwohl beide experimentelle Ansätze also zu einer Modulation der Tumor-assoziierten 
lymphatischen Vaskulatur führten, sowie entweder die Ausbreitung zu den lokalen LNs 
oder zu den Lungen beeinflussten, schienen diese Effekte in diesen bestimmten 
Tumormodelle eher nicht durch einer Interaktion zwischen den Lymphgefäßen und dem 
Tumor Mikroumfeld zustande gekommen zu sein. 
 
Schlüsselwörter: Brustkrebs, Metastase, Tumor Microenvironment, Lymphgefäße, 
VEGF-C, VEGFR-3  
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1.1 The lymphatic vascular system in breast cancer 
 
1.1.1 Structure and function of the lymphatic vascular system 
 
The circulatory system consists of the blood and lymphatic vascular system, which, 
although functionally related yet distinct, act in concert to maintain tissue homeostasis. 
The blood circulation, a closed system featuring the heart as a central pump, serves to 
provide sustenance through transportation of nutrients, hormones and cells to tissues, as 
well as removal of carbon dioxide and waste products. Although often considered the 
second vascular system, the lymphatic vascular system fulfills vital functions in tissue 
fluid homeostasis and absorption of dietary fats and fat-soluble vitamins in the intestine 
that complement the actions of the blood vascular system (Tammela and Alitalo, 2010). 
Furthermore, as a significant component of the immune system, lymphatic vessels 
mediate immune surveillance by providing a conduit system for the transport of antigens 
and antigen-presenting cells (APCs) from the periphery to the draining lymph node 
(LN), where subsequent adaptive immune responses are mounted (Tammela and Alitalo, 
2010). Moreover, more recent research has also demonstrated an important role of 
lymphatic vessels in the maintenance of peripheral tolerance (Swartz, 2014). 
Correspondingly, dysfunctional lymphatic vessels can give rise to pathological conditions 
with significant morbidity, such as chronic edema, obesity and impaired immune 
responses. 
Lymphatic vessels are commonly found in most vascularized tissues, with the exception 
of the bone marrow and certain avascular tissues such as the epidermis, hair and nails, 
although the density of the lymphatic plexus can vary greatly between the different 
organs (Swartz and Skobe, 2001). In general, tissues with frequent exposure to foreign 
antigens, such as the skin, lungs and gastrointestinal tract, are particularly rich in 
lymphatic vessels (Tammela and Alitalo, 2010). Interestingly, despite the fact that the 
central nervous system was previously believed to be devoid of lymphatic vasculature, 
the presence of functional lymphatic vessels was recently discovered in the brain 
(Louveau et al., 2015). 
Excess protein-rich interstitial fluid and cells of the immune system enter the lymphatic 
vascular system through blind-ended initial lymphatic capillaries, which constitute the 
absorptive part of the lymphatic vascular network in the periphery, and are collectively 
designated as lymph once inside (Alitalo et al., 2005). Initial lymphatic vessels converge 
into larger pre-collecting, and subsequently collecting lymphatic vessels, which are 
interspersed by one or more LNs that perform a sieving function, ultimately connecting 
to the thoracic duct, from which the fluid is returned to the blood circulation via the 
subclavian vein (Alitalo et al., 2005). In contrast to the blood vascular system, the 
lymphatic vascular system thus represents an open system, in which transport of protein-
rich fluid and cells occurs solely unidirectional.  
The structure of the lymphatic vascular system is optimally adapted to its physiological 
functions. Initial lymphatic vessels are thin-walled vessels of 30-80 μm in diameter, and 
consist of a single layer of lymphatic endothelial cells (LECs), which are surrounded by a 
thin layer of fenestrated basement membrane, but not covered by pericytes or smooth 
muscle cells, thus rendering these vessels highly permeable for the uptake of interstitial 
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fluid and cells (Alitalo et al., 2005). LECs lining the initial lymphatic vessels display a 
characteristic oak-leaf shape, and partially overlapping flaps of neighboring LECs are 
interconnected by discontinuous ‘button-like’ junctions, which create primary valve 
structures in the endothelium that are indispensable for the formation of lymph and 
facilitate the entry of cells into lymphatic vessels (Baluk et al., 2007). Finally, thin 
anchoring filaments consisting of fibrillin and emilin-1 connect the LECs of initial 
capillaries to the extracellular matrix (ECM), where they also regulate the entry of lymph 
(Tammela and Alitalo, 2010). In contrast to initial lymphatic capillaries, however, pre-
collector and collector vessels are surrounded by a basement membrane and show an 
increased coverage by smooth muscle cells. LECs of collecting lymphatic vessels are 
connected by zipper-like junctions, which prevent leakage of its contents into the 
extracellular space (Baluk et al., 2007). Finally, collecting vessels typically contain valves, 
which prevent retrograde flow of lymph to the periphery. The vessel segment between 
two valves is commonly referred to as the lymphangion, and represents the primary 
pumping unit of the lymphatic vascular system (Padera et al., 2016).  
The development of the lymphatic vascular system occurs principally during gestation, 
and once formed, lymphatic vessels are largely quiescent in the adult (Coso et al., 2014).  
With the notable exception of postnatal mammary gland remodeling, lymphangiogenesis, 
or the growth of new lymphatic vessels from pre-existing ones, is thus a phenomenon 
that is mostly associated with pathological conditions in the adult, such as inflammation 
(both acute and chronic), wound healing and tumor metastasis (Betterman et al., 2012; 
Tammela and Alitalo, 2010).  
 
 
1.1.2 Clinical manifestations of breast cancer 
 
Breast cancer is the most common cancer in women worldwide, with an estimated 1.7 
million newly diagnosed cases in 2012, corresponding to 25% of all new cases of cancer 
in women (WHO GLOBOCAN 2012, Global Cancer Facts and Figures, 3rd edition). 
Notwithstanding the notion that cancer is generally viewed as a disease of the western 
world, more than 50% of new breast cancer cases occur in developing countries. 
Nevertheless, as the developing world includes the majority of the world population, 
breast cancer incidence varies greatly worldwide as a result, being lowest in economically 
developing and highest in developed countries, respectively. Even so, despite its low 
incidence in developing countries, breast cancer is associated with high mortality in these 
geographical locations. Indeed, with an estimated 522'000 deaths in 2012, breast cancer 
is also the leading cause of mortality in women worldwide, accounting for nearly 15% of 
cancer-related deaths in women (WHO GLOBOCAN 2012, Global Cancer Facts and 
Figures, 3rd edition). Up to present date, the exact causes of breast cancer are not known, 
but important risk factors for development of the disease include family history, i.e. 
germ line mutations in BRCA1 or BRCA2, reproductive history, particularly increased 
exposure to estrogen due to early menarche or late onset of menopause, or advanced-age 
pregnancy, and lifestyle factors, such as diet, alcohol intake and lack of exercise. 
Although typically considered as one disease, breast cancer is in fact a complex and 
heterogeneous disease, which can manifest itself in many different forms and result in at 
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least as many different outcomes. In the clinic, breast cancers are primarily distinguished 
based on the anatomical location where the disease first emerges. Amongst these 
histological subtypes, invasive ductal carcinoma, which arises in the epithelial cells lining 
the milk ducts, is by far the most common and constitutes approximately 80% of all 
breast cancers, followed by invasive lobular carcinoma, which originates in the milk-
producing lobules and constitutes another 10-15% of all breast cancers (Cancer Facts 
and Figures, 2015; Reed et al., 2015). The remaining 5-10% of diagnosed breast cancers 
comprises relatively rare types of breast cancer, including sarcomas of the connective 
tissue. 
In addition to a distinction based on the histological features of the tumor, extensive 
gene expression profiling recently classified ductal carcinomas of the breast into four 
molecular subtypes that were observed to correlate with clinical outcome, further adding 
to the heterogeneity of the disease (Perou et al., 2000; Sørlie et al., 2001; Koboldt et al., 
2012). These so-called 'intrinsic subtypes' of breast cancer include estrogen receptor 
(ER)+ and/or progesterone receptor (PR)+ luminal tumors, which can be further divided 
into luminal A and luminal B subtypes, respectively, as well as HER2-enriched and basal-
like tumors as discernible disease entities. Accordingly, the improved taxonomy of ductal 
carcinomas not only confirms previous observations that hormone receptor-positive and 
HER2-amplified tumors represent distinct cancers that display different behavior in the 
clinic, but also provides an improved organization of the remaining tumors that neither 
express hormone receptors nor HER2, often referred to as triple-negative breast cancers 
(TNBCs), as these were observed to constitute a separate group. Interestingly, similar 
gene expression profiling studies were recently performed for lobular carcinomas of the 
breast, which, among other findings, confirmed loss of E-Cadherin expression as one of 
the main features of these tumors (Ciriello et al., 2015). 
Among ductal carcinomas of the breast, ER+ luminal tumors are distinguished based on 
expression of a luminal signature, which includes expression of cytokeratins 8 and 18, 
which are specifically expressed by the luminal epithelium, as well as ER, PR, and ER-
regulated genes, including ESR1, GATA3, FOXA1 and XBP1 (Koboldt et al., 2012). 
Although the luminal subtype comprises two distinct groups, luminal A and luminal B, 
which amount to 40% and 20% of all ductal carcinomas, respectively, these tumors can 
be difficult to distinguish in the clinic, as many features that define this subtype are 
shared among both groups of tumors. In general, luminal tumors have a relatively 
favorable prognosis, with luminal A cancers being associated with the highest overall and 
disease-free survival (OS and DFS, respectively) (Sørlie et al., 2001). As such, luminal A 
tumors are often low-grade, show low levels of proliferation, and mostly retain the 
activity of tumor suppressors TP53 and RB1, whereas luminal B tumors, on the other 
hand, show higher levels of proliferation, and more frequent mutations in TP53, 
correlating with their overall better and worse disease outcome, respectively. 
Tumors of the HER2-enriched subtype comprise 15-20% of all ductal carcinomas, and 
are most clearly distinguished based on expression of the HER2-cluster, which includes 
amplification of the HER2 gene, and genes that are located in close proximity to HER2 
in the genome, such as GRB7 (Koboldt et al., 2012). In contrast to luminal tumors, 
tumors of the HER2-enriched subtype are typically associated with a worse prognosis, 
and as such are often high-grade and highly proliferative (Sørlie et al., 2001). 
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Interestingly, only approximately 50% of HER2+ tumors are allocated to the HER2-
enriched subtype when based on gene expression data alone, with the remaining tumors 
typically being observed among the luminal B tumors, suggesting that the clinical 
behavior of these tumors cannot be predicted solely upon histological examination of 
HER2 expression. 
Finally, the fourth group portrays basal-like tumors, which constitute approximately 15% 
of all ductal carcinomas. Basal-like tumors are mainly distinguished based on expression 
of the basal cluster, which includes cytokeratins 5, 6, 14 and 17 that are specific for 
myoepithelial cells of the milk duct (Koboldt et al., 2012). As these tumors are mostly 
negative for ER, PR and HER2, basal-like tumors are often referred to as triple-negative; 
however, only 75% percent of triple-negative tumors are contained within this group. 
Tumors of the basal-like subtype generally are associated with the worst prognosis, as 
these tumors show high expression of the proliferation cluster, as well as the highest 
frequency of TP53 mutations and loss of RB1 (Sørlie et al., 2001). An intriguing finding 
among tumors of this subtype is the notion that germ line mutations in BRCA1 were 
almost exclusively found to lead to the formation of basal-like ductal carcinoma of the 
breast. 
 
 
1.1.3 Lymphatic metastasis in breast cancer 
 
Although the different clinical manifestations described in paragraph 1.1.2 are associated 
with different clinical outcomes, metastatic disease is the leading cause of death in 
patients diagnosed with breast cancer (Fidler, 2003). The circulatory system represents 
the primary route of metastatic dissemination of malignant tumor cells to distant organs, 
and the relative contributions of hematogenous and lymphogenous spread, respectively, 
depend largely on the origin of the primary tumor. Epithelial tumors, most notably 
breast and skin cancers, are known to preferentially disseminate through the lymphatic 
vascular system (Ran et al., 2010). Indeed, clinical data has demonstrated that, although 
blood vessel and lymphatic vessel invasion (in the following abbreviated as BVI and 
LVI, respectively) both occur in surgical specimens of breast cancer, tumor cells 
preferentially invade lymphatic vessels (van den Eynden et al., 2006). Moreover, LVI has 
also been found to correlate with metastatic dissemination of the primary tumor to the 
tumor-draining LN, as well as worse disease outcome (van den Eynden et al., 2006; 
Schoppmann et al., 2004). Interestingly, the tumor-draining LN has since long been 
observed to be the initial site of metastasis in patients diagnosed with breast cancer, and 
the presence of tumor cells in sentinel or distant nodes is a major prognostic factor for 
survival, independent of size or histological grade of the primary tumor, thus illustrating 
the importance of lymphatic vessels for metastatic dissemination of breast cancer 
(Tuttle, 2004).  
Invasive tumors may enter the lymphatic vasculature either by engaging pre-existing 
vessels, or by actively driving lymphangiogenesis in their microenvironment. Although 
lymphangiogenesis is thought to expedite metastatic dissemination of the primary tumor, 
whether or not tumors induce the formation of new lymphatic vessels has been a matter 
of intense dispute, mainly due to limited detection of actively proliferating lymphatic 
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endothelium within the tumor (Williams et al., 2003). Furthermore, intratumoral 
lymphatic vessels are often observed to be collapsed and non-functional (Padera, 2002). 
Consequently, the role of tumor-associated lymphatic vessels in metastatic dissemination 
of the incipient tumor has largely been considered passive by solely providing an escape 
route for invasive tumor cells to the tumor-draining LN. However, more recent research 
shows that tumors actively induce remodeling of the lymphatic vasculature, both at the 
level of the primary tumor and beyond (Stacker et al., 2014). Indeed, despite the initially 
presumed absence of lymphangiogenesis within the tumor, more detailed analysis 
demonstrated frequent lymphatic hyperplasia in the tumor periphery in clinical 
specimens of breast cancer, which was found to positively correlate with LN metastasis 
and decreased OS (Bono et al., 2004; Mohammed et al., 2009). 
In line with these observations, expression of vascular endothelial growth factor 
(VEGF)-C, the principal growth factor known to induce proliferation and expansion of 
the lymphatic vasculature through activation of VEGF receptor (VEGFR)-3 (a process 
that is outlined in more detail in section 1.1.4), in human ductal carcinomas of the breast 
has been shown to associate with increased LN metastasis, as well as reduced DFS and 
OS (Mohammed et al., 2007; Nakamura et al., 2005, 2003). Moreover, modulation of the 
VEGF-C/VEGF-D - VEGFR-3 signaling axis in various experimental models of breast 
cancer has provided additional evidence for a causal link between induction of 
lymphangiogenesis and tumor metastasis, as enhanced expression of VEGF-C or 
VEGF-D resulted in lymphatic hyperplasia in and around the tumor, as well as an 
increased incidence of regional and distant metastasis (Skobe et al., 2001a; Karpanen et 
al., 2001; Mattila et al., 2002; Stacker et al., 2001). Conversely, inhibition of VEGFR-3-
mediated activation of the lymphatic endothelium led to a reduction in lymphatic density 
in the tumor, and also reduced metastatic dissemination of the primary tumor to the LN 
and lungs (Roberts, 2006).  
Expression of VEGF-C, however, may also promote metastasis by inducing lymphatic 
remodeling well beyond the initial lymphatic vessels associated with the primary tumor, 
as enhanced expression of VEGF-C in different experimental models also induced 
expansion of both afferent and efferent collecting lymphatic vessels, which transport 
lymph towards and away from the tumor-draining LN, respectively (He et al., 2005; 
Gogineni et al., 2013). Furthermore, VEGF-C-induced expansion of the lymphatic 
endothelium, as well as other changes in the tumor-draining LN that are inferred by the 
tumor prior to the arrival of disseminated tumor cells, may yield a more hospitable 
environment for metastatic lesions, often referred to as the lymphvascular niche 
(Hirakawa, 2009; Hirakawa et al., 2006; Qian et al., 2006). Notably, lymphangiogenesis in 
the sentinel LN was found to associate with metastasis to the axillary LN in patients 
diagnosed with breast cancer, suggesting that expansion of the lymphatic vascular 
network in the tumor-draining LN may indeed promote further spread of disseminated 
tumor cells (van den Eynden et al., 2007). Collectively, these observations thus underline 
the importance of the lymphatic vascular system in metastatic dissemination of invasive 
carcinomas of the breast, and suggest that therapeutic targeting of tumor-associated 
lymphatic vessels may prevent the spread of the primary tumor to the tumor-draining 
LN and possibly beyond. 
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1.1.4 Molecular regulation of lymphangiogenesis 
 
The delicate balance between the formation and maintenance of the blood and 
lymphatic vasculature requires precise control and is in large part mediated through 
complex signaling pathways that are induced by vascular endothelial growth factors 
(VEGFs) (Simons et al., 2016). The most important and widely studied modulators of 
lymphangiogenesis to date are VEGF-C and VEGF-D, respectively, which upon binding 
to their cognate receptor VEGFR-3, promote survival, proliferation and migration of 
LECs (Joukov et al., 1996; Achen et al., 1998; Mäkinen et al., 2001). Moreover, VEGF-C 
and the structurally related VEGF-D potently increase lymphatic vessel density and 
diameter in both experimental models and cancer (Jeltsch, 1997; Skobe et al., 2001a; 
Stacker et al., 2001). However, in contrast to VEGF-C, VEGF-D seems to function 
mainly postnatally, as VEGF-D expression is dispensable for development of the 
lymphatic system (Karkkainen et al., 2004; Baldwin et al., 2005). 
Structurally, VEGFR-3 consists of an extracellular domain comprising seven 
immunoglobulin (Ig)-like domains, a transmembrane domain and an intracellular 
tyrosine kinase domain, which becomes autophosphorylated upon binding of VEGF-C 
or VEGF-D (Joukov et al., 1996; Achen et al., 1998). Activation of the receptor tyrosine 
kinase VEGFR-3 by its ligands induces various downstream signaling pathways, 
including protein kinase C (PKC)-mediated stimulation of ERK1/ERK2, or induction 
of AKT via phosphatidylinositide 3-kinase (PI3K) through the recruitment of adapter 
proteins, which mandate the subsequent biological response of the lymphatic vascular 
endothelium (Mäkinen et al., 2001; Deng et al., 2015). Furthermore, proteolytic 
processing of both VEGF-C and VEGF-D also generates shorter isoforms with an 
increased affinity for VEGFR-2, which, in contrast to VEGFR-3, is predominantly 
expressed on blood endothelial cells (BECs) and is known to be a potent mediator of 
angiogenesis (Joukov et al., 1997; Stacker et al., 1999). However, activation of VEGFR-2 
by its ligand VEGF-A, and to a lesser extent through VEGF-C, constitutes the principal 
axis for the induction of blood vessel growth (Simons et al., 2016). Nonetheless, the 
common development and the close resemblance of the blood and lymphatic vascular 
systems imply that some redundancy in the molecular regulation of angiogenesis and 
lymphangiogenesis must exist. Indeed, more recently, VEGF-A was also discovered to 
possess lymphangiogenesis-inducing activity, both in the context of chronic 
inflammation, as well as in cancer (Nagy et al., 2002; Halin et al., 2007; Hirakawa et al., 
2005). However, rather than induction of sprouting, VEGF-A was observed to rather 
increase lymphatic vessel diameter, suggesting that the various growth factors of the 
VEGF family may exert different effects on the blood and lymphatic vascular 
endothelium, respectively (Wirzenius et al., 2007). 
Moreover, induction of angiogenesis and lymphangiogenesis may be additionally 
regulated upon the recruitment of different co-receptors, such as neuropilins, further 
adding to the complexity in the molecular regulation of the sustenance of vascular 
endothelium (Tammela and Alitalo, 2010). Neuropilin (Nrp)-2, for example, is expressed 
on the lymphatic endothelium, and can act as a co-receptor for VEGFR-3 ensuing 
VEGF-C-induced activation of the lymphatic vasculature. Notably, inhibition of Nrp-2 
with an antagonistic antibody inhibited tumor-associated lymphangiogenesis and reduced 
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regional and distant metastasis, demonstrating its importance in VEGFR-3-mediated 
activation of the lymphatic vascular endothelium (Caunt et al., 2008). 
Following the discovery of VEGF-VEGFR signaling, the TIE receptors and their 
angiopoietin (Ang) ligands have been identified as the second vascular tissue-specific 
receptor tyrosine kinase system that regulates vascular morphogenesis and homeostasis 
(Augustin et al., 2009). In contrast to the VEGF-VEGFR axis, Ang-TIE signaling is 
implicated in the control of vessel quiescence. However, as most research concerning 
the Ang-TIE axis has focused on delineating the role of the TIE receptors and their 
ligands in the regulation of developmental and tumor-associated angiogenesis, its role in 
the regulation of the lymphatic vascular system remains elusive. Nevertheless, Ang-1 has 
been shown to promote the formation and sprouting of lymphatic vessels, while Ang-2 
is required for postnatal lymphatic patterning (Tammela, 2005; Gale et al., 2002). 
However, much work remains to be done to elucidate the role of Ang-TIE signaling in 
lymphatic vessel formation and maturation.  
In addition to VEGF and angiopoietin signaling, other growth factors, such as platelet-
derived growth factor (PDGF; (Cao et al., 2004) and Ephrin-B2 (Mäkinen et al., 2005), 
as well as pro-inflammatory cytokines (Ristimaki, 1998), have also been shown to induce 
lymphangiogenesis, but these effects may be secondary to the induction of VEGF-C and 
VEGF-D expression in different stromal cells, such as inflammatory cells (Schoppmann 
et al., 2002). Finally, among its many previously described roles, transforming growth 
factor (TGF)-β1 has also been described as a negative regulator of lymphangiogenesis 
(Oka et al., 2008). 
 
 
1.1.5 Interactions between lymphatic vessels and tumor cells 
 
Although the architecture of lymphatic vessels, dictated by their function in fluid 
absorption and immune cell trafficking, accordingly renders these vessels highly suitable 
as a highway for metastatic dissemination of tumor cells, not much is known about how 
tumor-induced remodeling of the lymphatic vasculature may promote the spread of the 
primary tumor. In line with the notion that lymphatic vessels were initially considered as 
passive structures that merely provide a conduit for tumor cells, VEGF-C-mediated 
expansion of the lymphatic vasculature also enhances lymphatic drainage, which in turn 
increases the transport of invasive tumor cells from the primary tumor to the tumor-
draining LN (Pathak, 2006; Hoshida, 2006; Ruddell et al., 2008). Nevertheless, 
expression of VEGF-C in carcinomas of the breast may induce other changes in the 
lymphatic vascular endothelium as well, and thus actively favoring lymphogenous 
metastasis of the primary tumor (Swartz and Lund, 2012).  
First and foremost, VEGF-C expression by breast cancer cells enhances tumor cell 
chemoinvasion towards lymphatic vessels via both autocrine and paracrine signaling. 
Notably, VEGF-C-mediated activation of the lymphatic endothelium enhances the 
expression of CCL-21, which in turn attracts CCR-7+ tumor cells, reminiscent of 
dendritic cell (DC) trafficking to the draining LN in inflammation (Issa et al., 2009). 
Moreover, increased interstitial flow that is due to an expansion of the tumor-associated 
lymphatic vasculature may also enhance CCR-7+ tumor cell invasion towards lymphatic 
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vessels via autologous chemotaxis by generating small, localized gradients of chemotactic 
factors, such as CCL-21, that direct their migration in the direction of the flow (Shields 
et al., 2007). Importantly, increased interstitial flow in the tumor margin may directly 
contribute to lymphangiogenesis in the tumor microenvironment, as interstitial flow was 
shown to act as a morphoregulator of lymphatic vessel formation, thus reinforcing the 
effects of VEGF-C-induced lymphangiogenesis (Boardman, 2003; Helm et al., 2005).  
However, active remodeling of lymphatic vessels in the tumor-draining LN by metastatic 
tumor cells may also contribute to further spread. For instance, LN lymphatic sinuses 
were recently discovered to control the entry of CCR-8+ tumor cells via secretion of 
CCL-1 (Das et al., 2013). Nevertheless, besides the interplay between the lymphatic 
vasculature and tumor cells, interactions between lymphatic vessels and the surrounding 
cells of the tumor microenvironment may additionally promote transition to malignancy 
and metastatic dissemination in breast cancer. 
 
 
1.2 The tumor microenvironment in breast cancer 
 
1.2.1 General concept of the tumor microenvironment 
 
Cancer is a disease with complexity beyond measure. For decades, cancer research has 
focused on the cancer cell itself, trying to understand the transformations leading to 
uncontrolled cell division and subsequent growth of tumor masses through identification 
of hitherto unknown dominant oncogenes or tumor suppressor genes. In 2000, 
Hanahan and Weinberg defined six intrinsic hallmarks of cancer that constitute an 
organizing principle for rationalizing the complexities of human cancers (Hanahan and 
Weinberg, 2000). However, this list is not exhausted as new emerging hallmarks and 
enabling capabilities continue to be discovered. Only recently, reprogramming energy 
metabolism and evading immune destruction were added to the list of core biological 
capabilities as emerging hallmarks that are integral to the development of cancer 
(Hanahan and Weinberg, 2011). Moreover, in recent years the notion that not only 
changes in tumor cells themselves, but also the surrounding stromal cells actively 
contribute to manifesting the disease has become more apparent, and the importance of 
the tumor microenvironment is now widely accepted (Hanahan and Coussens, 2012). 
Stromal cells promote cancer growth and metastasis via an intrinsicate cross-talk 
between the two compartments, and these interactions have also been suggested to lead 
to the co-evolution of tumor cells and their microenvironment as the disease progresses 
(Polyak et al., 2009). Notably, the tumor stroma can make up as much as 90% of the 
tumor mass, and the most important cellular constituents include cancer stem cells 
(CSCs), endothelial cells (ECs) that form the blood and lymphatic vasculature, 
respectively, pericytes, cancer-associated fibroblasts (CAFs) and infiltrating immune cells 
(ICs) (Hanahan and Weinberg, 2011). However, components of the biophysical 
microenvironment, such as increased interstitial flow and mechanical stress-induced 
changes, may play an equally important role in tumor growth and progression (Swartz 
and Lund, 2012). 
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1.2.2 Cancer-associated fibroblasts and tensional homeostasis 
 
Fibroblasts are the non-vascular, non-epithelial and non-inflammatory cells of the 
connective tissue and constitute its prevailing cellular component (Kalluri and Zeisberg, 
2006). Among the many functions of these connective tissue cells, their main function is 
to provide structural integrity and support to the tissue through deposition of the 
various components of the extracellular matrix (ECM), which include constituents of the 
fibrillar ECM, such as type I, III or V collagen and fibronectin, as well as type IV 
collagen and laminin, which are indispensable for the formation of the basement 
membrane (Kalluri and Zeisberg, 2006). As such, fibroblasts are instrumental in 
maintaining tissue homeostasis, but also play a prominent role in the regulation of 
wound healing and inflammation (Tomasek et al., 2002; Schäfer and Werner, 2008).  
The term fibroblast, however, represents an expansive designation for various cells of 
the connective tissue that exhibit considerable heterogeneity, as fibroblasts from 
different anatomical locations display distinct functional behavior (Chang et al., 2002). 
Moreover, a lack of general fibroblast-specific markers further complicates investigation 
of the disparate biological roles of these stromal cells, and at present, fibroblast-specific 
protein 1 (FSP-1) seems to be the most specific marker for the detection of fibroblasts 
in different tissues (Strutz et al., 1995). 
Fibroblasts in the tumor stroma, collectively termed cancer-associated fibroblasts 
(CAFs), acquire an activated phenotype that is similar to the phenotype of 
myofibroblasts that is observed during wound healing and that is identified by the 
expression of α-smooth muscle actin (α-SMA) (Skalli et al., 1986; Chang et al., 2004). In 
fact, already as early as 1986, Dvorak described similarities between the composition of 
the tumor stroma and the granulation tissue of healing wounds, postulating that 'tumors 
are wounds that do not heal' (Dvorak, 1986). Notably, early developing tumors of the 
breast, i.e. carcinomas in situ, are typically associated with a similar stroma, which is 
frequently referred to as reactive stroma, and characterized by enhanced fibroblast 
proliferation, as well as increased deposition of type I collagen and fibrin, whereas 
continued activation of fibroblasts during cancer progression induces further deposition, 
as well as changes in the composition of the ECM, which is then designated as 
desmoplastic stroma (Rønnov-Jessen et al., 1996).  
TGF-β1 is an important activator of fibroblast activation during the wound healing 
response, but it can also induce the phenotypic features of CAFs (Desmoulière et al., 
1993; Vaughan et al., 2000). Breast cancers in particular express high levels of TGF-β1, 
preferably at the invasive edge of the tumor (Gorsch et al., 1992). However, altered 
mechanical properties of the developing tumor, such as an aberrant fluid balance as a 
result of the expansion of tumor-associated blood and lymphatic vessels, may also 
directly influence the differentiation of fibroblasts in the tumor, as increased levels of 
interstitial flow can also induce fibroblast-to-myofibroblast differentiation via autocrine 
production of TGF-β1 by fibroblasts, resulting in matrix alignment and contraction (Ng 
et al., 2005). Activated myofibroblasts, in turn, also produce TGF-β1, thus further 
enforcing the previously initiated contraction of the matrix. Furthermore, in addition to 
inducing myofibroblast differentiation, flow can also directly activate latent stores of 
TGF-β1 that are stored in the ECM (Wipff et al., 2007). Interestingly, mechanical 
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tension maintains the myofibroblast phenotype, thus suggesting that upon initial 
activation of fibroblasts, which induces the formation of a reactive stroma, CAFs may 
continue to contribute to cancer progression and metastasis by promoting a positive 
feedback loop between sustained fibroblast activation and ensuing deregulated tensional 
homeostasis.  
CAFs may endorse tumor initiation, growth, invasion and metastasis via a variety of 
mechanisms. Indeed, besides providing a structural scaffold, fibroblasts may also 
contribute to tissue homeostasis via secretion of growth factors and epithelial-
mesenchymal interactions. Notably, these interactions with the adjacent epithelium are 
fundamental in the development and differentiation of the mammary gland (Wiseman, 
2002; Kuperwasser et al., 2004). However, once fibroblasts become activated in the 
vicinity of developing neoplastic lesions, these stromal cells may directly promote tumor 
growth upon release of various growth factors, such as epidermal growth factor (EGF), 
hepatocyte growth factor (HGF), insulin-like growth factor (IGF), platelet-derived 
growth factor (PDGF) and TGF-β1 that act in a paracrine manner to support the 
transformed epithelium (Bhowmick et al., 2004).  
Moreover, altered tensional homeostasis as a result of enhanced ECM deposition by 
activated CAFs may also contribute substantially to tumor growth and progression.  
Although the reactive stroma is primarily characterized by increased amounts of fibrillar 
collagens, of which type I collagen is the most abundant, as well as fibronectins 
containing the extra domain (ED)-A splice variant, proteoglycans and 
glycosaminoglycans, formation of the desmoplastic stroma also induces de novo 
expression of various ECM constituents, such as tenascin-C, which is absent in the 
mammary gland under physiological conditions (Rønnov-Jessen et al., 1996). 
Furthermore, in addition to increased ECM deposition, augmented expression of lysyl 
oxidase (LOX), an enzyme that covalently and irreversibly cross-links collagen, promotes 
desmoplastic tissue formation and is correlated with stromal stiffening and tumor 
progression (Levental et al., 2009). Accordingly, in breast cancer, increased 
mammographic density is an important prognostic factor that is routinely used in the 
clinic (Butcher et al., 2009). Interestingly, increased ECM rigidity was demonstrated to 
directly promote malignant transformation of epithelial cells (Paszek et al., 2005). 
Finally, altered ECM turnover also encompasses altered expression of matrix 
metalloproteases (MMPs) and tissue inhibitors of metalloproteases (TIMPs). One 
mechanism how increased MMP secretion by fibroblasts increases tumor invasion is by 
creating channels in the matrix, facilitating tumor cell invasion and metastatic 
dissemination (Shieh et al., 2011). Alternatively, MMPs may also liberate matrix-bound 
growth factors, such as VEGF-A, that subsequently stimulate tumor growth through 
induction of angiogenesis (Bergers et al., 2000). VEGF-A also induces vascular 
permeability, leading to the extravasation of plasma and plasma proteins into the tumor, 
which may additionally induce the infiltration of macrophages that may further 
contribute to the formation of desmoplastic stroma as well as alter host anti-tumor 
immunity. However, consistent with their role in inflammation, CAFs may also directly 
coordinate tumor-induced inflammation through secretion of pro-inflammatory 
cytokines (Erez et al., 2010). 
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1.2.3 Innate and adaptive immune responses in cancer 
 
Although the link between cancer and inflammation was established more than a century 
ago, the seemingly paradoxical role of the immune system in enabling or eradicating the 
growing tumor mass, however, remains a matter of controversial debate. Most evidence 
for the link between cancer and inflammation comes from epidemiological studies, 
which have shown that chronic inflammation, whether caused by infection or 
autoimmune disease, or idiopathic, predisposes for a variety of cancers (de Visser et al., 
2006; Mantovani et al., 2008). Moreover, even tumors where no causal relationship 
between inflammation and cancer development has been established, such as breast 
cancer, are characterized by 'smoldering' inflammation (Balkwill et al., 2005). In fact, the 
microenvironment of most tumors, if not all, contains an inflammatory component of 
varying size, composition and distribution that contributes to tumor growth, both 
directly via growth factors and indirectly by inducing angiogenesis, and metastasis.  
The immune system consists of two compartments that are distinguished based on 
antigen specificity and the kinetics of activation: innate and adaptive immunity, 
respectively. Inflammation is a mechanism of innate immunity and represents the first 
line of defense that is activated to restore the balance when tissue homeostasis is 
perturbed (de Visser et al., 2006). Normal inflammation is self-limiting and characterized 
by a plasticity that is due to pro- and anti-inflammatory cytokines that are sequentially 
induced, whereas chronic inflammation seems to result from the persistence of 
inflammation-inducing factors, or the failure of mechanisms that normally resolve 
inflammation (Coussens and Werb, 2002). Cancer-related inflammation is promoted, in 
part, by cytokines that are secreted either directly by the tumor cells, or by the tumor-
infiltrating immune cells, and a pro-inflammatory signature of TNF-α, IL-1β and IL-6 in 
particular seems to be associated with a tumor immune microenvironment that favors 
tumor growth (Germano et al., 2008). Alternatively, the innate cells of the immune 
infiltrate in developing tumors can also contribute to cancer-related inflammation by the 
production of cytotoxic mediators and matrix remodeling proteases.  
Nevertheless, the concept of immune surveillance also implicates a role for adaptive 
immune responses in tumor development. High mutation rates drive the expression of 
immunogenic tumor-specific antigens, and, consequently, adaptive immune responses 
against the growing tumor can be mounted (Dunn et al., 2004). Nevertheless, nascent 
tumors can efficiently escape immune destruction through immunoediting and immune 
subversion via direct cell-cell contacts or production of cytokines that suppress 
immunity, such as TGF-β1, resulting in immunological tolerance (Zitvogel et al., 2006). 
Furthermore, developing tumors have also been observed to promote an 
immunosuppressive environment in the tumor-draining LN. Interestingly VEGF-C-
induced remodeling of the tumor-associated lymphatic vasculature in the draining LN 
can also directly suppress the anti-tumor response, thereby further promoting tolerance 
to the tumor (Lund et al., 2012). Evading immune destruction therefore, is an integral 
component of tumors and has hence been proposed as an emerging seventh hallmark of 
cancer (Hanahan and Weinberg, 2011; Dunn et al., 2004). 
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1.2.4 Tumor-associated macrophages 
 
Macrophages are marked by their high capacity to phagocytose cellular debris, dead cells 
and antigens, which is integral in their function in maintaining tissue homeostasis, 
wound healing and inflammation (Murray and Wynn, 2011). As such, macrophages are 
the primary danger sensors of the host and form an essential part of the first line of 
defense against invading pathogens. However, macrophages also fulfill trophic roles in 
organ development, tissue homeostasis and wound healing via their secretion of growth 
factors, cytokines, and proteolytic enzymes, as well as their expression of scavenger 
receptors (Murray and Wynn, 2011). The ability of macrophages to respond to 
profoundly distinct environmental stimuli is reflected in their inherent plasticity that 
enables them to adopt different functional states. The M1/M2 paradigm is the result of 
an attempt to classify the variety of functional states that macrophages can assume, and 
is based on the TH1-TH2 nomenclature for polarized T cell responses (Sica and 
Mantovani, 2012). M1, or 'classically' activated, macrophages are induced by interferon-γ 
(IFN-γ) priming and subsequent exposure to toll-like receptor (TLR) ligands, such as 
lipopolysaccharide (LPS) and are characterized by increased phagocytic capacity, 
expression of activation molecules CD80, CD86 and major histocompatibility (MHC) 
class II, and a pro-inflammatory cytokine signature. Furthermore, M1 macrophages 
produce large amounts of reactive oxygen and nitrogen species (ROS and RNS, 
respectively), increasing their ability to kill pathogens and cells (Biswas and Mantovani, 
2010). Conversely, M2 or 'alternatively' activated macrophages differentiate in response 
to IL-4 and IL-13 and play important trophic roles in tissue homeostasis and wound 
healing (Gordon and Martinez, 2010). M2 macrophages up-regulate expression of the 
mannose receptor (CD206), induce arginase-1 expression and are associated with an 
anti-inflammatory cytokine signature (Stein et al., 1992). However, alternative activation 
was soon to include all other macrophages than M1 and therefore the M1/M2 
classification represents an oversimplification of the large variety of macrophages 
polarization states observed in vivo. Instead, the M1 and M2 phenotype are more likely to 
represent two extremes of a continuum where the prevalence of intermediate 
phenotypes is skewed by microenvironmental cues (Sica and Mantovani, 2012). 
Tumor-associated macrophages (TAMs) make up a significant amount of the infiltrating 
immune cells in the tumor. Generally, a high density of TAMs has been found to 
correlate with poor prognosis in more than 80% of the studies published (Bingle et al., 
2002). In breast cancer, macrophage infiltration is associated with transition to 
malignancy and metastasis (Lin et al., 2001). Indeed, as macrophage polarization is highly 
context-dependent, this is a feature that can be readily exploited by tumors. Generally, 
TAMs are described to possess an 'M2-like' phenotype, but different TAM populations 
may co-exist in the same tumor depending on their localized microenvironment and on 
the tumor stage (Ruffell et al., 2012). The inflammatory response of macrophages is 
highly implicated in tumor initiation through the production of mutagenic ROS and 
RNS that can cause damage to the DNA of cells (Biswas and Mantovani, 2010). 
However, during tumor progression, tumors create a microenvironment that causes 
macrophages to suppress immune functions and adopt trophic roles found during 
development and repair instead (Condeelis and Pollard, 2006). As such, macrophages 
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have been shown to support tumor progression and metastasis by promoting 
angiogenesis, enhancing tumor cell invasion, intravasation into blood vessels and 
extravasation at the metastatic site (Qian and Pollard, 2010). Finally, TAMs may also 
promote tumor progression and metastasis by suppressing anti-tumor immune responses 
(Qian and Pollard, 2010). Accordingly, TAMs may contribute to an immune 
microenvironment that is supportive of tumor growth by altering the local cytokine 
milieu. Notably, TAMs constitute a prominent source of TGF-β1 in the tumor 
microenvironment, thereby exerting a suppressive effect on the various immune cells 
that are present in the tumor. However, excess amounts of TGF-β1 may also aid in the 
gradual progression from an 'M1-like' to an 'M2-like' phenotype of the TAMs within the 
tumor. Moreover, the transition from 'M1-like' to 'M2-like' is associated with decreased 
expression of pro-inflammatory cytokines, such as TNF-α and IL-12, and increased 
expression of IL-10 that may further aid in the induction of an overall 
immunosuppressive microenvironment (Noy and Pollard, 2014). Nevertheless, although 
macrophages may aid in actively subverting anti-tumor adaptive immune responses, 
polarized adaptive immune responses, in turn, may help to maintain a pro-tumor 'M2-
like' phenotype of TAMs, as was recently shown to be the case for IL-4-secreting CD4+ 
TH2 cells (DeNardo et al., 2009). 
 
 
1.2.5 Interactions between lymphatic vessels and stromal cells 
 
In addition to the different lymphangiogenic signals provided by the nascent tumor 
mass, various stromal cells may also promote the expansion of the lymphatic network in 
the tumor microenvironment. Among these, macrophages have been shown to induce 
lymphangiogenesis in a large variety of different cancers, including breast cancer 
(Schoppmann et al., 2006). Nevertheless, although the link between tumor-associated 
macrophages (TAMs) and tumor-associated lymphangiogenesis has previously been 
established, the exact nature of the contribution remains elusive. Even so, macrophages 
may contribute to lymphatic vessel growth via a multitude of mechanisms, such as 
production and secretion of vascular growth factors and cytokines, or physical contact 
which may distinctly regulate lymphangiogenesis both spatially and temporally 
depending on the context (Harvey and Gordon, 2012). Indeed, TAMs have been shown 
to be relevant, if not the main sources of the lymphangiogenic growth factors VEGF-C 
and -D in the tumor microenvironment (Schoppmann et al., 2002). Moreover, VEGF-C 
expressed by the tumor recruits VEGFR-3+ monocytes to the tumor where they 
differentiate into macrophages and switch on de novo synthesis of VEGF-C and -D, thus 
reinforcing the process of lymphangiogenesis initially induced by the developing tumor 
(Skobe et al., 2001b; Schoppmann et al., 2002). Additionally, VEGF-A may also directly 
recruit VEGF-C and -D-expressing macrophages into the tumor, thus providing another 
possibility for these cells to support tumor-associated lymphangiogenesis (Cursiefen et 
al., 2004). Importantly, the tumor immune microenvironment may also indirectly 
contribute to expansion of the lymphatic vasculature as pro-inflammatory cytokines, 
such as IL-1β and TNF-α, may also induce VEGF-C and -D expression in TAMs 
(Watari et al., 2008).  
 ? ???
Alternatively, a subpopulation of macrophages that express the lymphatic marker lyve-1, 
which is often observed in close association with the lymphatic vasculature, has also 
been reported to contribute to lymphangiogenesis via transdifferentiation into lymphatic 
progenitor cells (Maruyama et al., 2005; Schledzewski et al., 2006; Zumsteg et al., 2009). 
However, lineage-tracing experiments have provided strong evidence for the exclusion 
of cells of the myeloid lineage as a source of such lymphatic progenitor cells (Gordon et 
al., 2010). Instead, lyve-1+ macrophages that selectively interact with lymphatic vessels 
during developmental and tumor-associated lymphangiogenesis were shown to have a 
gene signature that closely resembles that of Tie2-expressing macrophages (TEMs), a 
distinct subpopulation of macrophages with enhanced pro-angiogenic activity (De Palma 
et al., 2005; Gordon et al., 2010). Interestingly, TEMs express higher levels of lyve-1 
than their Tie-2 negative counterparts, and it is thus tempting to speculate that a similar 
subset of macrophages may be involved in the regulation of tumor-associated 
lymphangiogenesis (Pucci et al., 2009). Indeed, such a subset of TEMs found in patients 
diagnosed with breast cancer was recently observed to possess pro-lymphangiogenic 
activity (Bron et al., 2016). Nevertheless, the exact roles of macrophages in modulating 
expansion of the lymphatic network are currently poorly understood and many questions 
still remain to be answered. 
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2.1 General aims 
 
Although the relevance of the lymphatic vascular system for metastatic dissemination of 
the primary tumor in patients diagnosed with breast cancer has been well established, 
less is known about how tumor-associated lymphatic vessels promote the spread of 
malignant tumor cells to regional LNs or distant organs. Whereas lymphatic vessels have 
traditionally been considered as passive conduits that solely mediate the transport of 
metastatic tumor cells, more recent research aimed at discerning the interactions 
between the developing tumor and its associated lymphatic vessels has revealed that the 
lymphatic vasculature actively promotes lymphogenous metastasis of invasive tumor 
cells. Of late, it has indeed become apparent that interactions between thwarted 
neoplastic cells and both tissue-resident, as well as recruited ancillary cells, which 
together constitute the tumor microenvironment, substantially contribute to tumor 
growth, progression and subsequent metastasis (Hanahan and Weinberg, 2000). 
However, collaborative interactions among the different stromal cells of the tumor 
microenvironment themselves may also synergize to promote metastatic dissemination 
of the primary tumor as well, and thus in the thesis work presented herein, I therefore 
aim to establish a link between previously unrelated components of the tumor stroma, 
specifically tumor-associated lymphatic vessels, tensional homeostasis and anti-tumor 
immunity, to elucidate their concerted role in transition to malignancy and metastatic 
dissemination of breast cancer (Swartz and Lund, 2012). 
 
To this end, the first part of the current thesis will elaborate on the experimental 
modulation of lymphatic vessels in the context of breast cancer. As activation of the 
receptor tyrosine kinase VEGFR-3 by its ligands VEGF-C or VEGF-D constitutes the 
main axis known to induce lymphangiogenesis during development, but also in various 
pathological conditions in the adult, including cancer, the growth of lymphatic vessels is 
attuned upon manipulation of different components of the VEGF-C/VEGF-D - 
VEGFR-3 signaling axis in different experimental breast cancer models. The first 
approach, which is described in section 3.1, aims to restrict the growth of lymphatic 
vessels upon administration of an antagonistic antibody that specifically binds to and 
ablates VEGFR-3-mediated signaling in a relevant preclinical transgenic mouse model of 
breast cancer (Pytowski et al., 2005). Conversely, the second approach, which is 
described in section 3.2, aims to induce the growth of lymphatic vessels upon 
orthtotopic implantation of a murine breast cancer cell line that was transduced to stably 
over-express VEGF-C in the fat tissue surrounding the inguinal mammary gland. 
 
Subsequently, the second part of the current thesis will focus on dissecting the 
interactions between lymphatic vessels and the disparate stromal cells of the tumor 
microenvironment in the different experimental models of breast cancer that were 
employed in this thesis. Notably, as expansion of the lymphatic vasculature in 
developing tumors also enhances lymphatic drainage to the regional LN, increased 
interstitial flow at the tumor margin may alter tensional homeostasis within the tumor 
through local activation of TGF-β1, which in turns stimulates tissue-resident fibroblasts 
to induce the formation of a desmoplastic stroma. Furthermore, in light of the recently 
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described immunomodulatory roles of the lymphatic endothelium in cancer, direct 
interactions between lymphatic vessels and infiltrating immune cells may additionally 
induce an immunosuppressive environment that fosters tumor growth and progression 
(Swartz, 2014). Indeed, inflammation and lymphangiogenesis are two processes that are 
intimately linked, and, as important mediators of the innate immune response, 
macrophages have been implicated to contribute to lymphangiogenesis by secreting 
VEGF-C and VEGF-D in inflammatory settings. Interactions between lymphatic vessels 
and macrophages, however, may be reciprocal, and conversely, activated lymphatic 
vessels in the primary tumor may also shift the phenotype of infiltrating TAMs to 
support progression to malignancy and metastatic dissemination of invasive tumor cells. 
Finally, VEGF-C-induced remodeling of the tumor-associated lymphatic vasculature has 
also been shown to directly suppress the adaptive anti-tumor immune response, thereby 
promoting tolerance to the nascent tumor (Lund et al., 2012). Thus, taking these 
previous observations into consideration, section 3.3 will therefore focus on the 
presumed interactions between tumor-associated lymphatic vessels and the different 
components of the tumor microenvironment, i.e. tensional homeostasis, as well as the 
innate and adaptive immune responses to the developing tumor.  
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3.1 Characterization and modulation of tumor-associated lymphatic vessels in a 
genetically engineered mouse model of breast cancer 
 
3.1.1 Tumor growth and progression in the MMTV-PyMT model of breast cancer 
is accompanied by tumor-associated lymphangiogenesis and angiogenesis 
 
The mouse mammary tumor virus (MMTV)-polyoma middle T antigen (PyMT) model, 
in the following abbreviated as MMTV-PyMT, currently represents one of the most 
widely used preclinical transgenic mouse models of breast cancer, as tumor growth and 
progression in MMTV-PyMT+ transgenic animals is known to recapitulate human 
disease (Guy et al., 1992; Lin et al., 2003). The left panel in Fig. 1A shows a normal 
mammary gland in the inguinal fat pad in a wildtype (WT) littermate. In female MMTV-
PyMT+ transgenic mice, expression of the PyMT oncogene, which is under the control 
of the MMTV promoter and thus directed to the mammary epithelium, results in its 
transformation throughout the ductal tree, leading to the development of hyperplastic 
lesions at 6-7 weeks of age that resemble ductal carcinoma in situ in humans (Fig. 1A, 
middle). Hyperplastic lesions then gradually progress and give rise to an invasive 
carcinoma at 11-12 weeks of age (Fig. 1A, right) that eventually disseminates to form 
pulmonary metastases, with micrometastatic lesions present in 30% of the animals at this 
point in time (data not shown). Tumor growth and progression in our transgenic animals 
therefore follows the kinetics of this model as heretofore described (Lin et al., 2003). 
Although the onset of hyperplasia and subsequent development of invasive carcinoma 
has been outlined in detail, it is not known whether this process simultaneously 
coincides with the induction of tumor-associated lymphangiogenesis in this particular 
model. To assess its feasibility as a preclinical model in order to examine the importance 
of tumor-associated lymphangiogenesis for tumor progression and metastatic 
dissemination in the context of breast cancer, I set out to characterize the growth of 
tumor-associated lymphatic vessels in MMTV-PyMT+ transgenic animals. Analysis of 
expression levels of VEGF-C and VEGF-D, the principal growth factors known to 
induce proliferation and expansion of the lymphatic endothelium, demonstrated 
somewhat elevated levels of VEGF-C, but not of VEGF-D in developing tumors in the 
MMTV-PyMT mouse model of breast cancer, as compared to corresponding wildtype 
(WT) littermates, which further increase during progression towards invasive lesions, 
suggesting that these tumors actively induce remodeling of the lymphatic vasculature 
(Figs. 1B and C, respectively). Concurrently, the level of VEGF-A within the tumor was 
also found to be elevated in transgenic MMTV-PyMT+ animals, suggesting that these 
tumors also induce extensive angiogenesis (Fig. 1D). Expression of VEGF-C within the 
tumor correlates with an induction of tumor-associated lymphangiogenesis, as the 
number of CD31+gp38+ lymphatic endothelial cells (LECs) was observed to increase at 
the time of tumor onset, and continued to increase further during tumor progression as 
compared to WT tumor-free mice (Fig. 1E). Expansion of tumor-associated lymphatic 
vessels occurred at least partially at the level of initial lymphatics, as among the LEC 
population the number of lyve-1+ LECs was also increased (Fig. 1F). Finally, tumor 
growth and progression was also associated with induction of angiogenesis, as the 
number of CD31+gp38- blood endothelial cells (BECs) was increased in both 
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hyperplastic as well as invasive lesions (Fig. 1G). Taken together, these results indicate 
that development of hyperplastic lesions and their continuous progression towards an 
invasive carcinoma is accompanied by induction of both tumor-associated 
lymphangiogenesis, as well as angiogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Tumor growth and progression in the transgenic MMTV-PyMT model of breast cancer 
coincides with the growth of tumor-associated lymphatic vessels.  
A Depiction of a normal mammary gland in an age-matched WT littermate (left), a hyperplastic lesion at 
6-7 weeks of age (middle) and an invasive carcinoma at 11-12 weeks of age (right). H&E, magnification 
20x, scale bar 50 μm. B Immunoassay for growth factors of the VEGF family on whole tumor lysates 
shows an increase in VEGF-C, C but not VEGF-D expression, which was even strongly decreased in 
invasive tumors as compared to WT tumor-free mice. D VEGF-A expression levels, however, are elevated 
during tumor growth in transgenic MMTV-PyMT+ tumor-bearing mice as compared to WT littermate 
controls. E Increased expression of VEGF-C in hyperplastic lesions and invasive carcinoma correlates 
with the induction of tumor-associated lymphangiogenesis as the number of CD31+gp38+ LECs, as well 
as F the number of lyve-1+ LECs in within the total LEC population increase. G Concurrently with 
tumor-associated lymphangiogenesis, developing tumors also induce angiogenesis in their 
microenvironment for sustenance during tumor onset and progression. Plotted values represent mean ± 
SEM, statistical analysis by two-tailed unpaired Student's t- test. Experiments were performed twice 
(analysis of expression levels of angiogenic and lymphangiogenic growth factors by ELISA), and once 
(analysis of the number of LECs and BECs by flow cytometry) with n = 10 transgenic MMTV-PyMT+ 
animals and n = 6 FvB WT littermate controls per group, respectively. 
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3.1.2 Invasive mammary tumors in MMTV-PyMT+ transgenic mice infrequently 
induce the formation of metastatic lesions in the local tumor-draining LN 
 
Given the importance of tumor-associated lymphatic vessels for regional metastatic 
dissemination of the primary tumor to the tumor-draining lymph node (LN) in breast 
cancer, I next asked whether invasive lesions in MMTV-PyMT+ transgenic animals 
induced the formation of LN metastases (Ran et al., 2010; Skobe et al., 2001a). Routine 
pathology analysis of H&E-stained sections of the inguinal LN could not detect the 
presence of disseminated tumor cells, except in one case in which it was unclear whether 
the tumor cells had entered the tumor-draining LN upon spread via the tumor-
associated vasculature, or merely invaded the LN due to an expansion of the 
transformed epithelium in the adjacent inguinal fat pad (Fig. 2A, incidence 1/10 or 
10%). Furthermore, the tumor-draining LNs of MMTV-PyMT+ tumor-bearing mice 
were not enlarged compared to the LNs draining the inguinal mammary fat pad in age-
matched WT littermate controls, suggesting that these LNs were indeed not involved 
(Fig. 2B). Subsequent immunofluorescence with an antibody that specifically recognizes 
the PyMT antigen also failed to detect the presence of disseminated tumor cells in the 
inguinal LNs downstream of invasive carcinomas, but confirmed the single invasive 
lesion previously observed upon histological analysis (Fig. 2C, right, enlarged in inset). 
Despite the previously observed low incidence of metastatic LNs, however, tumor-
induced changes in the draining LN, such as an expansion of the lymphatic plexus, have 
previously been suggested to precede and promote distant metastasis of malignant tumor 
cells, and thus I also asked whether developing tumors induce LN lymphangiogenesis in 
this model (Hirakawa et al., 2006). Quantification of the lyve-1+ lymphatic vessel area in 
the inguinal LN, however, showed no significant change in the percentage of area 
covered by the lymphatic endothelium (Fig. 2D). Flow cytometry analysis of the tumor-
draining LN confirmed these findings, as no change in the total number of CD31+gp38+ 
LECs, nor in the subpopulation of lyve-1+ LECs, could be observed in the inguinal LN 
at either time point between tumor-bearing animals and WT littermate controls (Figs. 2E 
and F, respectively). Moreover, the same appeared to be true for the total number of 
CD31+gp38- BECs in the draining LN, which showed no difference in the total number 
in the tumor-draining LN as compared to the LN draining the inguinal mammary gland 
(Fig. 2G). These findings were also reflected in the ratio of LECs to BECs in the 
inguinal LN, which remained the same in MMTV-PyMT+ tumor-bearing mice as 
compared to WT littermate controls at 7 and 12 weeks of age, respectively (Fig. 2H). 
Collectively, these data demonstrate that tumor growth and progression in MMTV-
PyMT+ transgenic animals does not induce expansion of the lymphatic endothelium in 
the inguinal tumor-draining LN, suggesting that the lymphatic vasculature in the LN may 
not be involved in metastatic dissemination in this model. Consistent with these 
findings, and despite the observation of micrometastatic lesions do occur in the lungs of 
MMTV-PyMT+ tumor-bearing mice of 12 weeks of age, metastatic dissemination of 
invasive carcinomas to the inguinal tumor-draining LN is infrequent in the MMTV-
PyMT model of breast cancer, suggesting that lymphatic metastasis may not precede 
distant metastasis, and hematogenous spread may be the preferred route of metastatic 
dissemination of the primary tumor instead in this model. 
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Fig. 2: Invasive carcinomas in MMTV-PyMT+ tumor-bearing mice only infrequently metastasize 
to the local tumor-draining LN. 
A Representative H&E images of the inguinal LN draining the fat pad containing the mammary gland in 
FvB/N WT tumor-free mice at 12 weeks of age (left), or MMTV-PyMT+ animals with invasive 
carcinomas (middle), respectively. The formation of a metastatic lesion in the tumor-draining LN upon 
pathological analysis was only observed in 1 out of 10 MMTV-PyMT+ transgenic animals (right, incidence 
10%). Magnification 20x, scale bar 200 μm. B The inguinal LN of MMTV-PyMT+ tumor-bearing animals 
was not enlarged compared to age-matched WT FvB/N littermate controls, suggesting that these LNs 
indeed are not involved. C Immunofluorescence for the PyMT antigen (red) also failed to detect 
metastatic tumor cells in the tumor-draining LN of MMTV-PyMT+ transgenic animals at 12 weeks of age 
(middle), but confirms the metastatic lesion observed upon analysis of H&E-stained sections by a 
pathologist (right, enlarged in inset). Lyve-1 staining (teal) of the lymphatic endothelium of the inguinal 
LN shows that invasive carcinomas of the mammary gland do not induce LN lymphangiogenesis in the 
MMTV-PyMT model of breast cancer, which is also shown D upon quantification of the lymphatic vessel 
density in the inguinal LN. Magnification 20x, scale bar 200 μm. Values represent the percentage of lyve-
1+ area relative to the DAPI+ area in one imaging plane. E Analysis of the total number of LECs in the 
tumor-draining LN by flow cytometry confirmed lack of LN lymphangiogenesis in the MMTV-PyMT 
model of breast cancer, both in of the overall number of CD31+gp38+ LECs, as well as F in the number 
of CD31+gp38+lyve1+ LECs. G Furthermore, the number of CD31+gp38- BECs did also not change in 
the inguinal LN of MMTV-PyMT+ transgenic animals, which is also reflected in H the ratio of LECs to 
BECs in the tumor, which also remained the same. Plotted values represent mean ± SEM, statistical 
analysis by two-tailed unpaired Student's t- test. Experiment was performed once with n = 10 transgenic 
MMTV-PyMT+ animals and n = 6 FvB WT littermate controls per group, respectively. 
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3.1.3 Inhibition of VEGFR-3 signaling with an antagonistic antibody does not 
affect primary tumor growth, but reduces pulmonary metastasis 
 
Although the relevance of lymphatic vessels for breast cancer metastasis has been well 
established, less is known about how tumor-induced lymphangiogenesis may aid in the 
metastatic dissemination of malignant tumor cells. To investigate the interplay between 
tumor-associated lymphatic vessels and the tumor microenvironment, I sought to inhibit 
lymphangiogenesis in the MMTV-PyMT model of breast cancer upon administration of 
mF4-31C1, a function-blocking antibody to VEGFR-3 (i.e. α-VEGFR-3), which is 
predominantly restricted to the lymphatic endothelium in adults (Pytowski et al., 2005). 
To this end, treatment with α-VEGFR-3, or its corresponding control IgG, respectively, 
was initiated upon onset of hyperplasia, and continued until lesions progressed to 
invasive tumors. As shown in Figs. 3A and 3B, respectively, inhibition of VEGFR-3-
signaling in MMTV-PyMT+ transgenic mice did not affect the growth of the primary 
tumor. Administration of mF4-31C1, however, did result in reduced pulmonary 
metastasis, as micrometastases could be observed in the lungs of 2 out of 7 IgG-treated 
MMTV-PyMT+ tumor-bearing mice (i.e. 28.6%), whereas none were found in the lungs 
of α-VEGFR3-treated animals (Figs. 3C and D). Upon examination of the tumor-
associated vasculature, treatment with mF4-31C1 specifically targeted the lymphatic 
endothelium, as administration of the function-blocking antibody reduced the number 
of CD31+gp38+ LECs in the primary tumor, as compared to IgG-treated tumor-bearing 
mice, whereas the number of CD31+gp38+ BECs in the tumor was not affected (Figs. 
3E-G, respectively).  
Next, I assessed the tumor-draining LN. Administration of mF4-31C1 to MMTV-
PyMT+ tumor-bearing mice did not affect the size or weight of the tumor-draining LN 
(Figs. 4A and B). In contrast to the observed effects of inhibition of VEGFR-3-
mediated signaling on the lymphatic vasculature in developing tumors, but consistent 
with a lack of lymphangiogenesis in the inguinal LN draining invasive carcinomas, 
however, treatment with mF4-31C1 appeared to have no effect on the lymphatic 
endothelium in the tumor-draining LN, as histological examination showed no 
difference in the lymphatic vessel area in the LNs draining either invasive lesions of α-
VEGFR-3- or IgG-treated tumor-bearing mice (Figs. 4C and D, respectively). Flow 
cytometry analysis confirmed these findings, as the number of CD31+gp38+ LECs within 
the tumor-draining LN of α-VEGFR3- and IgG-treated MMTV-PyMT+ mice remained 
the same (Figs. 4E and G). Finally, treatment with mF4-31C1 also did not alter the 
number of CD31+gp38- BECs in the tumor-draining LN (Fig. 4F). 
In conclusion, these results demonstrate that, although inhibition of VEGFR-3-
mediated signaling within the primary tumor in the MMTV-PyMT model of breast 
cancer did not affect tumor growth, the treatment did result in reduced pulmonary 
metastasis. While administration of mF4-31C1 specifically reduced the number of 
CD31+gp38+ LECs, but not of CD31+gp38- BECs in the primary tumor, no such 
reduction could be observed for the number of CD31+gp38+ LECs or CD31+gp38- 
BECs in the tumor-draining LN, suggesting that administration solely targets the tumor-
associated lymphatic endothelium in MMTV-PyMT+ transgenic mice. 
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Fig. 3: Inhibition of tumor-associated lymphangiogenesis in the MMTV-PyMT model of breast 
cancer does not affect primary tumor growth but reduces pulmonary metastasis.  
A Administration of mF4-31C1 does not affect the growth of the primary tumor, as shown by H&E 
staining of the inguinal mammary fat pad containing the transformed mammary epithelium (magnification 
20x, scale bar 1 mm), B or the tumor weight upon termination of the treatment. C Inhibition of tumor-
associated lymphangiogenesis in tumor-bearing MMTV-PyMT+ mice did, however, result in reduced 
formation of micrometastases in the lungs of α-VEGFR-3-treated as compared to IgG-treated animals. 
H&E, magnification 40x. D Examination of the lungs by a pathologist revealed the presence of multiple 
micrometastases in the lungs of IgG-treated animals (filled bars), whereas none of the lungs of α-VEGFR-
3-treated animals contained disseminated tumor cells. E Analysis of the lymphatic and blood vasculature 
associated with the nascent tumors by flow cytometry showed that the treatment with mF4-31C1 
specifically reduced the numbers of CD31+gp38+ LECs in the tumor, F while not affecting the number of 
CD31+gp38- BECs, suggesting that abrogated VEGFR-3 signaling specifically reduces lymphangiogenesis. 
G The specificity of the treatment is also reflected in the ratio of LECs to BECs in the tumor, which is 
reduced, albeit not significantly, upon inhibition of VEGFR-3-mediated signaling in MMTV-PyMT+ 
transgenic animals. Flow cytometry for vascular endothelial cells performed by Maria Broggi. Plotted 
values represent mean ± SEM, statistical analysis by two-tailed unpaired Student's t- test. Experiment was 
performed once with n = 7 MMTV-PyMT+ transgenic animals per treatment group. 
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Fig. 4: Administration of an antagonistic antibody that ablates VEGFR3 signaling does not affect 
the sinusoidal lymphatic endothelium of the draining LN. 
A Representative H&E image of the inguinal tumor-draining LN. Magnification 20x, scale bar 200 μm. B 
Administration of mF4-31C1 does not affect the size of the draining LN, as shown by the LN weight 
upon termination of the treatment. Plotted values represent the weight of 3 pooled LNs, i.e. the brachial, 
axillary and inguinal LN. C Histological examination and D quantification of the lymphatic vessel area in 
the inguinal LN shows that mF4-31C1 does not affect the lymphatic endothelium in the draining LN. E 
Flow cytometry analysis confirmed these findings, as there was no change in the number of CD31+gp38+ 
LECs. F Analogous to the observations for the primary tumor, mF4-31C1 did also not affect the number 
of CD31+gp38- BECs in the draining LN, also shown by G the ratio of LECs to BECs. Flow cytometry 
for vascular endothelial cells performed by Maria Broggi. Plotted values represent mean ± SEM, statistical 
analysis by two-tailed unpaired Student's t- test. Experiment was performed once with n = 7 MMTV-
PyMT+ transgenic animals per treatment group. 
 
To validate the results obtained upon inhibition of VEGFR-3-signaling in MMTV-
PyMT+ transgenic animals, I also aimed to perform similar experiments upon induction 
of lymphangiogenesis in the primary tumor. However, as previously described 
orthotopic models based on enhanced expression of VEGF-C all depend on the use of 
immune deficient animals due to the human origin of the cell lines that were utilized to 
inoculate the tumors, and as such limits the investigation of the interaction between 
lymphatic vessels and the tumor microenvironment, I set out to develop a novel model, 
which is described in section 3.2. 
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3.2 Development of an orthotopic tumor model to induce lymphatic vessel 
growth in the context of breast cancer 
 
3.2.1 Production and titration of lentiviral vectors for transduction of murine 
breast cancer tumor cell lines 
 
Lentiviral vector stocks for the generation of stable VEGF-C-overexpressing (i.e. 
VEGF-C+) or control murine breast cancer cell lines were generated by co-transfecting 
human embryonic kidney (HEK)293T cells with the pD2109-mVEGF-C or pD2109-
control transfer plasmid, as well as packaging plasmids pMDLg/pRRE and pRSV-Rev, 
and envelope plasmid pMD2 to yield third-generation chimeric pseudo-lentiviral 
particles. Calculation of the physical titer from the total concentration of HIV-1-specific 
p24 antigen as determined by immunoassay yielded 4.69?109 and 1.86?1010 pseudo-
lentiviral particles of pD2109-mVEGF-C and pD2109-control per ml of unconcentrated 
vector supernatant, respectively. The biological titer, i.e. the number of infectious 
particles contained in each vector stock, was determined by TaqMan qPCR assay for 
HIV-1-specific gag, and yielded 1.62?108 and 2.31?108 transducing units (TU) per ml of 
unconcentrated vector for pD2109-mVEGF-C and pD2109-control lentiviral vector 
stocks, respectively. Calculation of the ratio of infectious particles to physical particles 
demonstrated an adequate packaging efficiency of 0.034 and 0.012 for the newly 
generated pD2109-mVEGF-C and pD2109-control vector stocks.
 
 
 
3.2.2 Characterization of stable VEGF-C+ and control breast cell lines in v i tro 
 
An invasive primary tumor cell line isolated from the spontaneous MMTV-PyMT mouse 
model of breast cancer, in the following abbreviated as PyMT tumor cells, were 
transduced with either pD2109-mVEGF-C or pD2109-control lentiviral vector stock 
(Fig. 5A) to yield stable VEGF-C+ or control-transduced cell lines, respectively. Upon 
incubation with a 1:1, 1:5 and 1:20 dilution of each vector stock, corresponding to a 
multiplicity of infection (MOI) of 8.10?102 and 1.16?103 for pD2109-mVEGF-C and 
pD2109-control in the highest dose, none of the cells demonstrated visible signs of 
lentiviral-mediated toxicity. To select only those tumor cells that stably integrated the 
proviral DNA into their genome, the tumor cells were incubated in the presence of 
2μg/ml puromycin (Fig. 5B). The resulting polyclonal batch cultures were then analyzed 
for residual p24 antigen to ensure that no replication-competent recombinant pseudo-
lentiviral particles had emerged (data not shown). Prior to functional experiments in vivo, 
each cell line was characterized extensively in vitro to ensure proper expression and 
secretion of the VEGF-C transgene, and that none of the VEGF-C+ or control PyMT 
tumor cell lines were compromised by artifacts induced by exposure to the lentiviral 
vectors used to generate each cell line. Determination of the number of proviral DNA 
copies that integrated into the genome of each VEGF-C- and control-transduced PyMT 
tumor cell line shows a higher genomic copy number of HIV-1-specific gag for each 
control-transduced cell line as compared to their VEGF-C-overexpressing counterpart, 
 ? ???
reflecting the higher titer of the pD2109-control vector stock (Fig. 5C). However, the 
increased lentiviral copy number in control-transduced PyMT tumor cells did not affect 
cell proliferation rates as demonstrated upon determination of the generation time (Fig. 
5D). Notably, solely the tumor cells transduced with the lowest MOI of pD2109-control 
vector stock showed a significant reduction in generation time. This observation, 
however, might rather represent an artifact in cell culture, as it is likely due to the fewer 
cells resulting after the initial selection of antibiotic-resistant cells. Finally, analysis of 
VEGF-C expression levels in vitro showed increased production and secretion of VEGF-
C in PyMT tumor cells transduced with pD2109-mVEGF-C as compared to control-
transduced PyMT tumor cells (Figs. 5E and 5F, respectively), demonstrating functional 
expression of the transgene. Therefore, the VEGF-C+ and control-transduced PyMT cell 
lines generated with the highest dose of lentiviral vector stock (i.e. dilution 1:1) were 
selected for all in vivo experiments described in the following sections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5: Generation and characterization of newly generated VEGF-C+ and control-transduced 
breast cancer cell lines in  v i t ro .  
A Schematic representation of the lentiviral vectors used to generate both the VEGF-C+ PyMT tumor cell 
lines and their corresponding control-transduced counterparts. B Determination of the sensitivity of the 
parental PyMT tumor cell line to puromycin yielded an optimal dose of 2μg/ml for selection of 
successfully transduced cell lines. C Analysis of the copy number of lentivirus that integrated into the 
genome upon incubation of the parental PyMT tumor cell line with each vector stock shows that cell lines 
transduced with pD2109-control vector stock had increased copy numbers, which was due to the higher 
titer of the lentiviral vector stock. D However, this did not affect cell behavior in vitro as based on 
determination of the proliferation rate. E Analysis of VEGF-C expression in vitro showed that the cell lines 
transduced with pD2109-mVEGF-C expressed increased VEGF-C at both the mRNA and F protein 
level. Statistical analysis by 2-way ANOVA. Two independent experiments were performed, one of two 
representative experiments shown.  
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3.2.3 Expression of VEGF-C within the tumor does not affect the growth rate of 
the primary tumor in v ivo  
 
Orthotopic inoculation of either 2.5?105 VEGF-C+ or control PyMT tumor cells into the 
fat tissue surrounding the inguinal mammary gland reproducibly led to the formation of 
tumors in the fat pad. The injection procedure and timeline for each experiment are 
illustrated in Fig. 6A, whereas a representative image of a tumor implanted in the fat pad, 
and its draining LN below the timeline. Enhanced expression of VEGF-C by the tumor 
cells did not accelerate the establishment of the primary tumor, nor did it affect its 
growth rate, though VEGF-C+ tumors were consistently slightly larger than control 
tumors (Fig. 6B). Pathology analysis of the lungs showed that the formation of 
pulmonary micrometastases occurred in the lungs of both VEGF-C+- and control-
tumor-bearing animals 35 days post-tumor inoculation, though there was no difference 
in the incidence at this time point (1/10 or 10% in each group, Fig. 6C). Therefore, 
although the primary tumor can be observed to form distant metastases, these data 
suggest that it is likely too early to detect a difference in the rate of metastasis between 
VEGF-C+ and control tumor cells. 
 
 
3.2.4 Expression of VEGF-C within the tumor reliably induces tumor-associated 
lymphangiogenesis in v ivo  
 
Although increased expression of VEGF-C did not affect tumor growth or the rate of 
pulmonary metastasis, VEGF-C+ tumors were observed to drive substantial peritumoral 
lymphangiogenesis and promote metastasis to the tumor-draining LN (see Fig. 8). 
Corresponding to enhanced expression of the transgene in vitro, VEGF-C+ PyMT tumor 
cells were found to secrete increased levels of VEGF-C in vivo as compared to their 
control-transduced counterparts, translating into a 44-fold increase in VEGF-C 
expression within the primary tumor (Fig. 6D). No significant difference could be 
observed in expression levels of either VEGF-D or VEGF-A within the tumor (Figs. 6E 
and F, respectively), indicating that any expansion of tumor-associated vessels is due to 
increased expression and secretion of VEGF-C. Overexpression of VEGF-C specifically 
induced lymphangiogenesis in and around the primary tumor, as the number of 
CD31+gp38+ LECs within VEGF-C+ tumors significantly increased as compared to 
control tumors, whereas the number of CD31+gp38- BECs did not change (Figs. 7A-C).  
Interestingly, in addition to CD31 and gp38, more than 90% of the LECs isolated from 
VEGF-C+ tumors were observed to also express lyve-1, a marker that is mainly found 
on lymphatic capillaries, suggesting that increased VEGF-C expression first and 
foremost induced expansion of initial lymphatic vessels surrounding the tumor (see Fig. 
7D). Histological analysis of the primary tumor confirmed these findings, as newly 
formed lymphatic vessels were almost exclusively found peritumorally (Fig. 7D an E, 
respectively). In addition, these lymphatic capillaries were also observed to express 
VEGFR-3 (Fig. 7D). However, histological analysis and quantification of the 
CD31+lyve-1- blood vessel area also showed an increase upon increased expression of 
VEGF-C, suggesting that VEGF-C may not solely affect tumor-associated lymphatic 
 ? ???
vessels (Fig. 7F). In conclusion, these results thus provide proof-of-concept that 
inoculation of VEGF-C+ tumor cells within the fat surrounding the inguinal mammary 
gland reliably induces the formation of lymphangiogenic tumors in vivo, thereby 
demonstrating that the chosen method is a feasible strategy for the development of an 
orthotopic tumor model that allows modulation of tumor-associated lymphatic vessels in 
vivo in the context of breast cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: Experimental design and characterization of tumor growth after orthotopic injection of 
VEGF-C+ and control-transduced breast cancer cell lines in  v ivo . 
A Experimental design for orthotopic injection of VEGF-C+ PyMT tumor cells into the inguinal 
mammary fat tissue of 8-10 week old female FvB/N WT mice. All experiments described in the following 
were terminated at 4.5-5 weeks post-tumor inoculation, at which point in time the blood and lymphatic 
vasculature, as well as the composition of the tumor microenvironment were analyzed, respectively. The 
image shown below the timeline depicts a representative H&E-stained longitudinal section of a tumor 
inoculated into the fat tissue surrounding the inguinal mammary gland and its draining LN. Magnification 
20x, scale bar 1 mm. B Tumors inoculated upon injection of VEGF-C+ or control-transduced PyMT 
tumor cells did not show a difference in growth rate, nor in C the rate of pulmonary metastasis formation 
(filled part of each bar). D Consistent with the analysis of the newly generated cell lines in vitro, orthotopic 
inoculation of sVEGF-C+ PyMT tumor cells yields tumors with enhanced VEGF-C expression as 
compared to injection of control-transduced tumor cells, translating into a 44-fold difference in expression 
levels. E While VEGF-C expression is enhanced, expression levels of VEGF-D and F VEGF-A are not 
affected. Plotted values represent mean ± SEM, statistical analysis by two-tailed unpaired Student's t- test. 
Tumor growth was measured in 4 out of 5 experiments, evaluation of pulmonary metastasis in one 
experiment. Figs. 6D-F show one out of two representative experiments for analysis of expression levels 
of VEGF family members. All experiments were performed with n = 10 animals per group. 
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Fig. 7: Orthotopic injection of VEGF-C+ breast cancer cell lines in  v ivo  reproducibly leads to the 
formation of tumors that are rich in lymphatic vessels. 
A VEGF-C overexpression reproducibly resulted in the formation of lymphangiogenic tumors in vivo, as 
the number of CD31+gp38+ LECs was increased in these tumors as compared to control tumors. B More 
than 90% of the LECs found in VEGF-C+ tumors also expressed lyve1, suggesting an expansion of intial 
lymphatic vessels. C In contrast, orthotopic inoculation of VEGF-C+ PyMT tumor cells did not affect the 
number of CD31+gp38- BECs found in the tumor, as compared to control tumors. D Histological analysis 
demonstrated that increased VEGF-C expression led to the formation of peritumoral lymphatic vessels. 
Immunofluorescence for CD31 (red), lyve-1 (teal) and VEGFR-3 (green) shows that, whereas blood 
vessels were found scattered throughout the tumor, the formation of new lymphatic vessels was largely 
induced at the tumor periphery. Immunofluorescence for VEGFR-3 (green) showed its expression on 
most of lyve-1+ lymphatic vessels surrounding the tumor, though it could also be detected on some lyve-1- 
vessels. Magnification 20x. E Quantification of the percentage of positive CD31+lyve-1+ lymphatic vessel 
area showed a significant increase in the area covered by newly induced lymphatic vessels, whereas F 
quantification of the percentage of positive CD31+lyve-1- blood vessel area revealed also an increase the 
area covered by blood vessels in VEGF-C+ as compared to control tumors, albeit not significant. Plotted 
values represent the average of 3 imaging planes. All experiments were performed twice, one of two 
representative experiments shown. Plotted values show mean ± SEM, statistical analysis performed with 
two-tailed unpaired Student's t-test. All experiments were performed with n = 10 animals per group. 
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3.2.5 Disseminated VEGF-C+ tumor cells induce expansion of the sinusoidal 
lymphatic endothelium in the draining LN 
 
Given the clinical relevance of tumor-associated lymphangiogenesis for regional and 
distant metastasis in breast cancer, I next examined the inguinal tumor-draining LN for 
the presence of disseminated tumor cells upon reaching the legal size limit of the 
primary tumor 35 days post-tumor inoculation. Although enhanced expression of 
VEGF-C did not affect the growth of the primary tumor, VEGF-C+ PyMT tumor cells 
more readily metastasized to the inguinal tumor-draining LN than control-transduced 
tumor cells. In line with previous observations, the draining LNs of VEGF-C+ tumors 
were found to be greatly enlarged compared to the draining LNs downstream of control 
tumors, which is reflected in a three-fold increase in LN weight (Figs. 8A and B, 
respectively, (Skobe et al., 2001a). Concurrently, a notable expansion of the lymphatic 
vascular network within the inguinal draining LN downstream of VEGF-C+ tumors was 
observed, as the total number of CD31+gp38+ LECs was found to be significantly 
increased in VEGF-C+ tumor-draining LNs as compared to control tumor-draining LNs 
(Fig. 8C). Tumor cell-derived VEGF-C, however, did not affect the number of 
CD31+gp38- BECs within the draining LN, thus increasing the ratio of LECs to BECs 
within the VEGF-C+ tumor-draining LN (Figs. 8D and E, respectively). Histological 
examination of VEGF-C+ and control tumor-draining LNs confirmed the expansion of 
the lymphatic sinusoidal endothelium within the VEGF-C+ tumor-draining LNs (Fig. 
8F). Moreover, in addition to expression of lyve-1, these enlarged lymphatic structures 
were also found to be positive for VEGFR-3 (Fig. 8F). Finally, immunostaining for the 
PyMT antigen revealed an increased presence of tumor cells in the tumor-draining LNs 
downstream of VEGF-C+ tumors as compared to those downstream of control tumors 
(Figs. 8F and H, respectively). Interestingly, all disseminated tumor cells were found in 
close proximity to the lymphatic vessels of the LN. In conclusion, these results 
demonstrate that VEGF-C-induced peritumoral lymphangiogenesis around the primary 
tumor promotes regional dissemination of the tumor cells to the tumor-draining LN, 
while subsequent remodeling of the lymphatic endothelium in the draining LN may yield 
a favorable environment for metastasis progression. 
 
Taken together, these data show that experimental modulation of tumor-associated 
lymphatic vessels can be achieved upon both inhibition, as well as induction of the 
VEGF-C /VEGFR-3 signaling axis in different experimental models of breast cancer. 
Section 3.3 will subsequently address the interaction of the lymphatic vasculature with 
the various components, i.e. the desmoplastic stroma, the innate inflammatory response, 
and T-cell mediated adaptive immunity, of the tumor microenvironment. 
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Fig. 8: Orthotopic inoculation of VEGF-C+ tumors promotes regional metastasis of the primary 
tumor to the tumor-draining LN. 
A Tumor-draining inguinal LNs downstream of VEGF-C+ tumors are greatly enlarged as compared to 
those downstream of control tumors. H&E, magnification 20x, scale bar 200 μm. B This enlargement is 
also reflected by a three-fold increase in the weight of the VEGF-C+ tumor-draining LN. C Concurrently, 
an expansion of the lymphatic sinusoidal endothelium was observed in the tumor-draining LN, as the 
number of CD31+gp38+ LECs was significantly increased in LNs draining VEGF-C+ tumors. D Similarly 
to the effects of VEGF-C on the vasculature described for the primary tumor, the number of CD31+gp38- 
BECs in the draining LN was not affected. E The specific expansion of LN LECs is also reflected in the 
ratio of LECs to BECs in the draining LN. F Histological analysis of the tumor-draining LN showed a 
distorted architecture of the lymphatic network in the LN, with enlarged lumens. Magnification 20x. G 
Quantification of the percentage of area covered by lyve-1+ lymphatic vessels confirmed the induction of 
LN lymphangiogenesis in the VEGF-C+ tumor-draining LN. Values represent the average of 3 imaging 
planes. H Staining for the PyMT antigen (red) revealed the presence of tumor cells in the draining LN, in 
particular in close proximity to the lymphatic vessels. Magnification 20x. I Quantification of the relative 
area of the tumor cells in the tumor-draining LN showed an increase in the size of the metastatic lesions in 
the LN, as, in contrast to the single cells in control tumor-draining LNs, large clusters of tumor cells could 
be detected in VEGF-C+ tumor-draining LNs, suggesting that VEGF-C expression in the primary tumor 
promotes regional metastasis of the primary tumor. Plotted values represent mean ± SEM of n = 10 
animals per group, statistical analysis with two-tailed unpaired Student's t-test. 
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3.3 Deconvolution of the breast cancer microenvironment during tumor growth 
and progression, and its interactions with tumor-associated lymphatic vessels 
 
3.3.1 Tumor-associated lymphatic vessels do not alter the desmoplastic response 
that accompanies incipient tumors 
 
The notion that not only changes in aberrant neoplastic cells (i.e. tumor-intrinsic 
factors), but also the surrounding tumor stroma, consisting of both tissue-resident and 
recruited ancillary cells (i.e. tumor-extrinsic factors), substantially contribute to tumor 
initiation, progression and metastasis gave rise to the concept of the tumor 
microenvironment (Hanahan and Weinberg, 2000). The MMTV-PyMT model of breast 
cancer currently represents the gold standard to investigate the interactions between the 
tumor and its associated stroma, as well as possible ramifications for tumor growth, 
progression and metastasis. Similar to human breast cancer, developing tumors in 
MMTV-PyMT+ transgenic mice are associated with the induction of a substantial 
reactive stroma that results in altered tensional homeostasis upon co-evolution of the 
transformed epithelium and the fibroblasts of the connective tissue. To investigate how 
tumor-associated lymphatic vessels may alter the desmoplastic response in breast cancer, 
I first characterized the expanse and composition of the ECM in transgenic MMTV-
PyMT+ tumor-bearing mice during tumor growth and progression. Histological analysis 
of the total collagen content in invasive carcinomas by picrosirius red staining showed 
that, similar to human breast cancer, incipient tumors in MMTV-PyMT+ transgenic mice 
are associated with the induction of a considerable reactive stroma (Fig. 9A). 
Furthermore, expression of lysyl oxidase (LOX), the principal enzyme that mediates 
crosslinking of collagen fibers, coincided with the presence of newly deposited collagen 
within the tumor stroma (Fig. 9A, right). Quantification of the total collagen content in 
the tumor confirmed these observations (Fig. 9C). Corresponding to the enhanced 
production of ECM, increased expression of TGF-β1 was detected in developing tumors 
in MMTV-PyMT+ transgenic mice as compared to age-matched WT littermate controls 
(Fig. 9B). Interestingly, TGF-β1 expression levels appeared more elevated in early 
hyperplastic lesions than invasive carcinomas, suggesting that TGF-β1-mediated CAF 
activation generates the reactive stroma that surrounds the transformed epithelium.  
 
Nevertheless, inhibition of VEGFR-3-mediated signaling upon administration of mF4-
31C1 in trasngenic MMTV-PyMT+ tumor-bearing mice did not reduce the deposition of 
fibrillar collagens at the tumor margin compared to IgG-treated control animals, as 
demonstrated by picrosirius red staining and subsequent quantification of collagen 
density (Figs. 9D and E, respectively). Furthermore, upon closer examination of other 
constituents of the desmoplastic stroma, administration of mF4-31C1 did also not 
notably alter the density of either collagen-III, fibronectin, or tenascin-C at the tumor 
margin, respectively (Figs. 10A-F). Collectively, these results demonstrate that tumor-
associated lymphatic vessels do not alter the induction or expanse of the desmoplastic 
response in the transgenic MMTV-PyMT model of breast cancer. 
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Fig. 9: Tumor growth and progression in the transgenic MMTV-PyMT model of breast cancer is 
accompanied by increased collagen deposition and crosslinking. 
A Invasive lesions in transgenic MMTV-PyMT+ tumor-bearing animals show increased deposition of 
collagen in the stroma as compared to age-matched WT littermate controls. Visualization of these invasive 
lesions under polarized light shows the collagen fibrils, which are thicker and more cross-linked in the 
tumor. Immunohistochemistry for LOX (brown) shows that the principal enzyme that mediates cross-
linking of the newly deposited collagen spatially coincides with thick bundles of collagen fibrils during 
tumor progression. Magnification 20x, scale bar 50 μm. B Immunoassay for TGF-β1 shows elevated levels 
in MMTV-PyMT+ tumor-bearing animals as compared the levels in the inguinal mammary gland in WT 
FvB/N mice, particularly in hyperplastic lesions. C Quantification of the density of total collagen shows 
an increase in collagen deposition in the tumor as compared to WT tumor-free mice. D Evaluation of the 
desmoplastic response upon administration of mF4-31C1 in MMTV-PyMT+ transgenic mice does not 
notably alter the deposition of collagen in the desmoplastic stroma compared to IgG-treated control 
animals, which is E confirmed by quantification of the relative fraction of collagen at the invasive margin 
of the tumor. Plotted values represent mean ± SEM, statistical analysis with two-tailed unpaired Student's 
t-test. Experiment was performed once with n = 7 MMTV-PyMT+ transgenic animals per treatment 
group. 
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Fig. 10: Inhibition of VEGFR-3-mediated signaling in transgenic MMTV-PyMT+ tumor-bearing 
mice did not affect ECM deposition at the invasive edge of the tumor. 
A Inhibition of VEGFR-3-mediated signaling with an antagonistic antibody in MMTV-PyMT+ tumor-
bearing animals did not notably alter the total deposition or the composition of the fibrillar ECM in the 
desmoplastic stroma surrounding invasive carcinomas, as compared to IgG-treated control animals. 
Specifically, immunofluorescence for different components of the fibrillar ECM, i.e. collagen-III, C 
fibronectin, and E tenascin-C (all shown in red) showed no difference in the density of these ECM 
components in invasive lesions upon termination of the treatment with mF4-31C1 in MMTV-PyMT+ 
tumor-bearing mice as compared to IgG-treated control animals. The basement membrane is visualized 
upon immunofluorescence for collagen-IV (which is shown in green), and used to define the invasive edge 
of the tumor, as it is disrupted once the tumor invades the surrounding stroma. Quantification of the 
density of each of these ECM components, i.e. collagen-III, fibronectin and tenascin-C, is shown in B, D, 
and F, respectively. Plotted values represent mean ± SEM, statistical analysis with two-tailed unpaired 
Student's t-test. Experiment was performed once with n = 7 MMTV-PyMT+ transgenic animals per 
treatment group. 
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3.3.2 Tumor-associated lymphatic vessels do not alter the innate immune 
response to the developing tumor 
 
Long since the initial description of the link between inflammation and cancer, innate 
immune cell infiltrates have now been recognized as a major component of the tumor 
immune microenvironment, and have been observed to potentiate cancer development 
(de Visser et al., 2006). As lymphangiogenesis is a process that is closely associated with 
inflammation, I next asked whether the modulation of components of the VEGF-C / 
VEGFR-3 signaling axis in different experimental models of breast cancer could affect 
the innate immune response to the tumor. 
First, in order to determine whether inhibition of VEGFR-3-mediated signaling upon 
treatment with mF4-31C1 might affect the innate inflammatory cells within the incipient 
tumor, I characterized the infiltration of the different myeloid cell populations during 
tumor growth and progression in the MMTV-PyMT model of breast cancer by flow 
cytometry. Overall, although the percentage of CD11b+ cells of the myeloid lineage 
remained the same at either tumor stage in MMTV-PyMT+ tumor-bearing animals as 
compared to age-matched WT littermate controls, the number of CD11b+ myeloid cells 
increased in both hyperplastic and invasive lesions (Figs. 11A and D, respectively). 
Furthermore, while among the CD11b+ myeloid cells that were present in hyperplastic 
lesions the infiltration of Ly6C+F4/80- monocytes did not change, a significant increase 
in the fraction of F4/80+ tumor-associated macrophages (TAMs) could be observed as 
compared to WT tumor-free mice, that also continued to further increase as the 
developing tumors progressed (Figs. 11B and C, respectively). Nevertheless, though 
analysis of the number of infiltrating F4/80+ TAMs confirmed the increase seen in the 
relative fraction of these cells, analysis of the number of infiltrating Ly6C+F4/80- 
monocytes showed an increase in inflammatory monocytes, particularly in invasive 
carcinomas, thus demonstrating an increase in cells of the myeloid lineage in late-stage 
tumors in MMTV-PyMT+ tumor-bearing mice as compared to the untransformed 
inguinal mammary gland in WT tumor-free mice (Figs. 11E and F). Interestingly, the 
majority of the infiltrating TAMs were strongly polarized towards an inflammatory 
CD11c+ M1-like phenotype in both hyperplastic and invasive lesions, whereas an 
increase in pro-tumor CD206+ M2-like TAMs could only be observed in late-stage 
tumors (Figs. 11G, H, J and K, respectively). Considering the overall ratio of CD11c+ 
M1-like to CD206+ M2-like TAMs in these tumors, the phenotype of infiltrating TAMs 
shows a strong bias towards an M1-like phenotype, implying that tumor development in 
the MMTV-PyMT model is accompanied by a potent inflammatory response that is 
mediated by TAMs, especially during tumor onset in early lesions (Fig. 11I). 
 
Fig. 11: Early hyperplastic lesions in the MMTV-PyMT model of breast cancer are accompanied 
by a potent inflammatory reaction to the developing tumor.   
A Flow cytometry analysis of developing hyperplastic lesions and invasive carcinomas revealed that 
although the relative CD11b+ myeloid cell infiltration does not change at either time point, significant 
differences in subsets of CD11b+ myeloid cells do occur. B While the infiltration of inflammatory 
monocytes did not change over time, C a significant infiltration of TAMs could be observed in 
hyperplastic lesions, which continues as the tumor progresses towards an invasive lesion. D Analysis of 
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Fig. 11: Early hyperplastic lesions in the MMTV-PyMT model of breast cancer are accompanied 
by a potent inflammatory reaction to the developing tumor, continued from p. 64. 
the number of infiltrating cells of the myeloid lineage, however, shows that total CD11b+ myeloid cells, as      
well as E Ly6C+F4/80- monocytes and F Ly6C-F4/80+ TAMs are increased in invasive carcinomas of 
MMTV-PyMT+ tumor-bearing mice as compared to the inguinal mammary gland in WT tumor-free mice. 
G TAMs showed a strong polarization towards a CD11c+ M1-like phenotype both at both tumor stages, 
whereas H the fraction of CD206+ M2-like TAMs did not change until the tumors progressed to late-stage 
carcinomas, I resulting in a bias towards increased M1-polarization, especially at tumor onset. J Analysis of 
the number of CD11c+ M1-like and K CD206+ M2-like TAMs also showed the relative prevalence of the 
M1-like phenotype in the transformed mammary gland in MMTV-PyMT+ transgenic mice at both time 
points. Plotted values represent mean ± SEM, statistical analysis by two-tailed unpaired Student's t- test. 
Experiment was performed once with n = 10 transgenic MMTV-PyMT+ animals and n = 6 FvB WT 
littermate controls per group, respectively. 
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Nevertheless, administration of mF4-31C1 in transgenic MMTV-PyMT+ tumor-bearing 
mice did not notably alter the innate immune response to the tumor. First of all, the 
overall infiltration of CD11b+ myeloid cells, neither the relative fraction nor the number, 
did not change in α-VEGFR-3-treated MMTV-PyMT+ tumor-bearing mice, as compared 
to IgG-treated animals (Figs. 12A and D, respectively). Furthermore, among these 
infiltrating CD11b+ myeloid cells, mF4-31C1-mediated inhibition of VEGFR-3 signaling 
did not result in any difference in the relative fractions or the number of Gr1+F4/80- 
myeloid-derived suppressor cells (MDSCs) or Gr1-F4/80+ TAMs (Figs. 12B, C, E and F, 
respectively). A closer examination of the phenotype of the infiltrating TAMs also 
showed no difference in TAM phenotype, as the fractions of CD11c+ M1-like and 
CD206+ M2-like TAMs within the tumor remained the same, which is also reflected in 
the ratio of CD11c+ M1-like to CD206+ M2-like TAMs that did not change upon 
termination of the treatment (Figs. 12G, H, and I, respectively). Analysis of the number 
of CD11c+ M1-like, as well as the number of CD206+ M2-like TAMs confirmed these 
findings, as also no difference in the number of TAMs with either phenotype could be 
observed upon termination of the treatment with mF4-31C1 in MMTV-PyMT+ tumor-
bearing animals, as compared to IgG-treated animals (Figs 12J and K, respectively). In 
conclusion, these data thus demonstrate that, although tumor onset in the MMTV-
PyMT model is associated with a strong inflammatory response mediated by TAMs 
within the developing tumors, inhibition of VEGFR-3-mediated signaling does not 
affect the innate immune response, and TAMs in particular, to the tumor in this 
particular model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12: Inhibition of tumor-associated lymphangiogenesis in the MMTV-PyMT model of breast 
cancer does not alter tumor-related inflammation in the primary tumor.   
A Flow cytometry analysis showed that administration of mF4-31C1 in trasngenic MMTV-PyMT+ tumor-
bearing mice does not alter the fraction of CD11b+ myeloid cells of the innate immune system in the 
primary tumor, as compared to IgG-treated control animals. B Furthermore, among the infiltrating 
CD11b+ myeloid cells in the tumor, neither the fraction of Gr1+ MDSCs nor C the fraction of Gr1-
F4/80+ TAMs changed in α-VEGFR-3-treated MMTV-PyMT+ tumor-bearing mice as compared to IgG-
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Fig. 12: Inhibition of tumor-associated lymphangiogenesis in the MMTV-PyMT model of breast 
cancer does not alter tumor-related inflammation in the primary tumor, continued from p. 66. 
treated control animals. D Analysis of the number of infiltrating CD11b+ myeloid cells confirmed these 
findings, as also the number of these cells did not change upon termination of the treatment. E Similarly, 
the number of Gr1+ MDSCs or F Gr1-F4/80+ TAMs remained the same, confirming that abrogated 
VEGFR-3 signaling upon administration of mF4-31C1 did not affect myeloid cell infiltration into the 
tumor. G Finally, administration of mF4-31C1 did also not affect the phenotype of infiltrating TAMs, as 
the fractions of CD11c+ M1-like or H CD206+ M2-like TAMs, and consequently I the ratio of M1- to 
M2-like TAMs in the tumor did not change. J Analysis of the number of TAMs with either phenotype also 
showed that inhibition of VEGFR-3-mediated signaling did not affect the prevalence of CD11c+ M1-like 
or K CD206+ M2-like TAMs in the tumor. Plotted values represent mean ± SEM, statistical analysis by 
two-tailed unpaired Student's t- test. Experiment was performed once with n = 7 MMTV-PyMT+ 
transgenic animals per treatment group. 
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Conversely, enhanced expression of VEGF-C in the primary tumor upon orthotopic 
inoculation of VEGF-C+ PyMT tumor cells into the inguinal fat pad of immune 
competent FvB/N mice was also not observed to exert a noticeable effect on the 
immune response to the developing tumor. As shown in Fig. 13A, increased expression 
levels of VEGF-C did not influence the overall infiltration of CD45+ leukocytes into the 
tumor. Furthermore, there was no difference in the relative engagement of either the 
innate or the adaptive arm of immunity, as defined by the influx of CD11b+ innate cells 
of the myeloid lineage, NK1.1+ innate NK cells of the lymphocyte lineage, and TCRβ+ 
lymphocytes of the acquired immune response (Fig. 13B).  
To determine whether VEGF-C-induced lymphangiogenesis affects the innate immune 
response to the incipient tumor, again I first characterized the CD11b+ cells of the 
myeloid lineage in more detail, analogous to the description of innate immunity in 
transgenic MMTV-PyMT+ animals above. NK cells, as cells of the innate immune 
system, but of the lymphocyte lineage will be discussed together with the T lymphocytes 
of the adaptive immune system in section 3.3.3. Analysis of the CD11b+ myeloid cells 
within the tumor demonstrated that expression of VEGF-C in the primary tumor does 
not affect their overall recruitment, as no difference could be observed in the percentage 
or number of CD11b+ myeloid cells that was present in VEGF-C+ or control tumors, 
respectively (Figs. 13C and F). Moreover, upon further exploration of the various cells 
of the myeloid lineage in the tumor, there was also no difference in the proportion or 
the number of Ly6G+Ly6C-F4/80- neutrophils, or Ly6G-Ly6C+F4/80- inflammatory 
monocytes in the tumor (Figs. 13D and E, as well as G and H, respectively). Likewise, 
increased expression levels of VEGF-C did not affect the overall infiltration of Ly6G-
Ly6C-F4/80+ TAMs (Figs. 14A and B). RNA sequencing of F4/80+ TAMs isolated from 
invasive carcinomas of MMTV-PyMT+ transgenic mice showed that TAMs do not 
express VEGFR-3, thus demonstrating that modulation of the VEGF-C / VEGFR-3 
signaling axis could not affect the recruitment of TAMs in this particular model (Fig. 
14C). Interestingly, while tumors that formed upon orthotopic inoculation of PyMT 
tumor cells in the fat tissue surrounding the mammary gland contained a similar fraction 
of TAMs as invasive carcinomas in MMTV-PyMT+ transgenic mice of 12 weeks of age, 
contrary to the genetically engineered model, the phenotype of the TAMs present in 
these tumors showed a strong polarization towards an M2-like phenotype, as shown by 
the ratio of CD11c+ M1-like to CD206+ M2-like TAMs (Fig. 14F, compare with Fig. 
11I). However, though both models show an inherent difference in the predominant 
TAM phenotype, increased expression of VEGF-C did not alter the polarization of the 
TAMs present, as the relative distribution of CD11c+ M1-like or CD206+ M2-like TAMs 
did not change in VEGF-C+ or control tumors, respectively (Figs. 14G and H).  
 
Overall, the results obtained upon inhibition of VEGFR-3-mediated signaling within the 
tumor, as well as by induction of tumor-associated lymphangiogenesis upon enhanced 
expression of VEGF-C in the tumor are consistent between both models, and 
demonstrate that modulation of lymphatic vessels through the VEGF-C / VEGFR-3 
signaling axis does not alter the innate inflammatory response mediated by cells of the 
myeloid lineage, and TAMs in particular, to the tumor. 
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Fig. 13:  Enhanced VEGF-C expression in the primary tumor does not affect the innate immune 
cells of the myeloid lineage. 
A Increased expression levels of VEGF-C in the primary tumor did not alter overall CD45+ leukocyte 
infiltration, as determined by flow cytometry. B Furthermore, among the infiltrating leukocytes, there was 
no difference in the relative engagement of the innate or adaptive arm of the immune response in VEGF-
C+ tumors as compared to control tumors. C Total CD11b+ myeloid cell infiltration did not change upon 
increased VEGF-C expression in the primary tumor. D Among the CD11b+ cells within the tumor, the 
relative fractions of Ly6G-Ly6C+F4/80- inflammatory monocytes or E of Ly6G+ neutrophils did also not 
change with increased VEGF-C levels. F Consistent with the observation that the fraction of CD11b+ 
myeloid cells did not change in VEGF-C+ tumors, the number of infiltrating CD11b+ myeloid cells also 
remained the same upon orthotopic inoculation of VEGF-C+ tumor cells, as compared to control tumor 
cells. G Likewise, the number of Ly6G-Ly6C+F4/80- inflammatory monocytes or H Ly6G+ neutrophils 
also remained the same in VEGF-C+ tumors. Plotted values show mean ± SEM, each dot represents one 
animal. Statistical analysis performed with two-tailed Student's t-test. Experiment was performed once 
with n = 10 animals per group. 
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Fig. 14:  Enhanced VEGF-C expression in the primary tumor does not affect TAM infiltration or 
phenotype. 
A Consistent with the observations that inhibition of VEGFR-3-mediated signaling did not affect TAM 
infiltration or phenotype in the tumor, both the relative fraction as well as B the number of Ly6G-Ly6C-
F4/80+ TAMs did not change in VEGF-C+ tumors as compared to control tumors. C RNA sequencing of 
F4/80+ TAMs isolated from invasive carcinomas of MMTV-PyMT+ transgenic mice demonstrates that 
TAMs do not express VEGFR-3 in this particular model, thus providing an explanation as to why VEGF-
C expression did not affect TAM infiltration. D Furthermore, enhanced expression of VEGF-C in the 
primary tumor did also not affect the relative prevalence of CD11c+ M1-like or E CD206+ M2-like TAMs. 
H Indeed, though TAMs generally assumed an M2-like phenotype in this model, the ratio of M1-like to 
M2-like TAMs did not change in lymphangiogenic tumors as compared to control tumors. G Analysis of 
the number of CD11c+ M1-like or H CD206+ M2-like TAMs confirmed this, as also here no change was 
observed. Mario Squadrito kindly provided the RNA sequencing data. Plotted values show mean ± SEM, 
each dot represents one animal. Statistical analysis performed with two-tailed Student's t-test. Experiment 
was performed once with n = 10 animals per group. 
 
M1-like TAMs
PyMT VEGFC+ PyMT
0
10
20
30
40
50 n.s.
CD
11
c+
 T
AM
s
(%
 o
f F
4/
80
+  C
ell
s)
M2-like TAMs
PyMT VEGFC+ PyMT
0
100
200
300
400 n.s.
CD
20
6+
 T
AM
s
(C
ou
nt
 / 
m
g 
tis
su
e)
M1-like TAMs
PyMT VEGFC+ PyMT
0
20
40
60
80 n.s.
CD
11
c+
 T
AM
s
(C
ou
nt
 / 
m
g 
tis
su
e)
TAMs
PyMT VEGFC+ PyMT
0
100
200
300
400
500 n.s.
F4
/8
0+
 T
AM
s 
(C
ou
nt
 / 
m
g 
tis
su
e)
TAM Polarization
PyMT VEGFC+ PyMT
0.0
0.5
1.0
1.5 n.s.
TA
M
 P
ol
ar
iza
tio
n
(R
at
io
 M
1 
/ M
2)
M2-like TAMs
PyMT VEGFC+ PyMT
0
20
40
60
80
100 n.s.
CD
20
6+
 T
AM
s
(%
 o
f F
4/
80
+  C
ell
s)
VEGFR-3 Expression in TAMs
VEGFC VEGFR3
0.00
0.05
0.10
0.15
0.20
0.25
Ex
pr
es
sio
n 
(R
KP
M
)
TAMs
PyMT VEGFC+ PyMT
0
50
60
70
80
90
100 n.s.
F4
/8
0+
 T
AM
s 
(%
 o
f C
D1
1b
+  C
ell
s)
? ? ?
? ? ?
? ?
 ? ???
3.3.3 Tumor-associated lymphatic vessels do not alter the T-cell-mediated 
adaptive anti-tumor immune response 
 
The presence of tumor-related inflammation sets the stage for induction of the more 
sophisticated adaptive immune response, and therefore I next asked whether and how 
modulation of tumor-associated lymphangiogenesis upon administration of mF4-31C1 
in the MMTV-PyMT model, or orthotopic inoculation of VEGF-C+ PyMT tumor cells 
might affect the extent or the quality of the T-cell-mediated anti-tumor response.  
Analogous to the description of innate immunity in section 3.3.2, I first characterized the 
induction of the acquired immune response, and specifically T-cell-mediated acquired 
immunity, in MMTV-PyMT+ tumor-bearing mice upon tumor onset and in invasive 
lesions. Although total infiltration of TCRβ+NK1.1- T cells, or TCRβ-NK1.1+ NK cells 
innate cells of the lymphoid lineage did not change in either tumor stage as compared to 
WT littermate controls (Figs. 15A and B, respectively), the fraction of TCRβ+NK1.1+ 
NK T cells was significantly increased in hyperplastic, but not in invasive lesions in 
MMTV-PyMT+ transgenic animals (Fig. 15C). Determination of the number of 
TCRβ+NK1.1- T cells corroborated the observation that overall T cell infiltration did not 
change at either time point (Fig. 15D). However, although the relative fractions of 
TCRβ-NK1.1+ NK cells and TCRβ+NK1.1+ NK T cells did not seem different in 
invasive carcinomas, analysis of the number of these cells showed an increase of both 
TCRβ-NK1.1+ NK cells as well as TCRβ+NK1.1+ NK T cells in transgenic MMTV-
PyMT+ tumor-bearing mice as compared to the untransformed inguinal mammary gland 
in WT tumor-free mice (Figs. 15E and F). Among the infiltrating T cells in the tumor, an 
increase in CD8+ cytotoxic T cells was observed in early hyperplastic lesions, that 
continued as these lesions progressed to invasive carcinomas, whereas the fraction of 
CD4+ T cells did not change at either point in time (Figs. 15G and H, respectively). 
Nevertheless, whereas analysis of the number of infiltrating T cells also showed an 
increase in CD8+ cytotoxic T cells in the tumor, and in particular in hyperplastic lesions 
of MMTV-PyMT+ transgenic animals, it also showed an increase in CD4+ T cells at this 
point in time (Figs. 15J and K). Late-stage tumors, however, did contain a larger fraction 
and number of CD25+FoxP3+ regulatory T cells (Figs. 15I and L, respectively), 
suggesting that the anti-tumor immune response eventually becomes attenuated. Closer 
examination of the phenotype of the CD8+ cytotoxic T cells in the tumor confirmed this 
hypothesis, as these cells showed an increased expression of activation markers CD25 
and CD69 during tumor onset and progression, and a concurrent increase in the fraction 
of PD-1+ CD8+ cytotoxic T cells in invasive carcinomas (Figs. 15M-O), suggesting that 
upon initial activation of T-cell mediated immunity by early tumors, further development 
of the tumor may induce a functionally exhausted state of these cells. 
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Fig. 15: Tumor growth and progression in the MMTV-PyMT model of breast cancer is 
characterized by early CD8+ T cell activation that becomes eventually becomes dampened.  
A Flow cytometry analysis shows that the relative fraction of TCR-β+NK1.1- T cells does not change 
during the course of tumor progression. B Furthermore, in the MMTV-PyMT mouse model of breast 
cancer, although the fraction of TCR-β-NK1.1+ NK cells of the innate immune system does also not 
increase over time, C an increase in TCR-β+NK1.1+ NK T cells can be seen in early hyperplastic lesions as 
compared to WT tumor-free mice. D Analysis of the numbers of these cells corroborates that overall T 
cell infiltration did not change in the inguinal mammary gland of MMTV-PyMT+ tumor-bearing mice as 
compared to WT littermate controls, but did show an increase in both E TCR-β-NK1.1+ NK cells as well
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Fig. 15: Tumor growth and progression in the MMTV-PyMT model of breast cancer is 
characterized by early CD8+ T cell activation that becomes eventually becomes dampened, 
continued from p. 72. 
as F TCR-β+NK1.1+ NK T cells, particularly in invasive carcinomas. G Analysis of the different T cell 
subsets in the tumor revealed an increase in CD8+ cytotoxic T cells at onset of hyperplasia that continued 
until lesions progressed to invasive carcinomas, whereas H no particular change in the fraction of CD4+ T 
cells could be observed at either time point. I Among the CD4+ T cell subset, however, invasive 
carcinomas contain an increase in the percentage of CD25+FoxP3+ regulatory T cells, suggesting that the 
induced acquired immune response eventually becomes dampened. J Analysis of the number of either T 
cell subset showed that, although both CD8+ cytotoxic T cells and L CD25+FoxP3+ regulatory T cells 
indeed increased, particularly in early hyperplastic lesions, the number of CD4+ T cells was also increased 
at this point in time as compared to the inguinal mammary gland of WT tumor-free mice. M Analysis of 
the activation status of CD8+ cytotoxic T cells confirms this, as shown by expression levels of CD25 and 
N CD69, which increase during tumor progression, whereas O the fraction of PD-1+ CD8+ cytotoxic T 
cells also increases at this time point, suggesting that these cells may become functionally exhausted. 
Plotted values show mean ± SEM, each dot represents one animal. Statistical analysis performed with two-
tailed Student's t-test. Experiment was performed once with n = 10 animals per group. 
 
 
 
To investigate whether and how inhibition of VEGFR-3-mediated signaling affects the 
acquired immune response, I next evaluated the anti-tumor T cell response in MMTV-
PyMT+ tumor-bearing mice upon administration of mF4-31C1. Akin to innate 
immunity, abrogated VEGFR-3 signaling did not alter the induction or quality of the 
adaptive immune response to the developing tumor in MMTV-PyMT+ transgenic mice. 
Indeed, upon analysis of the overall infiltration of CD3e+NK1.1- T cells, CD3e-NK1.1+ 
NK innate cells of the innate immune response and NK1.1+CD3e+ NK T cells, no 
difference could be observed between the two conditions (Figs. 16A-C). Analysis of the 
number of these cells verified these findings, as neither the number of CD3e+NK1.1- T 
cells, CD3e-NK1.1+ NK cells or NK1.1+CD3e+ NK T cells in the tumor changed when 
VEGFR-3-mediated signaling was inhibited as compared to IgG-treated control animals 
(Figs. 16D, E and F, respectively). Furthermore, upon closer examination of the various 
T cell populations in the tumor, the relative fractions or numbers of CD8+ cytotoxic T 
cells and CD4+ T cells, respectively, did not change in α-VEGFR-3-treated MMTV-
PyMT+ tumor-bearing mice as compared to IgG-treated animals (Figs. 16G and H, as 
well as J and K). Moreover, among the latter subset, treatment with mF4-31C1 did also 
not alter the relative fraction or number of and CD25+FoxP3+ regulatory T cells, thus 
not changing the ratio of regulatory T cells to CD8+ cytotoxic T cells in the tumor (Figs. 
16I and L, as well as O, respectively). Finally, analysis of the phenotype of the infiltrating 
CD8+ cytotoxic T cells revealed that inhibition of VEGFR-3-mediated signaling in 
transgenic MMTV-PyMT+ mice did not change the activation status of these cells, as 
determined by the expression levels of CD25 and CD69 on the surface, respectively 
(Figs. 16M and N). In conclusion, although developing neoplastic lesions in the MMTV-
PyMT model of breast cancer induce a potent T-cell-mediated anti-tumor immune 
response, which eventually becomes exhausted as the nascent tumor progresses, these 
data suggest that inhibition of tumor-associated lymphangiogenesis does not alter the 
acquired immune response to the tumor. 
 
 ? ???
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16: Inhibition of VEGFR-3-mediated signaling does not affect the induction of an acquired 
T-cell-mediated immune response against the tumor. 
A Flow cytometry analysis of the primary tumor shows that, whereas abrogated VEGFR-3-mediated 
signaling did not alter the overall infiltration of CD3e+NK1.1- T cells into the tumor, the treatment also 
did not affect the relative fractions of B CD3e-NK1.1+ NK cells or C CD3e+NK1.1+ NK T cells. D 
Analysis of cell numbers verified that administration of mF4-31C1 in transgenic MMTV-PyMT+ tumor-
bearing mice indeed did not change the density of CD3e+NK1.1- T cells, E CD3e-NK1.1+ NK cells or F
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Fig. 16: Inhibition of VEGFR-3-mediated signaling does not affect the induction of an 
acquired T-cell-mediated immune response against the tumor, continued from p. 70. 
CD3e+NK1.1+ NK T cells in the tumor, as compared to IgG-treated control animals. G Examination of 
the different T cell subsets revealed that inhibition VEGFR-3-mediated signaling also did not affect the 
relative distribution of CD8+ cytotoxic T lymphocytes, as well as H CD4+ T cells in the tumor. I 
Furthermore, among the CD4+ subset, the fraction of CD25+Foxp3+ regulatory T cells also did not 
change in α-VEGFR-3-treated animals as compared to IgG-treated controls. J Furthermore, 
administration of mF4-31C1 also did not affect the number of CD8+ cytotoxic T lymphocytes and K 
CD4+ T cells in the tumor, including L CD25+Foxp3+ regulatory T cells within invasive carcinomas. M 
In-depth analysis of the phenotype of the infiltrating CD8+ cytotoxic T lymphocytes also showed that 
mF4-31C1 did not change the activation status of these cells, as assessed by their expression of CD25 and 
N CD69 on the cell surface. O Whereas the infiltration of both CD8+ cytotoxic T lymphocytes as well as 
CD25+Foxp3+ regulatory T cells did not change upon termination of the treatment, as a consequence, the 
overall ratio of CD25+Foxp3+ regulatory T cells to CD8+ cytotoxic T lymphocytes in the primary was not 
affected upon inhibition of tumor-associated lymphangiogenesis. Plotted values show mean ± SEM, each 
dot represents one animal. Statistical analysis performed with two-tailed Student's t-test. Experiment was 
performed once with n = 7 animals per treatment group. 
 
 
To assess whether induction of tumor-associated lymphangiogenesis could alter the 
adaptive immune response to the tumor, I next turned my attention to the induction of 
the acquired immune response, and the induction of T-cell-mediated immunity in 
particular, in the orthotopic model. Enhanced VEGF-C expression did not affect the 
relative fraction or number of TCRβ+NK1.1- T cells or TCRβ+NK1.1+ NK T cells into 
the tumor, nor the TCRβ-NK1.1+ NK cells of the innate cells of the lymphocyte lineage 
(Figs. 17A-F, respectively). Furthermore, analysis of the infiltrating T cells showed no 
difference in the relative distribution or the number of CD8+ cytotoxic T lymphocytes 
and CD4+ T lymphocytes in VEGF-C+ tumors, as compared to control tumors (Figs. 
17G and H, as well as J and K, respectively). Among the CD4+ T cells in the tumor, 
increased expression of VEGF-C also did not affect the infiltration of CD25+FoxP3+ 
regulatory T cells, neither the relative fraction nor their density (Figs. 17I and L). 
Interestingly, however, induction of VEGF-C-mediated lymphangiogenesis in the 
primary tumor was observed to slightly alter the activation status of CD8+ cytotoxic T 
lymphocytes in the tumor. In VEGF-C+ tumors, although CD25 expression levels did 
not change, these cells displayed less CD69 on their surface (Figs. 17M and N, 
respectively). Moreover, a trend towards an increase in the fraction of PD-1+ CD8+ 
cytotoxic lymphocytes was observed (Fig. 16O), suggesting that the CD8+ cytotoxic T 
cells might have been previously primed against the tumor, but are now functionally 
exhausted. 
 
 
Fig. 17: Enhanced expression of VEGF-C does not alter overall T cell infiltration, but affects the 
activation status CD8+ cytotoxic T cells in the tumor.  
A Flow cytometry analysis shows that enhanced expression of VEGF-C does not affect overall infiltration 
of TCRβ+NK1.1- T cells, B TCRβ-NK1.1+ NK cells of the innate cells of the lymphocyte lineage or C 
TCRβ+NK1.1+ NK T cells into the tumor. D Furthermore, VEGF-C+ tumors did also not contain a 
different number of TCRβ+NK1.1- T cells, E TCRβ-NK1.1+ NK cells or F TCRβ+NK1.1+ NK T cells, 
respectively. G Among the infiltrating T cells, also no difference in the fraction of CD8+ cytotoxic T cells,
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Fig. 17: Enhanced expression of VEGF-C does not alter overall T cell infiltration, but affects the 
activation status CD8+ cytotoxic T cells in the tumor, continued from p. 75. 
or H CD4+ T lymphocytes could be observed. I CD25+FoxP3+ regulatory T cell infiltration did also not 
change lymphangiogenic tumors as compared to control tumors. J Analysis of the number of each T cell 
subset confirmed these findings, as no difference in either CD8+ cytotoxic T lymphocytes, K CD4+ T cells 
or I CD25+FoxP3+ regulatory T cells was observed between VEGF-C+ and control tumors. M Finally, 
VEGF-C expression did not alter the CD25 expression levels, but N resulted in reduced CD69 expression 
levels on the CD8+ cytotoxic T cells in the tumor. O Finally, a trend towards an increase in PD-1+ T cells 
could also be observed upon overexpression of VEGF-C in the primary tumor. Plotted values show mean 
± SEM, each dot represents one animal. Statistical analysis performed with two-tailed Student's t-test with 
n = 10 animals per group. 
PD-1 Expression 
PyMT VEGFC+ PyMT
0
20
40
60
80
100 p = 0.08
PD
-1
+  C
D8
+  C
TL
s 
(%
 o
f C
D8
+  T
 ce
lls
)
CD69 Expression
PyMT VEGFC+ PyMT
0
500
1000
1500
2000 p = 0.05
CD
69
 E
xp
re
ss
io
n 
(g
M
FI
 o
n 
CD
8+
 C
TL
s)
CD25 Expression
PyMT VEGFC+ PyMT
0
20
40
60
80 n.s.
CD
25
+  C
D8
+  C
TL
s 
(%
 o
f C
D8
+  T
 ce
lls
)
FoxP3+ Treg Cells
PyMT VEGFC+ PyMT
0
200
400
600
800
1000 n.s.
CD
25
+  F
ox
P3
+  T
re
gs
 
(C
ou
nt
 / 
m
g 
tis
su
e)
CD4+ T cells
PyMT VEGFC+ PyMT
0
1000
2000
3000 n.s.
CD
4+
 T
 C
ell
s 
(C
ou
nt
 / 
m
g 
tis
su
e)
CD8+ CTLs
PyMT VEGFC+ PyMT
0
1000
2000
3000
4000 n.s.
CD
8+
 C
TL
s 
(C
ou
nt
 / 
m
g 
tis
su
e)
?????????????????????
PyMT VEGFC+ PyMT
0
100
200
300
400
500 n.s.
NK
1.
1+
 T
 C
ell
s 
??
??
???
???
???
???
??
?
????????????????????
PyMT VEGFC+ PyMT
0
500
1000
1500
2000 n.s.
NK
1.
1+
 C
ell
s 
??
??
???
???
???
???
??
?
??????????????????
PyMT VEGFC+ PyMT
0
2000
4000
6000
8000 n.s.
TC
R?
+  
T 
Ce
lls
 
??
??
???
???
???
???
??
?
FoxP3+ Treg Cells
PyMT VEGFC+ PyMT
0
20
40
60
80 n.s.
CD
25
+  F
ox
P3
+  T
re
gs
 
(%
 o
f C
D4
+  T
 C
ell
s)
CD4+ T cells
PyMT VEGFC+ PyMT
0
20
40
60
80 n.s.
CD
4+
 T
 C
ell
s 
(%
 o
f T
CR
?+
 C
ell
s)
CD8+ CTLs
PyMT VEGFC+ PyMT
0
20
40
60
80 n.s.
CD
8+
 C
TL
s 
(%
 o
f T
CR
?+
 T 
Ce
lls
)
?????????????????????
PyMT VEGFC+ PyMT
0
10
20
30
40 n.s.
NK
1.
1+
 T
 C
ell
s 
??
???
??
??
?+
???
??
??
???
??
????????????????????
PyMT VEGFC+ PyMT
0
10
20
30
40 n.s.
NK
1.
1+
 C
ell
s 
??
???
??
??
?+
 ??
??
??
???
??
??????????????????
PyMT VEGFC+ PyMT
0
10
20
30
40
50
60 n.s.
TC
R?
+  
T 
Ce
lls
 
??
???
??
??
?+
???
??
??
???
??
? ? ?
? ? ?
? ? ?
? ? ?
? ? ?
 ? ???
Interestingly, the observed effects of VEGF-C-induced lymphangiogenesis on the 
phenotype of CD8+ cytotoxic T cells in the tumor were also visible, and slightly more 
pronounced upon stimulation of the lymphatic network in the tumor-draining LN. 
Much the same to the primary tumor, VEGF-C-induced LN lymphangiogenesis did not 
affect the overall content in terms of relative fraction or number of TCRβ+NK1.1- T 
cells, TCRβ+NK1.1+ NK T cells, or the TCRβ-NK1.1+ NK cells of the innate cells of the 
lymphocyte lineage in the LN (Figs. 18A-F, respectively). Moreover, within the T cell 
population in the draining LN, the proportions of CD8+ cytotoxic T cells and CD4+ T 
cells, as well as the fraction of CD25+FoxP3+ regulatory T cells among the latter, did not 
change upon activation of the lymphatic endothelium (Figs. 18G, H and I). Moreover, 
the total number of each T cell subset also did not differ between LNs draining VEGF-
C+ or control tumors, respectively (Figs. 18J, K and L). Again, in agreement with the 
observed phenotype of the CD8+ cytotoxic T cells in the primary tumor, the CD8+ 
cytotoxic T lymphocytes in the LNs draining VEGF-C+ tumors showed no difference in 
the expression levels of CD25, but significantly reduced levels of CD69 on their surface, 
as compared to the CD8+ T cell population in the LN downstream of control tumors 
(Figs. 18M and N). Similarly, a trend towards an increase in the fraction of PD-1+ CD8+ 
cytotoxic T lymphocytes could be observed in VEGF-C+ tumor-draining LNs, 
suggesting that VEGF-C-mediated induction of LN lymphangiogenesis renders these 
cells functionally exhausted (Fig. 18O).  
 
Taken together, these results suggest that, modulation of tumor-associated lymphatic 
vessels via the VEGF-C / VEGFR-3 signaling axis does not notably alter the different 
components of the tumor microenvironment evaluated in the scope of this thesis, i.e. 
the desmoplastic response, as well as the innate and adaptive immune responses that are 
induced by the developing tumor in the experimental models of breast cancer that were 
employed for these experiments.  
 
 
 
 
 
 
 
 
 
 
Fig. 18: VEGF-C-mediated activation of the lymphatic vasculature in the tumor-draining LN 
changes the activation of CD8+ T cells in the LN.  
A VEGF-C expression by metastatic tumor cells in the regional LN does not alter the overall distribution 
of TCRβ+NK1.1- T cells, B TCRβ-NK1.1+ NK innate cells of the lymphocyte lineage, or C the 
TCRβ+NK1.1+ NK T cells in the LN. D Furthermore, the total number of TCRβ+NK1.1- T cells, E 
TCRβ-NK1.1+ NK cells, or F the TCRβ+NK1.1+ NK T cells in the draining LN downstream of VEGF-
C+ tumors did not differ from the total number of each cell population in control tumor-draining LNs, 
respectively. G VEGF-C-mediated activation of the lymphatic endothelium in the tumor-draining LN also 
does not alter the relative fractions of CD8+, H CD4+, or I CD25+FoxP3+ regulatory T cells among the 
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Fig. 18: VEGF-C-mediated activation of the lymphatic vasculature in the tumor-draining LN 
changes the activation of CD8+ T cells in the LN, continued from p. 77. 
latter. Analysis of the total number of each T cell subset confirmed that indeed CD8+ cytotoxic T cells, K 
CD4+ T cells, or L CD25+FoxP3+ regulatory T cells did not change in the regional LN draining 
lymphangiogenic tumors. M Finally, the expression levels of CD25 on CD8+ cytotoxic T cells in the 
draining LN did not change, whereas N CD69 expression levels were significantly decreased on these cells 
in lymphangiogenic LNs. O Concurrently, a trend towards an increase in the fraction of PD-1+ CD8+ 
cytotoxic T lymphocytes was observed in VEGF-C+ tumor-draining LNs as compared to control tumor-
draining LNs, suggesting that these cells are functionally exhausted. Plotted values show mean ± SEM, 
each dot represents one animal. Statistical analysis performed with two-tailed Student's t-test with n = 10 
animals per group. 
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Discussion and Perspectives 
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4.1 Experimental modulation of lymphatic vessels in the context of breast cancer 
 
In the thesis work presented herein, I investigated whether modulation of the tumor-
associated lymphatic vasculature could actively shape the tumor microenvironment to 
promote the regional and distant metastatic dissemination of the primary tumor in the 
context of breast cancer. Indeed, during the past decade, both clinical data and a 
multitude of experimental models have established the relevance of tumor-associated 
lymphatic vessels for breast cancer metastasis beyond question (Ran et al., 2010; Skobe 
et al., 2001a). Moreover, the presence of tumor cells in the tumor-draining LN 
represents an important prognostic indicator for disease outcome, and is routinely used 
in the clinic for staging of the disease upon its diagnosis (Tuttle, 2004). However, in 
recent years it has become apparent that not only thwarted neoplastic cells, but also the 
surrounding stromal cells, which under physiological conditions typically act to maintain 
tissue homeostasis, coercively contribute to tumor growth, progression and metastasis, 
and the concept of the tumor microenvironment is now widely accepted (Hanahan and 
Weinberg, 2000). In light of this novel conceptual progress, I therefore aimed to 
establish a link between previously unrelated components of the tumor stroma, 
specifically tumor-associated lymphatic vessels, tensional homeostasis and anti-tumor 
immunity, to elucidate their concerted role in transition to malignancy and metastatic 
dissemination of breast cancer (Swartz and Lund, 2012). 
As activation of VEGFR-3 by its ligands VEGF-C or VEGF-D is known as the 
principal pathway for the induction of lymphangiogenesis during embryonic 
development, but also in pathological conditions in the adult, such as inflammation and 
cancer, experimental modulation of tumor-associated lymphangiogenesis was achieved 
upon alteration of different components of the VEGF-C/VEGF-D - VEGFR-3 
signaling axis in various breast cancer models. In a first approach, I chose to inhibit 
VEGFR-3-mediated activation of the tumor-associated lymphatic vasculature in the 
transgenic MMTV-PyMT model of breast cancer upon administration of mF4-31C1, an 
antagonistic antibody that specifically binds to and ablates VEGFR-3 signaling (Pytowski 
et al., 2005). Conversely, a second approach, orthotopic implantation of a primary tumor 
cell line isolated from an invasive lesion of an MMTV-PyMT+ tumor-bearing transgenic 
mouse that was transduced to stably express increased levels of VEGF-C into the fat 
tissue surrounding the inguinal mammary gland, was employed to investigate whether 
induction of tumor-associated lymphangiogenesis yielded similar results. Although earlier 
experiments in similar orthotopic models have previously already firmly established a 
causal link between VEGF-C expression and tumor metastasis, these models depend on 
the use of immune deficient animals due to the human origin of the breast cancer cell 
lines that were employed to inoculate the tumor (Skobe et al., 2001a; Karpanen et al., 
2001; Mattila et al., 2002). However, given the recently uncovered immunomodulatory 
roles of lymphatic vessels in cancer progression (Swartz, 2014), this model thus 
represents the first experimental model to investigate the interplay between the 
lymphatic vasculature and the anti-tumor immune response upon induction of tumor-
associated lymphangiogenesis in the context of breast cancer. Hence, this work is based 
on two different models that allow experimental modulation of tumor-associated 
lymphatic vessels in order to discern their interactions with the tumor stroma. 
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4.2 Tumor-associated lymphangiogenesis and metastasis 
 
In consideration of the relevance of lymphatic vessels for breast cancer metastasis, I first 
explored whether modulation of tumor-associated lymphangiogenesis affected regional 
or distant metastasis in either experimental model described above. In line with previous 
experiments demonstrating reduced pulmonary metastasis upon systemic administration 
of mF4-31C1 in an orthotopic model of breast cancer (Roberts, 2006), I found that 
inhibition of VEGFR-3-mediated signaling upon administration of mF4-31C1 in 
trasngenic MMTV-PyMT+ tumor-bearing animals did not affect the growth of the 
primary tumor, but instead reduced distant metastasis of the primary tumor to the lungs. 
However, the second approach, i.e. induction of lymphangiogenesis upon orthotopic 
inoculation of VEGF-C+ PyMT tumor cells in the inguinal fat pad, yielded no such 
difference in pulmonary metastasis, as micrometastatic lesions were observed in the 
lungs of both VEGF-C+- and control-tumor-bearing animals 35 days post-tumor 
inoculation. These findings were somewhat unexpected, as forced expression of VEGF-
C in an orthotopic model of breast cancer has previously been reported to promote 
metastatic dissemination of the primary tumor to the lungs (Skobe et al., 2001a). Yet, as I 
opted for inoculation of tumors using only a small number of tumor cells in this model, 
so as to foster a slower tumor growth rate to favor co-evolution of the tumor and the 
recruited stromal cells, the chosen time point to assess pulmonary metastasis may have 
well been too early, and more time may be needed to observe a significant difference in 
the distant metastatic dissemination of the tumor upon induction of VEGF-C 
expression.  
Since modulation of various components of the VEGF-C/VEGF-D - VEGFR-3 
signaling axis has previously also been shown to have a pronounced effect on the rate of 
regional metastasis to the tumor-draining LN, I also investigated whether and to which 
extent the tumor-draining sentinel LN was involved (Roberts, 2006; Skobe et al., 2001a). 
Despite this notion, however, the presence of disseminated tumor cells was practically 
not detected in the LN draining invasive carcinomas of the inguinal mammary gland in 
transgenic MMTV-PyMT+ tumor-bearing animals, neither upon routine histological 
analysis of H&E-stained tumor sections by a pathologist, nor by immunostaining with 
an antibody specific for the PyMT antigen expressed by the transformed mammary 
epithelium, except in one case, in which a large focus of tumor cells was observed by 
both aforementioned methods. In consideration of the reputed importance of the 
tumor-associated lymphatic vasculature for regional metastasis to the tumor-draining LN 
in human disease, however, these findings thus raise the question whether 
lymphogenous metastatic dissemination of the primary tumor indeed occurs in this 
particular transgenic tumor model. The initial description of the model solely indicates 
the presence of foci of disseminated mammary carcinoma cells in the lungs of MMTV-
PyMT+ transgenic animals, whereas the presence of metastasic lesions in the inguinal LN 
are only described upon orthotopic inoculation of primary tumors into the fat pad of 
syngeneic hosts (Guy et al., 1992). Nevertheless, subsequent studies regarding metastatic 
dissemination in breast cancer, however, occasionally do detect similar tumor foci in the 
draining LN, yet the relative contributions of hematogenous and lymphatic spread in the 
formation of these LN metastases are unclear (Garmy-Susini et al., 2013). In fact, it has 
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also been postulated that disseminated tumor cells may even enter the tumor-draining 
LN via the high endothelial venules of the blood vasculature, rather than via tumor-
associated lymphatic vessels in the MMTV-PyMT model of breast cancer (Fantozzi and 
Christofori, 2006). Thus, as up to present date definite proof of lymphogenous 
metastasis in this particular transgenic tumor model has not yet been presented, these 
observations therefore might point out a possible discrepancy between the metastatic 
processes as it presumably occurs in human disease and in the animal model, rendering 
the transgenic MMTV-PyMT model unsuitable to study this aspect of human breast 
cancer.  
Consistent with the aforementioned study, however, I did observe an increase in 
metastasis to the inguinal LN draining VEGF-C+ tumors, particularly in the size of the 
metastatic foci, as compared to the inguinal LN downstream of control tumors, upon 
immunostaining for the PyMT antigen expressed by the tumor cells used to inoculate the 
primary tumor, confirming the notion that regional LN metastasis occurs early on in the 
metastatic process (Skobe et al., 2001a). Though initially an area of controversy, several 
reports have now indeed demonstrated a correlation between VEGF-C expression in the 
tumor, and increased LN metastasis, as well as reduced disease-free and overall survival 
(DFS and OS, respectively) in clinical specimens of breast cancer, suggesting that this 
particular model might better recapitulate lymphogenous metastasis as it is assumed in 
human disease (Mohammed et al., 2007; Nakamura et al., 2005, 2003). 
 
 
4.3 The tumor microenvironment 
 
Whereas the importance of lymphatic vessels for breast cancer metastasis has been well 
established, not much is known about how tumor-associated lymphatic vessels promote 
regional and distant metastatic dissemination of the primary tumor. Although lymphatic 
vessels have traditionally been considered as merely providing an escape route for 
invasive tumor cells, it is becoming increasingly clear that tumors actively induce 
remodeling of the lymphatic vasculature to facilitate metastasis to distant organs (Stacker 
et al., 2014). However, as previous experiments have predominantly focused on the 
interaction between the nascent tumor and its associated lymphatic vessels, the current 
thesis work thus aimed to discern whether interactions between the evolving tumor 
stroma and the lymphatic vasculature could promote the metastatic dissemination of 
invasive carcinomas of the breast. Remarkably, experimental modulation of VEGF-C / 
VEGFR-3-mediated activation of the lymphatic endothelium did not result in changes in 
the desmoplastic response, or the innate and adaptive immune responses to the tumor. 
Similar to human breast cancer, developing tumors in MMTV-PyMT+ transgenic mice 
are associated with the induction of a substantial desmoplastic stroma that results in 
altered tensional homeostasis upon co-evolution of the transformed epithelium and the 
fibroblasts of the connective tissue. However, inhibition of VEGFR-3-mediated 
signaling upon administration of mF4-31C1 did not alter the expanse or the composition 
of the desmoplastic ECM in MMTV-PyMT+ tumor-bearing mice, as compared to IgG-
treated control animals. Earlier experiments from our laboratory have shown that LECs 
can activate fibroblasts through production of TGF-β1 upon stimulation with VEGF-C 
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(manuscript in preparation). However, in this particular model, abrogated VEGFR-3 
signaling in the primary tumor did not translate into an effect on the desmoplastic 
stroma in transgenic MMTV-PyMT+ tumor-bearing animals. One reason for these 
findings may be that, although LECs may contribute directly to stromal stiffening during 
tumor growth and progression in developing tumors, these effects may be more relevant 
in early hyperplastic lesions, where the formation of the reactive stroma is induced. 
Notably, upon initiation of the treatment with mF4-31C1, there is already a substantial 
activation of the tumor stroma ongoing in transgenic MMTV-PyMT+ tumor-bearing 
animals, and as fibroblasts constitute the principal source of TGF-β1 in the tumor, 
activation of CAFs at this point in time may thus override the initial effects of TGF-β1 
that is secreted by LECs on the tumor stroma. 
In light of the close association of lymphangiogenesis and inflammation, I next assessed 
whether modulation of tumor-associated lymphatic vessels affected the inflammatory 
response to the tumor in both experimental models of breast cancer. In MMTV-PyMT+ 
transgenic mice, tumor development is accompanied by a potent inflammatory response, 
particularly in early hyperplastic lesions, that is mediated by infiltrating TAMs. However, 
upon treatment with mF4-31C1, which was initiated at the onset of hyperplasia and 
continued until the lesions had progressed to invasive carcinomas, I observed no 
changes in the infiltration of F4/80+ TAMs or their relative phenotype, respectively. 
Conversely, enhanced expression of VEGF-C in the primary tumor yielded similar 
results, as it did not alter the infiltration of innate myeloid cells, and TAMs in particular, 
into the tumor, suggesting that tumor-associated lymphatic vessels do not actively 
promote inflammation in the nascent tumor in the breast cancer models that were 
employed in this thesis. Furthermore, in contrast to earlier reports, these results also 
indicate that the recruitment of TAMs into developing tumors in these experimental 
models is not mediated by VEGF-C (Schoppmann et al., 2002). Indeed, RNA 
sequencing of TAMs isolated from invasive carcinomas in MMTV-PyMT+ tumor-
bearing mice demonstrated that, at least in this particular transgenic model, TAMs do 
not express VEGFR-3, thus providing an explanation for these observations. 
Finally, modulation of tumor-associated lymphangiogenesis did not notably alter the 
infiltration or phenotype of the T lymphocytes in the tumor in either model, suggesting 
that tumor-associated lymphatic vessels do not affect T-cell-mediated immunity in the 
experimental breast cancer models employed in this thesis. Yet, in VEGF-C+ tumors, I 
observed a slight trend towards immune suppression, reflected in an increase in the 
fraction of PD-1+ CD8+ cytotoxic T cells in the tumor, and simultaneous decrease in 
expression levels of CD69 on their surface, respectively, as compared to control tumors. 
However, as orthtotopic implantation of VEGF-C+ PyMT tumor cells in the inguinal fat 
pad resulted in a 44-fold increase in VEGF-C expression levels in these tumors, these 
observations thus raise the question how relevant these findings may be for human 
breast cancer. 
Altogether, the obtained results demonstrate that tumor-associated lymphatic vessels do 
not alter the tumor stroma in various experimental models of breast cancer. These 
observations were unusually consistent, in that both VEGF-C-mediated induction of 
tumor-associated lymphangiogenesis, as well as inhibition of VEGFR-3-mediated 
signaling did not bring about any changes, as far as the different parameters that were 
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measured to assess the various components of the tumor microenvironment in these 
experiments is concerned. Hence, these findings suggest that VEGF-C / VEGFR-3-
mediated signaling in breast cancer may thus promote metastatic dissemination of the 
tumor through specific interactions between the developing tumor and its associated 
lymphatic vasculature, and accordingly strengthen previous publications discerning 
mechanisms of tumor cell-lymphatic cross-talk that contribute to the preferential 
lymphogenous spread of invasive carcinomas of the breast (Issa et al., 2009; Shields et 
al., 2007). 
 
 
4.4 VEGF-C / VEGFR-3 signaling and angiogenesis 
 
All in all, the observation that inhibition of VEGFR-3-mediated signaling upon 
administration of mF4-31C1 in transgenic MMTV-PyMT+ tumor-bearing animals 
reduced pulmonary metastasis, while obvious lymphogenous spread of the primary 
tumor could not be detected in this model, is certainly interesting and prompts a more 
thorough investigation into the mechanism of metastatic dissemination in breast cancer. 
Although suppression of VEGFR-3 signaling significantly impeded the expansion of 
tumor-associated lymphatic vessels as compared to IgG-treated animals, it cannot be 
excluded that mF4-31C1 mediates the observed effect on pulmonary metastasis through 
an effect on the tumor-associated blood vasculature. In fact, the blood and lymphatic 
system are intimately linked, which is reflected in their common origin in the developing 
embryo, and as such modulation of VEGFs or their respective receptors might thus 
affect components of both vascular systems. Indeed, VEGFR-3 is initially expressed by 
the evolving blood vasculature before the onset of lymphatic vessel development, at 
which point it becomes largely restricted to the lymphatic endothelium (Kaipainen et al., 
1995). Accordingly, targeted deletion of vegfr3 in the early embryo resulted in lethality 
due to severe defects in the blood vasculature, demonstrating the importance of 
VEGFR-3 in the development of the cardiovascular system (Dumont et al., 1998). 
However, in the adult, weak expression of VEGFR-3 has also been found on capillaries 
of the blood vascular endothelium in normal breast tissue, which increases in angiogenic 
blood vessels in invasive tumors (Valtola et al., 1999). Likewise, administration of mF4-
31C1 led to a reduction in blood vessel density in various orthotopic and subcutaneous 
tumor models of breast and other solid cancers, respectively, thus supporting the 
hypothesis that administration of an antagonistic antibody that specifically binds to and 
ablates VEGFR-3 signaling exerts dual effects on both the tumor-associated blood and 
lymphatic vasculature (Roberts, 2006; Laakkonen et al., 2007). More specifically, 
VEGFR-3 was recently demonstrated to be highly expressed by the leading endothelial 
tip cells in angiogenic sprouts, and genetic and pharmacological disruption of VEGFR-3 
signaling in the context of various physiological and pathological settings significantly 
impaired the growth of blood vessels, demonstrating the importance of VEGFR-3-
mediated sprouting in both developmental and tumor angiogenesis (Tammela et al., 
2008). Nonetheless, despite these findings, I observed but a slight trend towards a 
reduction in the number of CD31+gp38- BECs in the primary tumor that was not 
significant (p = 0.23). However, functional experiments to dissect the relative 
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contributions of VEGFR-2- and VEGFR-3-mediated signaling to angiogenesis in vivo, 
showed that, although VEGFR-3 ligands VEGF-C or VEGF-D alone failed to induce 
an expansion of the blood vasculature, these growth factors could sustain angiogenesis 
in blood vessels that were previously primed with VEGFR-2 ligands, even in the 
presence of VEGFR-2 inhibitors (Tammela et al., 2008). These observations thus 
suggest that, whereas VEGFR-2-mediated signaling represents the main pathway for the 
induction of angiogenic growth of blood vessels during development or in incipient 
tumors, VEGFR-2 ligands may additionally act to sensitize these vessels to other growth 
factors of the VEGF family, including those that are principally known to induce 
lymphangiogenesis, which may then act in concert to support further development and 
maintenance of the blood vasculature.  In line with these findings, I observed a 
significant increase in the expression VEGF-A in early hyperplastic lesions in MMTV-
PyMT+ tumor-bearing mice, but not in VEGF-C or VEGF-D, which may indeed induce 
the expression of VEGFR-3 on tumor-associated blood vessels.  Interestingly, 
expression levels of VEGF-C were significantly increased in invasive carcinomas, as 
compared to WT tumor-free mice, suggesting that VEGF-C may, in addition to its 
effects on tumor-associated lymphatic vessels, additionally act to support angiogenic 
blood vessels at this point in time. Collectively, these considerations may thus provide an 
explanation for the observed reduction in pulmonary metastasis in the absence of 
lymphogenous spread of the primary tumor upon administration of mF4-31C1 in 
MMTV-PyMT+ transgenic mice. 
Conversely, in consideration of the complex reciprocal regulation of angiogenesis and 
lymphangiogenesis by the various endothelial growth factors of the VEGF family and 
their corresponding receptor tyrosine kinases, I also considered whether enhanced 
expression of VEGF-C in the primary tumor could affect the tumor-associated blood 
vasculature. In agreement with previous findings, I observed a 10-fold increase in the 
number of CD31+gp38+ LECs in the primary tumor upon orthotopic implantation of 
VEGF-C+ PyMT tumor cells into the inguinal fat pad, which translated into a substantial 
increase in peritumoral CD31+lyve-1+ lymphatic vessels as compared to tumors that 
were inoculated with control-transduced PyMT tumor cells (Skobe et al., 2001a). 
However, initially, forced expression of VEGF-C was not reported to induce an 
expansion of the tumor-associated blood vasculature (Skobe et al., 2001a). Yet, more 
recently, expression of VEGF-C was also associated with an increase in MVD in clinical 
specimens of breast cancer, thus suggesting that, besides promoting tumor-associated 
lymphangiogenesis, VEGF-C may indeed also exert an effect on the blood vessels within 
the tumor (Mohammed et al., 2007). Accordingly, although the number of CD31+gp38- 
BECs in the tumor was seemingly not affected by enhanced expression of VEGF-C in 
the primary tumor, histological analysis of CD31+lyve-1- blood vascular endothelium, on 
the other hand, demonstrated an increase, albeit not significant (p = 0.10), in the relative 
area occupied by these vessels. The apparent discrepancy between these findings might 
arise from the different approaches that were used to quantify MVD in the tumors, as 
the relative blood vessel density was previously determined in so-called 'hot spots' with 
the highest frequency of lymphatic vessels (Skobe et al., 2001a). In addition to the 
fundamental bias that may result from such measurements, the occurrence of new blood 
vessels may also not coincide spatially with the growth of lymphatic vessels. Indeed, 
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although the question whether lymphangiogenesis ensues in human breast cancer has 
been a matter of intense debate, lymphatic hyperplasia is frequently observed at the 
tumor periphery, whereas blood vessels usually appear scattered throughout the 
developing tumor (Mohammed et al., 2009). In my experiments, I assessed blood and 
lymphatic density using a whole-tissue based approach, thus avoiding a possible bias that 
may result from a manual selection of areas with the highest quantity of vessels. 
Although VEGF-C may mediate an expansion of tumor-associated blood vessels upon 
activation of VEGFR-3 on the blood vascular endothelium, another possibility may be 
that secreted VEGF-C may affect other VEGF receptor tyrosine kinases. Indeed, 
proteolytic processing of VEGF-C in the extracellular space yields shorter forms that 
have an increasing affinity for VEGFR-2 (Joukov et al., 1997). Although VEGF-C 
expression levels in the tumor were determined by an immunoassay that specifically 
detects full-length VEGF-C, it cannot exclude the presence of other, shorter forms of 
the protein, yet this possibility was not assessed in this thesis.  
In consideration of a surmised modulation of the blood vascular endothelium upon 
alteration of different components of the VEGF-C / VEGFR-3 signaling axis in the 
various breast cancer models employed in this thesis, one could accordingly anticipate 
possible consequences for tumor growth. Indeed, in various orthotopic models of breast 
and other cancers, anti-angiogenic effects mediated by mF4-31C1 translated into a 
reduction in the rate of tumor growth (Roberts, 2006; Laakkonen et al., 2007). However, 
neither administration of mF4-31C1 in MMTV-PyMT+ tumor-bearing mice, or 
enhanced expression of VEGF-C affected the size of the primary tumor. One possible 
explanation for these observations may be that, although VEGFR-3-mediated activation 
of the blood vascular endothelium may provide support to angiogenic blood vessels 
within the tumor, the relative contribution to the formation of new blood vessels may in 
fact be rather limited in comparison to VEGFR-2-mediated angiogenesis. In fact, 
VEGF-A is highly expressed in both the transgenic, as well as the orthotopic model, 
suggesting that canonical activation of VEGFR-2 by its ligand VEGF-A constitutes the 
main signal transduction pathway that induces blood vessel growth in these experimental 
models, and, activation of VEGFR-3 in angiogenic blood vascular endothelium may, as 
previously proposed, solely provide sustenance to the developing vasculature. 
Additionally, due to the heterogeneity of the transgenic MMTV-PyMT model, in which 
tumors often display different kinetics with regard to tumor growth and progression, a 
rather limited number of 7 animals per treatment group may not suffice to see an effect 
on tumor size upon administration of mF4-31C1. However, even upon orthotopic 
implantation of VEGF-C+ PyMT tumor cells in the inguinal fat pad, which induces 
tumors that grow more reproducibly, although VEGF-C+ tumors were consistently 
slightly bigger compared to control tumors, a significant effect on the rate of tumor 
growth could not be observed. Despite these findings, a reduction was only observed 
when tumors notably expanded. Hence, a possible effect on the primary tumor may not 
manifest itself until the tumor reaches a certain size, and due to the legal restrictions on 
tumor volume, a difference may thus not become apparent. Nonetheless, these results 
suggest that modulation of VEGF-C / VEGFR-3 signaling in experimental models of 
breast cancer may in part mediate metastatic dissemination via effects on the blood 
vasculature.  
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4.5 Lymphogenous or hematogenous metastasis? 
 
The possible contribution of the blood vasculature to breast cancer metastasis renders us 
at the initial debate on the relative contributions of hematogenous and lymphogenous 
spread in the formation of regional and distant metastases. The fact that tumor cells 
indeed preferentially invade lymphatic vessels rather than blood vessels, establishes a 
connection between LVI and LN metastasis (Van den Eynden et al., 2006). 
Nevertheless, although the presence of tumor cells in the draining LN is a major 
prognostic factor in the staging of breast cancer, it is not known whether disseminated 
tumor cells in the regional LN actively contribute to further metastatic spread. 
Consequently, two different models, which are not mutually exclusive, have been 
proposed to explain the formation of distant metastases in patients diagnosed with 
breast cancer (Ran et al., 2010). The first model suggests that lymphatic-independent 
hematogenous metastasis is the sole route for the emergence of metastatic lesions in 
distant organs is through invasion of tumor-associated blood vessels, with little or no 
contribution of the lymphatic vasculature beyond regional dissemination to the tumor-
draining LN. Indeed, metastatic tumor cells that emerge within the sentinel LN may 
merely reflect the aggressiveness of the primary tumor and nothing else. The fact that 
metastatic foci in the tumor-draining LN in themselves are not life threatening, which is 
reflected in the high DFS despite the spread of invasive tumor cells, supports this 
hypothesis. In contrast, the lymphatic-dependent sequential model of metastasis states 
that remodeling of the lymphatic vasculature associated with the tumor and beyond by 
the developing neoplastic lesion may actively promote metastatic dissemination of the 
primary tumor to the tumor-draining LN, and ultimately distant organs, which these cells 
may reach through either the blood or lymphatic vasculature upon egress from the LN. 
Although direct proof of the contribution of lymphatic vessels to distant metastasis is 
lacking, the prognostic value of LN status for disease outcome would suggest otherwise, 
and in view of this current debate it would thus be enticing to investigate whether and 
how the tumor-draining LN may promote metastasis progression (Van den Eynden et 
al., 2007). Interestingly, increased expression of VEGF-C in the primary tumor resulted 
in increased metastasis to the tumor-draining LN. However, as an inherent consequence 
of the model, metastatic tumor cells that arrive in the tumor-draining LN will continue 
to express VEGF-C, and as such stimulate the sinusoidal lymphatic endothelium in the 
LN. Considering the current controversy, it would thus be interesting to investigate 
whether different mitogenic stimuli may not only quantitatively, but also qualitatively 
alter the lymphatic endothelium in the LN to promote further metastatic spread of 
disseminated tumor cells. Moreover, in light of the different clinical manifestions of 
breast cancer, further efforts should also be directed towards discerning whether 
different tumors arising in different anatomical locations, i.e. ductal or lobular 
carcinomas of the breast, or different molecular subtypes within the histological 
subtypes may display a preference towards hematogenous or lymphatic metastasis. 
Regardless of the prevalence of either pathway for metastatic dissemination, the question 
whether and how inhibition or stimulation of VEGFR-3-mediated signaling may 
simultaneously affect both hematogenous and lymphatic metastatic dissemination of the 
primary tumor is intriguing, and opens up an avenue for combined targeting of the 
 ? ???
blood and lymphatic vasculature, which may display increased efficacy in the clinic. In 
consideration of this, other therapeutic modalities targeting related vascular signaling 
systems, such as the Ang-TIE signaling axis, that were previously reported to reduce 
distant metastasis upon inhibition of tumor-associated angiogenesis may simultaneously 
affect the lymphatic vascular endothelium (Mazzieri et al., 2011). Therefore, these 
findings definitely prompt further investigation to determine the effects of modulation 
of the VEGF-C / VEGFR-3 signaling axis, as well as related vascular signaling systems, 
on both the blood and lymphatic vasculature and their relative contributions to 
hematogenous metastasis, as opposed to lymphogenous spread, in breast cancer. 
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5 
 
 
Experimental Procedures 
?
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5.1 Modulation of tumor-associated lymphatic vessels in different mouse models 
of breast cancer 
 
5.1.1 Inhibition of tumor-associated lymphangiogenesis during tumor 
progression in a transgenic mouse model of breast cancer 
 
The MMTV-PyMT mouse model of breast cancer 
 
Transgenic FvB/N-Tg (MMTV-PyVT)634Mul/J mice (Cat. # 002374, Jackson 
Laboratories), also known as the mouse mammary tumor virus (MMTV)-polyoma 
middle T antigen (PyMT) model of breast cancer, have been previously described (Guy 
et al., 1992). In MMTV-PyMT+ transgenic animals, expression of the PyMT oncogene, 
which is under the control of the MMTV promoter and thus directed to the mammary 
epithelium, results in its transformation throughout the ductal tree, leading to the 
development of hyperplastic lesions that gradually progress to form invasive carcinomas, 
and eventually pulmonary metastases (Lin et al., 2003). Female wild-type FvB/N mice 
were bred in-house with FvB/N males bearing the MMTV-PyMT mutation to yield 
concurrent litters of female wildtype (WT) FvB/N and MMTV-PyMT+ transgenic mice. 
Genotyping of transgenic animals was routinely performed by Transnetyx (Memphis, 
Tennessee). For the experimental procedures described below, animals were used 
between 6-7 weeks of age (onset of hyperplastic lesions) and 11-12 weeks of age 
(progression to invasive carcinomas), respectively. All experimental procedures were 
approved by the Veterinary Authorities of the Canton Vaud according to Swiss Law.  
 
 
Inhibition of tumor-associated lymphangiogenesis  
 
To examine the importance of tumor-associated lymphangiogenesis on tumor growth 
and progression in a relevant preclinical model of breast cancer, a function-blocking 
antibody against murine (m)VEGFR-3 (mF4-31C1, ImClone / Eli Lilly and Company, 
(Pytowski et al., 2005)), the main receptor for the lymphangiogenic growth factors 
VEGF-C and -D, respectively, that is expressed predominantly on the lymphatic 
endothelium, was administered to female MMTV-PyMT+ transgenic mice upon onset of 
hyperplasia at 7 weeks of age. Prior to the treatment, mice were randomized according to 
tumor burden up to the extent that palpation allowed identification of tumor onset 
within the inguinal fat pad. Upon start of the trial, 500 μg of αVEGFR-3 or its 
corresponding rat IgG isotype control (purified rat IgG, Cat. # I4131, Sigma-Aldrich) 
was administered 3 times per week via intraperitoneal (i.p.) injection until these lesions 
progressed to an invasive carcinoma at 12 weeks of age. To determine whether treatment 
with therapeutic antibodies provoked adverse effects in healthy animals, one group of 
age-matched WT littermate controls received i.p. injections with rat IgG isotype control 
for the duration of the experiment. 
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5.1.2 Development of an orthotopic tumor model to induce lymphatic vessel 
growth in the context of breast cancer 
 
5.1.2.1 Generation of stable VEGF-C-overexpressing (VEGF-C+) tumor cell lines 
 
Plasmid DNA for lentiviral expression vectors 
 
pD2109 lentiviral expression vector containing the sequence for murine (m)VEGFC 
cDNA (GeneID 22341), in the following abbreviated as pD2109-mVEGFC, was 
purchased from DNA2.0 (Newark, California). The corresponding control lentiviral 
expression vector, designated as pD2109-control, was obtained by removing the 
aforementioned sequence from the original vector through restriction enzyme digest. 
Briefly, pD2109-mVEGFC was digested for 3 hours at 37°C with PstI and XbaI (Cat. # 
R3140 and R0145, New England Biolabs). Following separation of the plasmid 
fragments by gel electrophoresis, the linearized plasmid backbone was isolated using the 
High Pure PCR Product Purification Kit according to the manufacturers instructions 
(Cat. # 11 732 676 001, Roche). The circular plasmid was then obtained by blunting the 
5' and 3' overhangs generated upon enzymatic restriction digestion for 2 hours at room 
temperature with the Quick Blunting Kit (Cat. # E1201, New England Biolabs) and 
subsequent ligation for 20 minutes at room temperature with the Quick Ligase Kit (Cat. 
# M2200, New England Biolabs) following a plasmid purification step as described 
above.  
 
 
Amplification and purification of plasmid DNA 
 
For amplification of the pD2109-mVEGFC and pD2109-control plasmids, competent 
E. coli (One-Shot TOP10 Competent Cells, Cat. # C4040, Invitrogen) were transformed 
for 45 seconds at 42°C and plated on LB-agar plates containing 50 μg/ml kanamycin 
(CAS # 59-01-8, SV-IN, EPFL) to obtain single colonies. Following over night 
incubation at 37°C, 5-6 antibiotic-resistant colonies were picked and amplified in 3 ml of 
LB-kanamycin for 16-20 hours. To select the bacterial colonies that contain the correct 
pD2109-mVEGFC or pD2109-control plasmids, respectively, a diagnostic restriction 
digest was performed with XmaI and PvuII (Cat. # R0180 and R3151, New England 
Biolabs) upon purification of plasmid DNA from 2 ml of each bacterial culture using the 
Zyppy Plasmid Miniprep Kit (Cat. # D4019, Zymo Research). For further amplification 
of the correct transfer plasmids, the remaining 1 ml of one bacterial culture previously 
transformed with pD2109-mVEGFC or pD2109-control, respectively, was then 
inoculated in 500 ml of LB-kanamycin and incubated at 37°C and 225 rpm during 16 
hours. The corresponding plasmids were subsequently isolated using the NucleoBond 
Xtra Plasmid Maxiprep Kit (Cat. # 740414, Machery-Nagel) and the presence, or 
absence of the VEGF-C insert was confirmed by DNA sequencing prior to production 
of pseudo-lentiviral particles (Microsynth, Switzerland). 
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Production and titration of lentiviral vectors 
 
Lentiviral vectors for the generation of stable VEGF-C-overexpressing or control 
murine breast cancer cell lines were kindly provided by M. Squadrito. To this end, 
human embryonic kidney (HEK)293T cells (CRL-3216, ATCC) were co-transfected in 
the presence of 125 mM calcium chloride (CaCl2, CAS # 10043-52-4) with 32 μg of 
either transfer plasmid pD2109-mVEGFC or pD2109-control, respectively, as well as 
12.5 μg  and 6.25 μg packaging plasmids pMDL9/pRRE and pRSV-Rev (gifts of D. 
Trono, Addgene plasmids #12251 and #12253), and 9 μg envelope plasmid pMD2 (gift 
of D. Trono, Addgene plasmid #12259) to yield third-generation pseudo-lentiviral 
particles. To increase the efficiency of lentiviral vector production, 15 μg of pAdvantage 
vector (Cat. #1711, Promega) was added during the procedure. Total vector 
concentration and biological titer of each vector stock were determined by anti-p24 
immunoassay (Cat. # 0801111, ZeptoMetrix) and TaqMan qPCR assay for HIV-1-
specific gag with albumin as a reference gene as previously described (Table 1, Appendix 
A1.1, Barde et al., 2010). The packaging efficiency of the pseudo-lentiviral particles was 
then calculated for each vector stock by dividing the biological titer by the physical titer.  
 
 
Transduction of murine breast cancer cell lines 
 
An invasive primary tumor cell line isolated from the spontaneous MMTV-PyMT mouse 
model of breast cancer, in the following abbreviated as PyMT tumor cells, was kindly 
provided by I. Keklikoglou. PyMT tumor cells were routinely maintained in IMDM with 
GlutaMax (Cat. # 31980, Gibco), supplemented with 10% heat-inactivated FBS (Cat. # 
10-082, Gibco) and passaged 1:10 every 4-5 days, whereas medium was changed every 2-
3 days during subculture. P. Corthésy regularly tested cells for the absence of 
mycoplasma. To generate stable VEGF-C-overexpressing (VEGF-C+) or control murine 
breast cancer cell lines, PyMT tumor cells were transduced with unconcentrated 
pD2109-mVEGFC or pD2109-control vector. Briefly, 1.0?105 PyMT tumor cells were 
seeded per well in a 6-well-plate (CellStar, Cat. # 657160, Greiner) in full medium on the 
evening prior to infection. The following afternoon, the cells were transduced during 12-
16 hours with a multiplicity of infection (MOI) of ca.  103 transducing units (TU) of 
either pD2109-mVEGFC or pD2109-control lentiviral vector, resepctively. To avoid 
lentivirus-mediated toxicity, PyMT tumor cells were transduced with three doses of each 
vector, i.e. by addition of a 1:1, 1:5 or a 1:20 dilution of each lentiviral vector stock in full 
medium. The next morning, the cells were washed twice with 1x PBS (Cat. # 10010, 
Gibco), and fresh medium was added to allow the cells to recover for 48-72 hours prior 
to antibiotic selection of successfully transduced tumor cells. 
 
 
Selection of stable VEGF-C+ and control breast cancer cell lines 
 
To select only those tumor cells that integrated the proviral DNA into their genome, the 
cells were cultured in the presence of 2 μg/ml puromycin (CAS # 58-58-2, Cat. # 54041, 
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Calbiochem) in full medium for 4-5 days upon their recovery after infection. The 
sensitivity of the parental PyMT tumor cell line to puromycin was determined previously 
by treating the cells with different doses of the antibiotic in full medium, at 1, 2 or 5 
μg/ml for up to 72 hours. Cell viability was then assessed by flow cytometry after 24, 48 
and 72 hours upon addition of propidium iodide to a final concentration of 1 μg/ml (PI, 
CAS # 25535-16-4, Cat. # P4864, Sigma-Aldrich). Untreated cells were used to 
determine baseline viability at each time point. To confirm that no replication-competent 
recombinant viral particles emerged, the resulting polyclonal batch culture was 
subsequently tested for residual HIV-1-specific p24 antigen by immunoassay according 
to the manufacturers instructions (Cat. # 0801111, ZeptoMetrix) before further analysis. 
 
 
5.1.2.2 Characterization of stable VEGF-C+ and control breast cell lines in v i tro 
 
Calculation of lentiviral DNA copy number 
 
As transduction with different doses of lentiviral vectors yielded three VEGF-C-
overexpressing, i.e. VEGF-C+, and three control tumor cell lines, respectively, each cell 
line was characterized extensively prior to further functional experiments. First, as a 
measure of transduction efficiency, the number of proviral DNA copies that integrated 
into the genome was determined for each VEGF-C+ and control-transduced cell line by 
TaqMan qPCR assay for HIV-1-specific gag using titin as a reference gene as previously 
described (Table 1, Appendix A1.1, Barde et al., 2010). Briefly, 2.5?105 tumor cells were 
seeded per well in a 12-well plate (CellStar, Cat. # 665180, Greiner) in full medium in 
triplicate on the evening prior to the experiment. Untransfected PyMT cells were used as 
a negative control. The ensuing morning, genomic DNA was extracted using the High 
Pure PCR Template Preparation Kit (Cat. # 11 796 828 001, Roche) and the 
concentration of each sample was measured with Nanodrop. Samples were stored at -
20°C until needed. The proviral DNA copy number within the genome of each cell line 
was then calculated as follows: 
 
???????????????????????????????? ??? ? ? ???????????????????????????? ? ?  
 
 
Determination of cell division rate 
 
Next, as integration of the proviral DNA can occur randomly within the genome and 
may cause disruptions within functional genes, the proliferation rate was assessed for 
each cell line as compared to the parental PyMT cell line. To this end, 1.0?104 tumor cells 
were seeded per well in a 24-well plate (CellStar, Cat. # 662160, Greiner) in full medium, 
and the number of cells was then determined in 24-hour intervals for 5 consecutive days 
using a Neubauer chamber and 0.4% Trypan Blue solution (Cat. # 15-250-061, Gibco) 
to exclude dead cells. To determine the growth rate, total cell number was plotted on a 
logarithmic scale against the time of counting, and the generation time and division rate 
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of each cell line during the exponential growth phase were then calculated from the 
slope of each growth function using the following formulas: 
 
??????????????????????? ? ? ?????   , 
 
where k represents the specific growth rate in hours, and 
 
????????????????????? ?? ? ???????????????????????????????  
 
 
Analysis of VEGF-C expression levels in v i tro  
 
Finally, the functionality of the transgene was assessed by analysis of VEGF-C 
expression levels by qRT-PCR and immunoassay, respectively. In short, 2.5?105 tumor 
cells were seeded per well in a 12-well plate in full medium in triplicate on the evening 
prior to the experiment. For cell counts, one extra well was prepared per cell line. The 
next morning, the cells were washed twice with 1x PBS and IMDM medium containing 
2% FBS was added to the cells. After 24 hours, the supernatant was harvested, as well as 
total RNA of each corresponding sample extracted using the RNeasy Plus Micro Kit 
(Cat. # 74034, Qiagen) and samples were stored at -20°C until needed. VEGF-C mRNA 
expression levels were determined by two-step reverse transcription (RT)-qPCR. Briefly, 
1 μg of total RNA was reverse transcribed using the iScript cDNA Synthesis Kit (Cat. # 
1708890, BioRad) to yield cDNA. Following determination of the Cq values for vegfc and 
β-actin as a reference gene with Sybr Green I dye (Lightcycler 480 Sybr Green I Master 
Mix, Cat. # 04707516001, Roche) on a Lightcycler 480 qPCR instrument (Roche), 
VEGF-C mRNA expression levels were subsequently calculated using the 2-ΔΔCq 
method. Levels of secreted VEGF-C in the supernatant were determined by VEGF-C 
immunoassay (Quantikine Human VEGF-C ELISA kit, Cat. # DVEC00, R&D).  
 
 
5.1.2.3 Induction of tumor-associated lymphangiogenesis upon orthotopic 
injection of VEGF-C+ breast cancer cell lines in v ivo  
 
Orthotopic inoculation of tumor cells 
 
Female FvB/N mice were purchased from Charles Rivers Laboratory (France) and used 
between 8-10 weeks of age. All procedures were performed according to protocols 
approved by the Veterinary Authorities of the Canton Vaud according to Swiss law. For 
orthotopic inoculation of PyMT tumors, either 2.5?105 VEGF-C+ or control-transduced 
tumor cells were injected into the inguinal mammary gland as previously described 
(Fridman et al., 2012). To this end, mice were anesthetized by i.p. administration of 200 
μl of a mixture consisting of 1 mg/kg medetomidine (Dorbene®, Graeub) and 80 
mg/kg ketamine (Ketasol 100®, Graeub), and their left flank was shaved before making 
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a small incision located above the inguinal mammary gland. Once exposed, 2.5?105 
tumor cells were injected directly into the fat tissue surrounding the glands in a volume 
of 20 μl of growth factor (GF)-reduced MatrigelTM (Cat. # 356231, BD Biosciences) at a 
final concentration of 7 mg/ml per gland using a 30G needle (U-100 insulin syringes, 0.3 
ml capacity, Cat. #324826, BD Medical). For the duration of the surgical procedure, 
anesthetized animals were placed on a heating pad, and a layer of Viscotears® (Alcon) 
was applied on the eyes to protect the corneas. Upon its completion, the wounds were 
then closed using 7.5 mm wound clips (Cat. # BN507R, Aesculap, B. Braun), and the 
previously induced anesthesia was antagonized at least 30 minutes post-induction with 
by i.p. injection of 1 mg/kg of atipamezole (Alzane®, Graeub). Finally, to minimize 
pain, the animals received 0.1 mg/kg buprenorphine (Temgesic®, Reckitt Benckiser), 
administered s.c. in the scruff of the neck directly after the procedure, as well as 
paracetamol (Dafalgan®, Bristol-Meyers Squibb), 1 sachet of 250 mg administered in the 
drinking water (250 ml) during the next 3-4 days as analgesic. The surgical staples used 
to close the wound were removed one week post-surgery, and tumor growth was 
monitored twice per week by palpation and caliper measurement for the duration of 
each experiment. Tumor volumes were calculated assuming an ellipsoid shape of the 
tumor, using the following formula where r1 and r2 represent the long and short radius of 
the ellipsoid in mm, respectively: 
 
?????????????????? ?? ??? ? ? ??? ? ??? ? ? ???
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5.2 Deconvolution of the tumor microenvironment during tumor growth and 
progression in transgenic and orthotopic mouse models of breast cancer 
 
5.2.1 Enzyme-Linked ImmunoSorbent Assay 
 
Analysis of cytokine content was performed by immunoassay on whole-tissue protein 
extracts for the following secreted factors: VEGF-A (Mouse VEGF Quantikine ELISA 
kit, Cat. # MMV00, R&D), VEGF-C (Human VEGF-C Quantikine ELISA kit, Cat. # 
DVEC00, R&D), VEGF-D (Mouse DuoSet VEGF-D ELISA kit, Cat. # Dy469, R&D), 
and TGF-β1 (Mouse TGF-β1 DuoSet ELISA kit, Cat. # Dy1679, R&D) according to 
the manufacturers instructions. Briefly, mice were sacrificed by CO2 asphyxiation and 
tumors and their draining LNs harvested. The obtained tissues were then weighed and 
transferred to 2 ml-capacity tubes containing ceramic beads for sample lysis (Lysing 
Matrix D, Cat. # 116913, MP Biomedicals). Total protein was extracted in tissue protein 
extraction (T-PER) buffer (Cat. # 78510, Thermo Scientific), supplemented with one 
tablet of protease inhibitor (Complete EDTA-free, Cat. # 11873580001, Roche) per 20 
ml of buffer, upon disruption of the tissue using a rotary tissue homogenizer set to three 
cycles of 4.0 m/s (FastPrep®-24, MP Biomedicals). Protein lysates were cleared by two 
rounds of centrifugation at full speed and at 4°C in a table top centrifuge and stored at -
80°C until needed. Prior to each immunoassay, total protein content was determined 
using the Pierce BCA Protein Assay Kit (Cat. # 23227, Thermo Scientific). 
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5.2.2 Flow cytometry 
 
Preparation of single cell suspensions 
 
Stromal and immune cell populations in the tumor and tumor-draining LN were 
analyzed by flow cytometry. To this end, mice were sacrificed by CO2 asphyxiation and 
tumors and their draining LNs harvested, and processed to yield single-cell suspensions 
as previously described (Broggi et al., 2014). Briefly, upon coarse mechanical disruption 
with scissors, tumors were subsequently digested with 3.3 mg/ml Collagenase D  (Cat. # 
11088866001, Roche) and 40 μg/ml DNAse I (Cat. # 11284932001, Roche) in digestion 
medium consisting of DMEM, high glucose (Cat. # 41965, Gibco) supplemented with 
2% heat-inactivated FBS and 1.2 mM calcium chloride (CaCl2, CAS # 10043-52-4) for 1 
hour at 37°C under agitation. In addition, tumors were further disrupted by pipetting up 
and down 100 times with an automated pipette every 20 minutes during the digestion, 
before addition of EDTA (prepared in-house by P. Corthésy) to a final concentration of 
5 mM and filtration through a 70 μm cell strainer (Cat. # 352350, Falcon, Corning Inc.) 
to obtain a single-cell suspension. To process the draining LNs, the capsule of each LN 
was gently opened using a 26G needle prior to digestion. In contrast to tumors, tumor-
draining LNs were subjected to a two-step protocol, consisting of a first digestion in 
digestion medium containing 1 mg/ml Collagenase IV (Cat. # LS004188, Worthington) 
and 40 μg/ml DNAse I for 30 minutes at 37°C under agitation, followed by a second 
treatment in digestion medium containing 3.3 mg/ml Collagenase D and 40 μg/ml 
DNAse I. LNs were further disassembled upon one round of disruption with an 
automated pipette prior to addition of 5 mM EDTA and filtration through a 70 μm cell 
strainer as described above. Single cell suspensions of tumors and LNs were then 
washed once with 1x PBS, and prepared for flow cytometric analysis as described below.  
 
 
Staining procedure for flow cytometry 
 
Upon preparation of a single cell suspension, cells were first incubated with Live/Dead 
fixable Dead Cell Stain Kit (Blue, 1:1'000 final dilution in PBS, Cat. # 23105, Thermo 
Fischer Scientific) for 30 minutes on ice for cell viability. Subsequently, cells were 
washed once with 3 ml of FACS buffer consisting of 1x PBS supplemented with 2% 
heat-inactivated FBS. Prior to cell surface staining, cells were incubated with purified rat 
anti-mouse CD16/CD32 (1 : 200, Cat. # 553141, BD Pharmingen) for 10 minutes on 
ice to block Fc receptors. Cell surface staining was then performed without an 
intermediate wash for 20 minutes on ice. If required, subsequent staining for intracellular 
antigens was then performed over night at 4°C using the FoxP3/Transcription Factor 
Staining Buffer Set (Cat. # 005523, eBioscience) according to the manufacturers 
instructions. All antibodies used for cell surface and intracellular staining are listed in 
Table 3 (Appendix A1.2). Unless stated otherwise, both stromal and myeloid cell 
populations were analyzed directly without fixation on a BD LSR-II cytometer, whereas 
lymphocytes were then analyzed during the following day. 
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5.2.3 Histological analysis 
 
Preparation of tissue sections 
 
For histological analysis of the tumor or its draining LN, as well as pulmonary 
metastasis, the inguinal fat pads containing both the tumor and its draining LN, as well 
as the lungs were harvested from MMTV-PyMT+ transgenic animals, or from mice 
bearing orthotopically inoculated VEGF-C+ or control tumors, respectively, following 
CO2 asphyxiation and post-mortem cardiac perfusion with HBSS (Cat. # 14175, Gibco) 
supplemented with 5 ml of heparin (25'000 I.E./5 ml, B. Braun). The obtained tissue 
specimens were directly fixed over night in 20 volumes of 4% paraformaldehyde (PFA, 
prepared in-house by P. Corthésy), unless stated otherwise. The following day, tissue 
samples were washed three times with 20 volumes of 1x PBS under gentle agitation for 
ca. 2-3 hours per wash, prior to over night dehydration in a Leica ASP200 tissue 
processor and subsequent paraffin embedding. Using a Microm HM325 microtome, 4-
μm sections were prepared and captured on Superfrost Plus microscope slides (Cat. # 
J1800AMNZ, Thermo Scientific). Tissue sections were allowed to dry over night in an 
oven at 30°C prior to the staining procedures listed below. 
 
 
Histological evaluation of tumor progression and metastasis 
 
For a delineation of tumor growth and progression in our MMTV-PyMT+ transgenic 
mice bred in-house, as well as the extent of regional and distant metastasis to the 
inguinal LN and lungs in MMTV-PyMT+ tumor-bearing mice and their age-matched WT 
littermates, respectively, previously prepared 4-μm sections of tumors and lungs were 
stained in hematoxylin and eosin (H&E) for 30 minutes using an automated slide stainer 
(Sakura). Histological classification of tumor stage and evaluation of metastasis was 
kindly performed by Nadine Stokar (Pathology, HCF, EPFL). To ensure a thorough 
analysis of the extent of pulmonary metastasis in either breast cancer model, lungs were 
sectioned completely, and one section with 3 tissue specimens at every ca. 50 μm was 
evaluated for the presence of metastatic lesions. Images of micrometastatic lesions were 
recorded at 40x magnification in brightfield illumination using an Olympus Slide Scanner 
VSL120-L100. The presence of metastatic tumor cells in the regional tumor-draining LN 
was confirmed by immunofluorescence with an antibody specific for the PyMT antigen 
(Tables 4 and 5, Appendix A1.4, staining procedure described below). 
 
 
Immunofluorescence staining procedure 
 
Immunostaining of paraffin-embedded tissue specimens was performed as follows. 
Briefly, sections were rehydrated, and, if required, submitted to heat-mediated antigen 
retrieval in citrate buffer pH6.0 for 20 minutes at 95°C (PT module, Thermo Scientific), 
or epitope unmasking with proteinase K treatment (Cat. # 03115879001, Roche) in 1x 
tris-buffered saline (TBS, SV-IN, EPFL) for 10 minutes (Table 4, Appendix A1.4). 
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Subsequently, tissue specimens were washed three times for 5 minutes in TBS before 
drawing an outline of each sample with a water-repellent pen (ImmEdge, Cat. # H-4000, 
Vector Laboratories), blocked in 0.5% casein (Cat. # 218682, CAS 9000-71-9, 
Calbiochem) dissolved in TBS for 1 hour at room temperature, and directly incubated 
with the appropriate primary antibodies in 0.5% casein-TBS containing 0.01% Triton-
X100 (CAS 9002-93-1, Applichem) over night at 4°C in a humidified staining chamber 
(Table 4, Appendix A1.4). The next morning, slides were washed twice with 0.1% 
Triton-X100 in TBS, and once in TBS for 5 minutes per wash, and incubated with the 
corresponding secondary antibodies in 0.5% casein-TBS containing 0.01% Triton-X100 
for 1 hour at room temperature (Table 5, Appendix A1.4). Lastly, slides were washed 
once more as described above, and incubated with DAPI (Cat. # 1306, Thermo 
Scientific) diluted 1 : 5'000 in TBS  for 20 minutes at room temperature. Slides were 
washed once more, this time in TBS only, and mounted using ProLong Gold anti-fade 
mountant (Cat. # 36930, Molecular Probes), coverslipped (Menzel-Gläser #1, 24x60 
mm) and sealed with nail polish. All antibodies used for immunofluorescence staining 
are listed in Tables 4 and 5 in Appendix A1.4. Unless otherwise specified, sections were 
imaged at 20x magnification, using an Olympus Slide Scanner VSL120-L100. 
 
 
Immunohistochemistry and picrosirius red double chromogenic staining 
 
Total collagen content and collagen-crosslinking enzyme LOX in the tumor were 
visualized using double chromogenic staining of picrosirius red in combination with 3, 3-
diaminobenzidine (DAB) chromogen. To this end, sections were rehydrated and washed 
three times for 5 minutes in TBS before drawing an outline of each sample with a water-
repellent pen as described above in the staining procedure for immunofluorescence. 
Next, endogenous peroxidases were quenched using 3% H2O2 (Cat. # 107209, Merck 
Millipore) in 1x TBS for 10 minutes, after which sections were washed 3 times in TBS 
for 5 minutes per wash, blocked in 0.5% casein-TBS for 30 minutes at room 
temperature, and directly incubated with the appropriate primary antibody diluted in 
0.01% Triton-X100 in 0.5% casein-TBS over night at 4°C in a humidified staining 
chamber (Table 4, Appendix A1.4). The ensuing morning, sections were washed 3 times 
in TBS for 5 minutes per wash, and incubated with a secondary HRP-conjugated 
antibody diluted in 0.01% Triton-X100 in 0.5% casein-TBS at room temperature for 45 
minutes. Finally, sections were washed 3 times TBS for 5 minutes per wash once more 
before developing the sections with DAB substrate (SigmaFAST DAB tablets, Cat. # 
D4293, Sigma-Aldrich). Upon reaching the desired intensity, while background staining 
is still low, the reaction is quenched by dipping the slides in 1 x in Tris-HCl pH 7.6, 
washed 3 times and directly stained with picrosirius red using an automated slide stainer 
(Sakura). To enhance the contrast between picrosirius red and the DAB chromogen, the 
DAB substrate solution was supplemented with 10% nickel (CAS # 7440-02-0, Cat. # 
09885, Sigma). Pictures were taken at 20x magnification under brightfield and polarized 
illumination using an Olympus AX70 microscope. 
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Quantification of blood and lymphatic vessel area 
 
Lymphatic and blood vessel area were determined upon immunofluorescence for the 
tumor-associated vasculature with antibodies against pan-endothelial CD31, gp38, and 
lymphatic-specific lyve-1 and VEGFR-3, respectively (Tables 4 and 5, Appendix A1.4). 
To determine the area fraction covered by blood or lymphatic vessels in whole-tissue 
sections, respectively, a semi-automated approach was applied using a macro written by 
O. Burri (BIOP, EPFL, see Appendix A1.5). Briefly, to determine the percentage of area 
that is covered by lymphatic vessels, the tumor or draining LN was outlined manually on 
the DAPI channel as the region of interest (ROI), in which the lymphatic or blood 
vessel area was then quantified upon selection of the appropriate threshold. The area 
fraction of lymphatic vessels for each imaging plane was then obtained using the 
following formula: 
 
???????????????????????????? ? ?????????????????????????? ? ???? 
 
Unless stated otherwise, plotted values represent the average of the lymphatic and blood 
vessel density as quantified in three separate imaging planes. Initially, quantification of 
the area covered by lymphatic vessels in the inguinal LN of MMTV-PyMT+ tumor-
bearing animals or age-matched FvB/N WT tumor-free mice was determined upon 
quantification of the lyve-1+ area.  However, to distinguish between blood and lymphatic 
vessels, later on, an added image parser function in version 7 allowed quantification of 
both the CD31+lyve-1- blood vessel and CD31+lyve-1+ lymphatic vessel area in the 
tumor and draining LN of VEGF-C+- or control tumor-bearing mice, respectively. 
 
 
Quantification of ECM deposition 
 
To evaluate the desmoplastic response during tumor growth and progression, and upon 
VEGFR-3-mediated inhibition of tumor-associated lymphangiogenesis in MMTV-
PyMT+ transgenic animals, various ECM components, i. e. total collagen content, as well 
as collagen-III, fibronectin and tenascin-C, respectively, were analyzed using a 
combination of immunohistochemistry and immunofluorescence on zinc-fixed tissue 
sections (see previous sections on staining procedures, and Tables 4 and 5 in Appendix 
A1.4). Analogous to quantification of blood and lymphatic vessel area, ECM deposition 
in the tumor was determined in a similar manner by a semi-automated approach using 
the same macro for area measurements described in the previous section (see Appendix 
A1.5). Contrary the abovementioned approach, however, the density of the various 
ECM components was then determined in 3 ROIs each extracted from the core of the 
primary tumor, or the invasive edge at scaling 1, with the invasive edge of the primary 
tumor focus determined by staining of the basement membrane with collagen-IV, which 
is disrupted upon tumor progression from hyperplastic to invasive lesions. Calculation of 
the percentage of area coverage of each ECM component was then done using the same 
formula for lymphatic vessel density listed above. 
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Statistical analysis 
 
The statistical analysis of each experiment is described in the respective figure legends. 
Unless stated otherwise, the plotted values represent the standard error of the mean 
(SEM). The following symbols: *, **, and ***, indicate a statistical significance of p < 0.05, 
p < 0.01 and p < 0.001, respectively. For the most part, statistical analysis on the data 
was performed by unpaired student's t-test, with the exception of characterization of the 
murine breast cancer cell lines in vitro, which was analyzed by 2-way ANOVA. For 
assessment of lymphangiogenesis and angiogenesis, as well as deconvolution of the 
tumor immune microenvironment during tumor growth and progression in the MMTV-
PyMT model of breast cancer, statistical analysis was performed by unpaired student's t-
test, as only comparisons between transgenic MMTV-PyMT+ tumor-bearing mice and 
tumor-free WT littermate control of the same age were made. 
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Appendices 
 
 
Appendix 1: Supplementary Experimental Procedures 
 
A1.1: Primer sequences and qPCR conditions 
 
Table 1 - Primer sequences and qPCR conditions for TaqMan qPCR 
 
Gene name Sequence 
Albumin 
Forward 5'-GCTGTCATCTCTTGTGGGCTGT 
Reverse 5'-ACTCATGGGAGCTGCTGGTTC 
Probe 5'-CCTGTCATGCCCACACAAATCTCTCC 
Gag 
Forward 5'-GGAGCTAGAACGATTCGCAGTTA 
Reverse 5'-GGTGTAGCTGTCCCAGTATTTGTC 
Probe 5'-ACAGCCTTCTGATGTTTCTAACAGGCCAGG 
Titin 
Forward 5'-AAAACGAGCAGTGACGTGAGC 
Reverse 5'-TTCAGTCATGCTGCTAGCGC 
Probe 5'-TGCACGGAAGCGTCTCGTCTCAGTC 
   
  Table 1: Primer and probe sequences for TaqMan qPCR 
 
Conditions: 10 minutes at 95°C followed by 50 cycles of: 
• 95°C: 15 seconds 
• 60°C: 60 seconds 
 
 
Table 2 - Primer sequences and qPCR conditions for SYBR Green qPCR 
 
Gene name Sequence 
Vegfc Forward 5'-CAGCCCACCCTCAATACCAG 
Reverse 5'-GACGGACACACATGGAGGTT 
 
  Table 2: Primer and probe sequences for SYBR Green qPCR 
 
Conditions: 10 minutes at 95°C followed by 40 cycles of: 
• 95°C: 15 seconds 
• 60°C: 60 seconds 
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A1.2: Flow cytometry: antibodies and reagents  
 
Table 3 - Antibodies used for flow cytometry 
 
Antigen Clone Isotype Conjugate Conc. Dilution Cat. # Manufacturer 
CD3e 145-2C11 Hamster APC 0.2 mg/ml 1 : 800 100312 Biolegend 
CD4 RM4-5 Rat IgG2a, κ BV711 0.5 mg/ml 1 : 100 100549 Biolegend 
CD4 RM4-5 Rat IgG2b, κ Pacific Blue 0.5 mg/ml 1 : 800 100531 Biolegend 
CD8 53-6.7 Rat IgG2a BV650 0.2 mg/ml 1 : 100 100741 Biolegend 
CD8 53-6.7 Rat IgG2a, κ APC/eFl780 0.2 mg/ml 1 : 800 47-0081-82 eBioscience 
CD11b M1/70 Rat IgG2b, κ BV711 0.2 mg/ml 1 : 300 101241 Biolegend 
CD11c N418 Hamster PE 0.2 mg/ml 1 : 200 117308 Biolegend 
CD25 3C7 Rat IgG2b, κ FITC 0.5 mg/ml 1 : 200 101908 Biolegend 
CD25 PC61 Rat IgG1, δ PE-Texas-Red 0.2 mg/ml 1 : 200 562694 BD 
CD31 390 Rat IgG2a, κ eFl450 0.2 mg/ml 1 : 200 48-0311-82 eBioscience 
CD44 IM7 Rat IgG2a Percp-Cy5.5 0.2 mg/ml 1 : 800 45-0441-82 eBioscience 
CD45 30-F11 Rat IgG2b, κ APC/Cy7 0.2 mg/ml 1 : 300 47-0451-82 eBioscience 
CD45 30-F11 Rat IgG2b, κ BV786 0.2 mg/ml 1 : 200 564225 BD 
CD62L MEL-14 Rat IgG2a, κ APC/eFl780 0.2 mg/ml 1 : 200 47-0621-82 eBioscience 
CD69 H1.2F3 Hamster PE/Cy7 0.2 mg/ml 1 : 200 104512 Biolegend 
CD69 H1.2F3 Hamster APC 0.5 mg/ml 1 : 300 104518 Biolegend 
CD206 C068C2 Rat APC 0.5 mg/ml 1 : 400 141712 Biolegend 
EpCAM G8.8 Rat IgG2a, κ PE/Cy7 0.2 mg/ml 1 : 300 25-5791-80 eBioscience 
F4/80 BM8 Rat IgG2a, κ FITC 0.5 mg/ml 1 : 200 123120 Biolegend 
F4/80 BM8 Rat IgG2a, κ PercP-Cy5.5 0.5 mg/ml 1 : 200 123128 Biolegend 
FoxP3 FJK-16s Rat IgG2a, κ FITC 0.5 mg/ml 1 : 200 11-5773-82 eBioscience 
gp38 8.1.1 Hamster APC 0.5 mg/ml 1 : 200 127410 Biolegend 
Gr-1 RB6-8C5 Rat IgG2b, κ Biotin* 0.5 mg/ml 1 : 200 13-5931-82 eBioscience 
Ly6C HK1.4 Rat IgG2c, κ PE/Cy7 0.2 mg/ml 1 : 500 128017 Biolegend 
Ly6G 1A8 Rat Pacific Blue 0.5 mg/ml 1 : 300 127612 Biolegend 
LYVE-1 Polyclonal Rabbit AF488** 0.2 mg/ml 1 : 200 103-PA50 Reliatech 
MHC-II (IA-IE) M5/114.15.2 Rat IgG2b, κ Percp-Cy5.5 0.2 mg/ml 1 : 400 107626 Biolegend 
NK1.1 PK136 Rat IgG2b, κ PE 0.2 mg/ml 1 : 200 107608 Biolegend 
PD-1 RMP1-30 Rat IgG2b, κ PE/Cy7 0.2 mg/ml 1 : 200 109109 Biolegend 
TCR-β H57-597 Hamster eFl450 0.2 mg/ml 1 : 400 48-5961-82 eBioscience 
TGF-β (LAP) TW7-20B9 Mouse IgG1, κ PE 0.2 mg/ml 1 : 200 141306 Biolegend 
 
Table 3: Antibodies used for flow cytometry 
 
Application notes: 
* Use secondary streptavidin-pacific orange conjugate at 1 : 200 
**  Use secondary anti-rabbit AF488 conjugate at 1 : 400 
 
 
 ? ???
A1.3: Flow cytometry: phenotype of cells in the tumor microenvironment  
 
The cell populations in the tumor microenvironment, comprising the tumor and its 
draining LN, were analyzed by flow cytometry according to the phenotypes listed below: 
 
Stromal cells in the tumor and draining LN: 
 
• LECs:   CD45-EpCAM-CD31+gp38+ and Lyve-1+ or lyve-1- 
• BECs:   CD45-EpCAM-CD31+gp38- 
• FRCs:   CD45-EpCAM-CD31-gp38+ 
 
Stromal cell populations were analyzed as previously described in (Link et al., 2007). 
 
Myeloid cells in the tumor: 
 
• Myeloid cells:  CD45+CD11bhi 
• MDSCs:  CD45+CD11bhiGr-1+ 
• Neutrophils:  CD45+CD11bhiLy6G+Ly6C-F4/80- 
• Monocytes:  CD45+CD11bhiLy6G-Ly6C+F4/80- 
• TAMs:  CD45+CD11bhiLy6G-Ly6C-F4/80+ 
• M1-like TAMs:  CD11c+CD206- TAMs 
• M2-like TAMs:  CD11c-CD206+ TAMs 
 
The distinction between CD11c+ M1-like and CD206+ M2-like TAMs was made based 
on a previous description in (Squadrito and De Palma, 2011). 
 
T lymphocytes in the tumor and draining LN 
 
• T cells:  CD45+TCR-β+NK1.1- or CD45+CD3e+NK1.1- 
• NK cells:  CD45+TCR-β-NK1.1+ or CD45+CD3e-NK1.1+ 
• NK T cells:  CD45+TCR-β+NK1.1+ or CD45+CD3e+NK1.1+ 
• CD4+ T cells:   CD45+TCR-β+NK1.1-CD4+CD8- 
• CD8+ CTLs:  CD45+TCR-β+NK1.1-CD4-CD8+ 
• FoxP3+ Treg cells: CD45
+TCR-β+NK1.1-CD4+CD8-FoxP3+ 
• Activated CTLs: CD45+TCR-β+NK1.1-CD4-CD8+ and CD25+ or CD69+ 
• Suppressive CTLs: CD45+TCR-β+NK1.1-CD4-CD8+ and PD-1+ 
 
Note: alternative to TCR-β, CD3e has also been used as a marker to identify the T 
lymphocytes in the tumor and LN, in which case all subsequent subsets are described by 
expression of CD3e instead of TCR-β. 
 
 
 
 
 ? ???
A1.4: Histology: antibodies and reagents 
 
Table 4 - Primary antibodies used for histological analysis 
 
Antigen Clone Species  Antigen Retrieval Conc. Dilution Cat. # Manufacturer 
CD31 SZ31 Rat Citrate pH6.0 0.2 mg/ml 1 : 50 DIA-310 Dianova 
Collagen-III Polyclonal Rabbit N/D 1.0 mg/ml 1 : 200 Ab7778 Abcam 
Collagen-IV Polyclonal Rabbit N/D 1.0 mg/ml 1 : 500 Ab6581 Abcam 
Fibronectin Polyclonal Rabbit N/D 1.0 mg/ml 1 : 100 Ab23750 Abcam 
gp38 Polyclonal Goat Not necessary 0.1 mg/ml 1 : 200 AF3244 R&D Systems 
LOX Polyclonal Rabbit Citrate pH6.0 1.0 mg/ml 1 : 200 Ab31238 Abcam 
LYVE-1 Polyclonal Rabbit Citrate pH6.0, PK 0.2 mg/ml 1 : 200 103-PA50 Reliatech 
PyMT Monoclonal Rat Citrate pH6.0 - 1 : 50 MAB7374 Abnova 
Tenascin-C Polyclonal Goat PK 0.2 mg/ml 1 : 200 AF3358 R&D Systems 
VEGFR-3 Polyclonal Goat Citrate pH6.0, PK 0.2 mg/ml 1 : 50* AF743 R&D Systems 
 
Table 4: Antibodies used for histology 
 
Application notes: 
* Use intermediate anti-goat biotin conjugate at 1 : 200 to amplify signal 
N/D Not determined, used on zinc-fixed tissue specimens 
 
 
 
Table 5 - Secondary antibodies used for histological analysis 
 
Fluorophore Host Species  Antigen Retrieval Conc. Dilution Cat. # Manufacturer 
AF488 
Donkey Goat N/A 2.0 mg/ml 1 : 200 A-11055 Invitrogen 
Donkey Rabbit N/A 2.0 mg/ml 1 : 200 A-21206 Invitrogen 
Donkey Rat N/A 2.0 mg/ml 1 : 200 A-21208 Invitrogen 
AF546 
Goat Rabbit N/A 2.0 mg/ml 1 : 200 A-11010 Invitrogen 
Goat Rat N/A 2.0 mg/ml 1 : 200 A-11081 Invitrogen 
AF647 
Donkey Rabbit N/A 2.0 mg/ml 1 : 200 A-31573 Invitrogen 
Chicken Rat N/A 2.0 mg/ml 1 : 200 A-21472 Invitrogen 
Biotin Donkey Goat N/A N/A 1 : 200 N/A HCF, EPFL 
AF488-SA N/A N/A N/A 5 mM 1 : 200 S11223 Invitrogen 
AF647-SA N/A N/A N/A 5 mM 1 : 200 S21374 Invitrogen 
 
Table 5: Antibodies used for histology 
 ? ???
A1.5: Macro for area measurements 
 
 
// Action Bar for Area quantifications 
// By Olivier Burri 
// EPFL BIOP 2014 
 
// Install the BIOP Library 
call("BIOP_LibInstaller.installLibrary", "BIOP"+File.separator+"BIOPLib.ijm"); 
 
// Name ActionBar 
bar_name = "BIOP Ingrid version7"; 
 
bar_file = replace(bar_name, " ", "_")+".ijm"; 
bar_jar  = replace(bar_name, " ", "_")+".jar"; 
 
 
runFrom = "jar:file:BIOP/"+bar_jar+"!/"+bar_file; 
////////////////////////////////////////////////////////////////////////////////////////////// 
// The line below is for debugging. Place this VSI file in the ActionBar folder within Plugins 
////////////////////////////////////////////////////////////////////////////////////////////// 
runFrom = "/plugins/ActionBar/"+bar_file; 
 
if(isOpen(bar_name)) { 
 run("Close AB", bar_name); 
} 
 
run("Action Bar",runFrom); 
exit(); 
 
<codeLibrary> 
 
function toolName() { 
 return "Area Measurements Ingrid"; 
  
} 
 
function countRoisOfCategory(category) { 
 nRois = roiManager("count"); 
 roiNum = 0; 
 for (i=0; i<nRois; i++) { 
  name = call("ij.plugin.frame.RoiManager.getName", i); 
  expr = roiNameExp(category); 
  if (matches(name, expr)) { 
   roiNum++; 
  } 
 } 
 print("There are "+roiNum+" ROIs of category '"+category+"'"); 
 return roiNum; 
} 
 
function roiName(category, index) { 
 return category+" #"+index; 
} 
 
function roiNameExp(category) { 
 return category+" #\\d+"; 
} 
 
function renameLastRoi(category, index) { 
 nRois = roiManager("Count"); 
 roiManager("Select", nRois-1); 
 name = roiName(category, index); 
 roiManager("Rename", name); 
 roiManager("Sort"); 
 return name: 
} 
 
function DrawRois(category) { 
 if (getVersion>="1.37r") 
         setOption("DisablePopupMenu", true); 
 
 // Setup some variables. Basically these numbers 
 // Represent an action that has taken place (it's the action's ID) 
 shift=1; 
 ctrl=2;  
 ? ???
 rightButton=4; 
 alt=8; 
 leftButton=16; 
 insideROI = 32; // requires 1.42i or later 
 
 // Now we initialize the ROI counts and check if there are already ROIs with this name.  
  
 roiNum = countRoisOfCategory(category); 
 
 // done boolean to stop the loop that checks the mouse's location 
 done=false; 
 
 // rightClicked to make sure the function saves the ROI ONCE and not 
 // continuously while "right click" is presed 
 rightClicked = false; 
 print("Started mouse tracking for "+category+", press 'ALT' to stop"); 
 while(!done) { 
  // getCursorLoc gives the x,y,z position of the mouse and the flags associated 
  // to see if a particular action has happened, say a left click while shift is  
  // pressed, you do it like this:  
  // if (flags&leftButton!=0 && flags&shift!=0) { blah blah... } 
   
  getCursorLoc(x,y,z,flags); 
  // print(x,y,z,flags); 
  //If a freehand selection exists and the right button was clicked AND that right click was not pressed before 
already 
  if (flags&rightButton!=0 && selectionType!=-1 && !rightClicked) { 
   // set rightCLicked to true to stop this condition from writing several times the same ROI 
   rightClicked = true; 
 
   // Add the ROI to the manager 
   roiManager("Add"); 
    
   renameLastRoi(category, roiNum+1); 
   roiNum++; 
   print(roiNum+" saved."); 
  } 
 
  // Once we stopped pressing the right mouse button, we can then click it again and add a new ROI 
  if (flags&rightButton==0) { 
   rightClicked = false; 
  } 
   
  //We stop the loop when the user presses ALT 
  if(isKeyDown("alt")) { 
   done=true; 
   print("ALT Pressed: Done"); 
   setKeyDown("none"); 
  } 
 
 } 
  
} 
function addRoi(name) { 
 roiManager("Add"); 
 roiManager("Select", roiManager("Count")-1); 
 roiManager("Rename", name); 
} 
function drawRoi() { 
 isLymph = getDataD("Draw Lymph Node", 1); 
 isTumorCore = getDataD("Draw Tumor Core", 1); 
 isInvasiveEdge = getDataD("Draw Invasive Edge", 1); 
 isNonInvasiveTumor = getDataD("Draw Non-Invasive Tumor", 1); 
 
 roiManager("Reset"); 
  
 waitForUser("Draw a ROI for the background, then press OK"); 
 addRoi("BG"); 
 
 if (isLymph) { 
  waitForUser("Draw a ROI around the Lymph Node, then press OK"); 
  addRoi("Lymph Node"); 
 } 
 
 if (isTumorCore) { 
  waitForUser("Draw a ROI around the Tumor Core, then press OK"); 
  addRoi("Tumor Core"); 
 ? ???
 } 
 
 if (isInvasiveEdge) { 
  waitForUser("Draw a ROI around the Invasive Edge, then press OK"); 
  addRoi("Invasive Edge"); 
 } 
 
 if (isNonInvasiveTumor) { 
  waitForUser("Draw a ROI around the Non-Invasive Tumor, then press OK"); 
  addRoi("Non-Invasive Tumor"); 
 } 
 
 saveRois("Open"); 
} 
 
function selectRoi(name) { 
 n = roiManager("Count"); 
 //print("looking for"+name); 
 for (i=0; i<n; i++) { 
  rName = call("ij.plugin.frame.RoiManager.getName", i); 
  if (rName == name) { 
   roiManager("Select", i); 
   return i; 
  } 
 } 
 return -1; 
} 
 
function buildSettings() { 
 // Get the number of categories and Their Names 
 dapi  = getDataD("DAPI Channel", 1); 
 dapiTh = getDataD("DAPI threshold", "Huang"); 
 channels = getDataD("Channels Of Interest", "2,3,4"); 
 channelNames = getDataD("Channel Names", "GP38,Lyve1,CD31"); 
    channelThr = getDataD("Threshold Methods", "Moments,Triangle,Triangle"); 
    chClear = getDataD("Channels With Bright Artifacts",""); 
    isArea = parseInt(getDataD("Perform Area Logic", 1)); 
    areas = getDataD("Area Logic Measurements","A&&B&&C,A&&B,A&&B&&!C,A&&C,A&&!C"); 
   
  
 minSize = getDataD("Min Particle Size", 30); 
 isDebug = parseInt(getDataD("Debug", 0)); 
 
 isLymph = getDataD("Draw Lymph Node", 1); 
 isTumorCore = getDataD("Draw Tumor Core", 1); 
 isInvasiveEdge = getDataD("Draw Invasive Edge", 1); 
 isNonInvasiveTumor = getDataD("Draw Non-Invasive Tumor", 1); 
  
 methods = getList("threshold.methods"); 
 if (isDebug == 1) { 
  isDebug = true; 
 } else { 
  isDebug = false; 
 } 
 Dialog.create("Detection Settings"); 
 Dialog.addNumber("DAPI Channel", dapi); 
 Dialog.addString("DAPI threshold", dapiTh ); 
 Dialog.addString("Channels Of Interest", channels ); 
 Dialog.addString("Channel Names", channelNames ); 
 Dialog.addString("Threshold Methods", channelThr ); 
 Dialog.addString("Channels With Bright Artifacts", chClear ); 
 Dialog.addCheckbox("Perform Area Logic", isArea ); 
  
 Dialog.addString("Channel Logic For Area Measurement", areas ); 
  
 Dialog.addNumber("Minimum Particle Size", minSize); 
 Dialog.addCheckbox("Debug Mode", isDebug); 
 Dialog.addCheckbox("Draw Lymph Node", isLymph); 
 Dialog.addCheckbox("Draw Tumor Core", isTumorCore); 
 Dialog.addCheckbox("Draw Invasive Edge", isInvasiveEdge); 
 Dialog.addCheckbox("Draw Non-Invasive Tumor", isNonInvasiveTumor); 
 Dialog.show(); 
  
 dapi = Dialog.getNumber(); 
 dapiTh = Dialog.getString(); 
 channels = Dialog.getString(); 
 channelNames = Dialog.getString(); 
 ? ???
 channelThr = Dialog.getString(); 
 chClear = Dialog.getString(); 
 isArea =  Dialog.getCheckbox(); 
 areas   = Dialog.getString(); 
 minSize = Dialog.getNumber(); 
 isDebug = Dialog.getCheckbox(); 
 isLymph = Dialog.getCheckbox(); 
 isTumorCore = Dialog.getCheckbox(); 
 isInvasiveEdge = Dialog.getCheckbox(); 
 isNonInvasiveTumor = Dialog.getCheckbox(); 
 
 setData("DAPI Channel", dapi); 
 setData("DAPI threshold", dapiTh); 
 setData("Channels Of Interest", channels); 
 setData("Channel Names", channelNames); 
 setData("Threshold Methods", channelThr); 
 setData("Channels With Bright Artifacts", chClear); 
 
 setData("Perform Area Logic", isArea); 
 setData("Area Logic Measurements",areas); 
 setData("Min Particle Size", minSize); 
 setData("Debug", isDebug); 
 
 setData("Draw Lymph Node", isLymph); 
 setData("Draw Tumor Core", isTumorCore); 
 setData("Draw Invasive Edge", isInvasiveEdge); 
 setData("Draw Non-Invasive Tumor", isNonInvasiveTumor); 
  
} 
function cleanup() { 
 name = getTitle(); 
 getDimensions(x,y,c,z,t); 
 run("Select None"); 
 newName = name+" - BG Corrected"; 
 run("Duplicate...", "title=["+newName+"] duplicate"); 
 bg = newArray(c); 
 for (i=0; i<c; i++) { 
  selectRoi("BG"); 
  Stack.setChannel(i+1); 
  run("Measure"); 
  bg[i] = getResult("Mean", nResults-1); 
  run("Select None"); 
  run("Subtract...", "value="+bg[i]+" slice"); 
   
 } 
 IJ.deleteRows(nResults-c, nResults-1); 
 return newName; 
} 
function detectTissue() { 
 name = getTitle(); 
 dapi = parseInt(getData("DAPI Channel")); 
 dapiTh = getData("DAPI threshold"); 
 setSlice(dapi); 
 dapiFull = name+" - DAPI full"; 
 run("Duplicate...", "title=["+dapiFull+" tmp]"); 
 run("Gaussian Blur...", "sigma=10"); 
 setAutoThreshold(dapiTh+" dark"); 
 run("Analyze Particles...", "size=1000-Infinity pixel show=Masks"); 
 rename(dapiFull); 
 close(dapiFull+" tmp"); 
 selectImage(dapiFull); 
 run("Clear Results"); 
   
 setThreshold(128,255); 
 // Measure DAPI areas in all ROIs 
 nR = roiManager("Count"); 
 lab = newArray(0); 
 ar  = newArray(0); 
 for (r=1; r<nR; r++) { 
   roiManager("Select", r); 
   rName = Roi.getName; 
   run("Measure"); 
    
   lastLab = "DAPI"+ " - "+rName; 
   lastAr = getResult("Area", nResults-1); 
   lab = Array.concat(lab,lastLab); 
   ar = Array.concat(ar,lastAr); 
 ? ???
 } 
 // Add measurements to final table; 
 prepareTable("Area Measurements"); 
  
 n = nResults; 
 setResult("Label", n, name); 
 for (r=0; r<lab.length; r++) { 
  setResult(lab[r], n, ar[r]); 
 } 
 closeTable("Area Measurements"); 
 return dapiFull; 
} 
 
function detectChannels(dapi) { 
 name = getTitle(); 
 minSize = getData("Min Particle Size"); 
 ch = split(getData("Channels Of Interest"), ","); 
 chNames = split(getData("Channel Names"), ","); 
 chThr = split(getData("Threshold Methods"), ","); 
 chClear = split(getData("Channels With Bright Artifacts"), ","); 
 nR = roiManager("Count"); 
 nchNames = newArray(chNames.length); 
  
 ar  = newArray(0); 
 lab = newArray(0); 
 imageNames = newArray(ch.length*2); 
 nR = roiManager("Count"); 
  
 for (i=0; i<ch.length;i++) { 
  selectImage(name); 
  nchNames[i] = name +" - "+chNames[i]; 
  // Extract the channel 
  run("Duplicate...", "title=["+nchNames[i]+" tmp] duplicate channels="+ch[i]); 
  // Blur it slightly 
  run("Smooth"); 
  // Apply thr 
  if (hasMatch(ch[i], chClear)) { 
   clearArtifacts(); 
  } 
  setAutoThreshold(chThr[i]+" dark"); 
  run("Analyze Particles...", "size="+minSize+"-Infinity pixel show=Masks"); 
  rename(nchNames[i]); 
  imageNames[2*i] = nchNames[i]; 
  selectImage(nchNames[i]+" tmp"); 
  close(); 
  // AND with DAPIs 
  imageCalculator("AND create",dapi,nchNames[i] ); 
  rename(nchNames[i]+" - DAPI"); 
  imageNames[2*i+1] = nchNames[i]+" - DAPI"; 
  setThreshold(128,255); 
   
  for (r=1; r<nR; r++) { 
    
   selectImage(nchNames[i]+" - DAPI"); 
   roiManager("Select", r); 
   rName = Roi.getName; 
   run("Measure"); 
    
   lastLab = chNames[i]+ " - "+rName; 
   lastAr = getResult("Area", nResults-1); 
   lab = Array.concat(lab,lastLab); 
   ar = Array.concat(ar,lastAr); 
  } 
 } 
 selectWindow("Results"); 
 prepareTable("Area Measurements"); 
 n = nResults; 
 for (i=0; i<lab.length; i++) { 
  print(lab[i]); 
  setResult(lab[i], n-1, ar[i]); 
   
 } 
 closeTable("Area Measurements"); 
 updateResults(); 
 isDebug=getData("Debug"); 
 if(isDebug == "1"){ 
  waitForUser("Check resulting masks"); 
 ? ???
 } 
 
  
 return imageNames; 
  
} 
 
function clearArtifacts() { 
 //Image is already duplicated, need to set bright things to NaN 
 run("32-bit"); 
 setAutoThreshold("MaxEntropy"); 
 run("NaN Background"); 
  
} 
 
function hasMatch(txt, array) { 
 for (i=0; i< array.length; i++) { 
  if (txt == array[i]) { 
   return true; 
  } 
 } 
 return false; 
  
} 
 
function measureCurrentImage() { 
bgImage = cleanup(); 
dapi = detectTissue(); 
selectImage(bgImage); 
detectChannels(dapi); 
 
isArea = parseInt(getDataD("Perform Area Logic", 1)); 
 
if(isArea == 1) { 
 channelLogic(); 
} 
 
} 
 
function channelLogic() { 
 
// Do some image logic 
logic = split(getData("Area Logic Measurements"),","); 
names = split(getData("Channel Names"),","); 
 
// Get image names that are matching and build expression 
str = ""; 
letters = newArray("a","b","c","d","e","f","g","h"); 
l=0; 
nR = roiManager("Count"); 
lab = newArray(0); 
ar = newArray(0); 
 
for(k=0; k<names.length; k++) { 
 
 for(i=0; i< nImages; i++) { 
  selectImage(i+1); 
  name = getTitle(); 
  print(name); 
  if(matches(name,".* - "+names[k]+" - DAPI")) { 
   print("Match between "+name+" and "+names[k]); 
   getVoxelSize(vx,vy,vz,vU); 
   str+=" "+letters[l]+"=["+name+"]";  
   l++; 
   i=nImages; 
  } 
 } 
} 
print(str); 
for (i=0; i<logic.length;i++){ 
 expression = logic[i]; 
 run("Image Expression Parser (Macro)", "expression="+expression+str); 
 setVoxelSize(vx,vy,vz,vU); 
 currentImage = getTitle(); 
 
 setThreshold(1,255); 
 // Measure All ROIs 
 ? ???
 for (r=1; r<nR; r++) { 
    
  selectImage(currentImage); 
  roiManager("Select", r); 
  rName = Roi.getName; 
  run("Measure"); 
    
  lastLab = currentImage+ " - "+rName; 
  lastAr = getResult("Area", nResults-1); 
  lab = Array.concat(lab,lastLab); 
  ar = Array.concat(ar,lastAr); 
 } 
 run("Select None"); 
} 
prepareTable("Area Measurements"); 
n = nResults; 
for (i=0; i<lab.length; i++) { 
 print(lab[i]); 
 setResult(lab[i], n-1, ar[i]); 
  
} 
closeTable("Area Measurements"); 
updateResults(); 
 
// Everyone in same stack 
run("Images to Stack", "name=Stack title=Parsed use"); 
 
} 
</codeLibrary> 
 
<line> 
<button> 
label=Select Image 
icon=noicon 
arg=<macro> 
 
selectImageDialog(); 
</macro> 
</line> 
 
<line> 
<button> 
label=Save image (+ ROI) 
icon=noicon 
arg=<macro> 
 
saveCurrentImage(); 
//Saves the ROI Set with the name of the current image 
saveRois("Open"); 
</macro> 
</line> 
 
<line> 
<button> 
label=Settings 
icon=noicon 
arg=<macro> 
buildSettings(); 
</macro> 
</line> 
 
<line> 
<button> 
label=Save Settings 
icon=noicon 
arg=<macro> 
saveParameters(); 
</macro> 
 
<button> 
label=Load Settings 
icon=noicon 
arg=<macro> 
loadParameters(); 
</macro> 
</line> 
 
 ? ???
<line> 
<button> 
label=Draw ROI 
icon=noicon 
arg=<macro> 
// Make user draw tissue ROI 
drawRoi(); 
</macro> 
 
<button> 
label=Batch Draw ROI 
icon=noicon 
arg=<macro> 
nI = getNumberImages(); 
 
for (i=0; i<nI; i++) { 
  
 openImage(i); 
 drawRoi(); 
 close(); 
} 
</macro> 
</line> 
 
<line> 
<button> 
label=Measure Current Image 
icon=noicon 
arg=<macro> 
 
measureCurrentImage(); 
 
</macro> 
</line> 
<line> 
<button> 
label=Batch Measure 
icon=noicon 
arg=<macro> 
 
run("Clear Results"); 
 
nI = getNumberImages(); 
print(nI); 
for (i=0; i<nI; i++) { 
 roiManager("reset"); 
 openImage(i); 
 measureCurrentImage(); 
 saveCurrentImage(); 
 //Close the image before going to the next one 
 close(); 
} 
</macro> 
</line> 
 
<line> 
<button> 
label=Close Others 
icon=noicon 
arg=<macro> 
close("\\Others"); 
</macro> 
</line> 
 
<line> 
<button> 
label=Area Logic 
icon=noicon 
arg=<macro> 
channelLogic(); 
</macro> 
</line> 

 ? ???
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